

PHARMACEUTICAL ASSISTANCE CONTRACT FOR THE ELDERLY

ANNUAL REPORT TO THE PENNSYLVANIA GENERAL ASSEMBLY

JANUARY 1 - DECEMBER 31, 2009

For the Pennsylvania Department of Aging

Director

Operations Chief

Administrative Assistant

Administrative Assistant

Applications and Enrollments Manager

Administrative Officer

Administrative Assistant

Research and Evaluation Chief

Program Analyst

Legislative Liaison

Thomas M. Snedden

Rose M. Paulus

Peggy Vespe

Linda Barlow

Darlene L. Shughart

Barbara Butler

Kyle Kessler

Theresa V. Brown

Antonino G. Vetranio

Metro Petrosky

Pennsylvania Department of Aging

The PACE Program

Forum Place Building

555 Walnut Street

6th Floor

Harrisburg, PA 17101-1919

717-787-7313

[aging@state.pa.us](mailto:aging@state.pa.us)

For Magellan Medicaid Administration, Inc.

Officer in Charge

Director, PACE Operations

Pharmacy Research Scientist

Associate Pharmacy Research Scientist

Business Services Manager

Quality Assurance Manager

Quality Assurance Coordinator

Mark B. Shaffer

Bradley I. Kohler

Debra A. Heller, Ph.D.

Judith S. Samkoff, M.D.

Donald G. Smith

Kimberly Matter

Colleen M. Brindamour

Magellan Medicaid Administration

4000 Crums Mill Road

Suite 301

Harrisburg, PA 17112

717-651-3600

Any questions or comments pertaining to information within this report may be addressed to the Pennsylvania Department of Aging at the address given above.



## TABLE OF CONTENTS

Executive Summary .....	1-3
History .....	5
Administration .....	7
<b>Section 1 – Program Research Highlights .....</b>	<b>9-16</b>
<b>Section 2 – Financial Data by Date of Service .....</b>	<b>17-36</b>
Table 2.1A    Historical Claim and Expenditure Data for PACE Enrolled..... and Participating Cardholders by Semi-Annual Period Based On Date of Service January 1991 - December 2009	19-20
Table 2.1B    Historical Claim and Expenditure Data for PACENET Enrolled..... and Participating Cardholders by Semi-Annual Period Based On Date of Service July 1996 - December 2009	21
Figure 2.1    PACE and PACENET Claim Distribution by Amount Paid per Claim .....	22
January - December 2009	
Figure 2.2    Distribution of PACE Annual Benefit.....	23
January - December 2009	
Figure 2.3    Distribution of PACENET Annual Benefit .....	24
January - December 2009	
Table 2.2    PACE and PACENET Expenditures and Recoveries .....	25
January - December 2009	
Figure 2.4    PACE and PACENET Enrollment, Claims, and .....	26
Claims Expenditures by Calendar Year 1988-2009	
Figure 2.5A    PACE Total Enrolled and Participating Cardholders .....	27
By Month January 1999 – January 2010	
Figure 2.5B    PACENET Total Enrolled and Participating Cardholders .....	28
By Month January 1999 – January 2010	
Figure 2.6A    Average Prescriptions per Participating PACE Cardholder .....	29
By Month January 1999 – January 2010	

Figure 2.6B	Average Prescriptions per Participating PACENET Cardholder ..... 30 By Month January 1999 – January 2010	
Figure 2.7A	PACE Average State Share per Claim ..... 31 By Month January 1999 – January 2010	
Figure 2.7B	PACENET Average State Share per Copaid Claim..... 32 By Month January 1999 – January 2010	
Figure 2.8A	Total PACE Expenditure by Month ..... 33 January 1999 – January 2010	
Figure 2.8B	Total PACENET Expenditure by Month..... 34 January 1999 – January 2010	
Figure 2.9	PACE Average Wholesale Price (AWP) and ..... 35 Average Manufacturer’s Price (AMP) by Quarter January 1997 – December 2009	
<b>Section 3 – Program Data by Date of Payment ..... 37-54</b>		
Table 3.1	PACE and PACENET Claims and Expenditures Paid by Fiscal Year ..... 39-41 July 1984 - December 2009	
Table 3.2A	PACE High Expenditure and High Volume Claims ..... 42-44 January - December 2009	
Table 3.2B	PACENET High Expenditure and High Volume Claims..... 45-47 January - December 2009	
Table 3.3	Annual Change in PACE Expenditure and Utilization for ..... 48-51 High Expenditure Therapeutic Classes 2008 - 2009	
Table 3.4	PACE and PACENET Number and Percent of ..... 52-53 Expenditures and Claims by Manufacturer January - December 2009	
Table 3.5	Manufacturers' Rebate Cash Receipts by Quarter ..... 54 Billed and by Fiscal Year Received January 1991 - December 2009	
<b>Section 4 – Cardholder Utilization Data ..... 55-70</b>		
Table 4.1	PACE and PACENET Cardholder Enrollments by Quarter ..... 57-59 July 1984 – December 2009	
Table 4.2A	PACE Cardholder Enrollment, Participation, Utilization,..... 60-61 and Expenditures by Demographic Characteristics January - December 2009	

Table 4.2B	PACENET Cardholder Enrollment, Participation, Utilization, ..... and Expenditures by Demographic Characteristics January - December 2009	62-63
Figure 4.1A	Percent of Enrolled PACE Cardholders by Income ..... and Marital Status January - December 2009	64
Figure 4.1B	Percent of Enrolled PACENET Cardholders by Income ..... and Marital Status January - December 2009	65
Table 4.3	Other Prescription Insurance Coverage of PACE and..... PACENET Enrolled Cardholders January - December 2009	66
Table 4.4	Part D Cardholder Enrollment, Participation, and Expenditures..... January - December 2009	67-68
Figure 4.2	PACE Generic Utilization Rates by Quarter ..... December 1988 - December 2009	69
<b>Section 5 – County Data</b> .....		71-78
Table 5.1	Number and Percent of PACE and PACENET Cardholders ..... and Number of Providers by County January - December 2009	73-75
Figure 5.1	PACE and PACENET Cardholder, Claim, and Provider..... Information by County Type January - December 2009	76
Figure 5.2	Percent of Elderly Enrolled in PACE and PACENET by County..... January - December 2009	77
<b>Section 6 - Provider Data</b> .....		79-90
Table 6.1	PACE Claims and Expenditures by Provider Type ..... January - December 2009	81
Table 6.2	PACE Claims Volume by Product and Provider Type ..... January - December 2009	82
Table 6.3	PACE Expenditures by Product and Provider Type ..... January - December 2009	83
Table 6.4	Average State Share per PACE Claim by Product ..... and Provider Type January - December 2009	84
Table 6.5	PACENET Claims and Expenditures by Provider Type..... January - December 2009	85

Table 6.6	PACENET Claims Volume by Phase of Coverage, ..... Product Type, and Provider Type January - December 2009	86
Table 6.7	PACENET Expenditures by Phase of Coverage, ..... Product Type, and Provider Type January - December 2009	87-88
Table 6.8	Average Cardholder and State Share Cost per PACENET ..... Claim by Phase of Coverage, Product Type, and Provider Type January - December 2009	89
<b>Section 7 - Therapeutic Class Data and Drug Utilization Review Data .....</b>		<b>91-100</b>
Table 7.1A	Number and Percent of PACE Claims, State Share Expenditures, ..... and Cardholders with Claims by Therapeutic Class January – December 2009	93-94
Table 7.1B	Number and Percent of PACENET Claims, State Share..... Expenditures, and Cardholders with Claims by Therapeutic Class January – December 2009	95-96
Figure 7.1	Percent of PACE State Share Expenditures by Therapeutic Class..... January - December 2009	97
Figure 7.2	Timeline of ProDUR Implementation .....	98
Figure 7.3	Number and Percent of PACE and PACENET Claims..... with a Prospective Review Message by Therapeutic Class January - December 2009	99-100
<b>Section 8 - The Pennsylvania Patient Assistance Program Clearinghouse (PA PAP) ..</b>		<b>101-104</b>
Appendix A - The PACE/PACENET Medical Exception Process.....		105
Appendix B - American Hospital Formulary Service (AHFS) Classifications .....		106
Appendix C - PACE Prospective Drug Utilization Review Criteria .....		107-124

## EXECUTIVE SUMMARY

Over the past 25 years, the PACE Program has provided life sustaining medication to over 1.3 million older Pennsylvanians in need of assistance. The Pennsylvania Department of Aging prepares an annual report as a resource for information and research and a review of Program operations, expenditures and benefits to older persons. Within the annual report, there is an administrative overview of the PACE/PACENET Programs which is followed by eight sections of information about the pharmaceutical utilization of older Pennsylvanians, including:

- collaborative research efforts,
- financial information,
- program measures,
- utilization parameters,
- data stratified by county,
- provider statistics,
- therapeutic drug utilization review results, and
- prescription coverage assistance referrals.

### ENROLLMENT, UTILIZATION, AND EXPENDITURES

Prescription drug benefits constitute 97% of the Program's total gross expenses while administrative costs are 3%. Mandated manufacturer rebates and other recoveries reduced the 2009 total state share for prescription drug cost by 27.2%. The analysis of trends for the three drivers of PACE/PACENET expenditures, enrollment, utilization, and cost per enrollee, reveals several findings. Below are significant data elements for 2008 and 2009.

#### PACE and PACENET

- *PACE Plus Medicare:* The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established a Medicare prescription drug benefit, known as Part D, which went into effect on January 1, 2006. As a qualified State Pharmaceutical Assistance Program (SPAP), PACE received authorization from the Centers for Medicare & Medicaid Services (CMS) to coordinate its benefits with those offered by Medicare Part D prescription drug plans. In September 2006, PACE implemented the PACE Plus Medicare Program. Each year since 2006, the Program has facilitated the enrollment of cardholders into partner Part D plans. In January 2009, the Program assigned 139,000 PACE and PACENET cardholders to five partner plans. In January 2010, the assignment included 126,000 cardholders into three plans. In January 2011, the Program anticipates the facilitated enrollment of 123,000 into three plans. Approximately 252,000 cardholders are currently enrolled in Part D.

#### PACE

- *Decrease in Enrollment:* The total number of PACE enrolled cardholders in 2009 decreased by 11% relative to 2008, from 171,225 to 152,419. This decrease is the result of fixed upper income limits for the program. PACE enrollees who exceed the upper income limit for the program are likely to be eligible for benefits in the PACENET program.
- *Decrease in Utilization Trend:* During 2009, claims per participating cardholder were 1.4% lower than the average in 2008 (41.1 vs. 41.7).
- *Decreased State Share Cost per Cardholder:* With the implementation of PACE Plus Medicare, the Program realized savings in the state share payments through avoided costs, shown by the substantial decrease in state share expenditures since 2005. These decreases are apparent by comparing the cost per cardholder in 2005 with values for 2009. At \$931, the average state share per participating cardholder in 2009 is substantially lower (-40%) than the 2005 average of \$1,563.

## PACENET

- *Increase in Enrollment:* The number of PACENET enrolled cardholders in 2009 increased by 2% relative to 2008, from 190,000 to 193,781.
- *Decreased Utilization Trend:* The average number of claims per participating PACENET cardholder during 2009 was 3% lower than that observed in 2008 (38.6 vs. 39.9).
- *Decreased Cost per Cardholder:* The average cost per PACENET cardholder declined during 2009. Cost per participating cardholder fell from \$1,045 during 2008 to \$1,020 during 2009, a decline of 2%.

### **MAGNITUDE OF NEED**

The magnitude of enrollee need for assistance is profound. A close examination of the distribution of the PACE annual benefit reveals that 11% of PACE enrollees, over 17,000 persons, received coverage valued between \$2,000 and \$5,000. About 2,500 PACE cardholders utilized \$5,000 or more in benefits that were paid by PACE.

### **DEPTH AND BREADTH OF THE BENEFIT**

The Program reaches across all Commonwealth counties. Cardholders and pharmacy providers in large and small counties are well represented. Statewide, 2,941 pharmacy providers received the benefit of increased business, reliable payments, stable customer base, and rapid Program response.

### **MEDICATIONS USED**

The medications used reflect the chronic disease burden experienced by many elderly. On average, participants used between four and five different medications each month. Over 80% of PACE enrollees utilized one or more cardiovascular drugs, accounting for approximately one-third of all claims and expenditures. Other frequently used classes include hormones and synthetic substances, gastrointestinal agents, and anti-infective agents.

### **ENSURING SAFE MEDICATION USE**

Since 1992, PACE has maintained an exemplary prospective drug utilization review (ProDUR) program. ProDUR assists the Program, physicians, and pharmacists in attaining the common goal of ensuring safe and effective use of medications by this special population – older Pennsylvanians. Prior to dispensing medications, the review checks for safety issues related to dosage, duplicative therapy, drug interactions, and other potential problems. The Program's medical exception process relies upon communication with physicians regarding individual patient needs.

### **OUTCOMES RESEARCH**

In 2009, researchers using Program data published and presented topics related to health outcomes and medication adherence, adverse drug reactions, and medication safety.

### **CONSUMER PHARMACEUTICAL ASSISTANCE**

The Program continues with its referral system for persons who are in need of pharmaceutical assistance but *ineligible* for PACE/PACENET benefits by responding to 14,297 inquiries over eight years and facilitating enrollment into patient assistance programs offered by pharmaceutical manufacturers and special funds received as a result of litigation settlements. At the end of 2009, 47% (6,852 persons) of inquirers were receiving medication assistance through the Pharmaceutical Assistance Program Clearinghouse. Among the 6,852 persons receiving assistance, a total of 44,349 medications were obtained.

## FREQUENTLY REQUESTED PROGRAM STATISTICS

The table below provides frequently requested Program information and lists references within the Annual Report for additional details.

<b>2009 PACE AND PACENET SUMMARY</b>			
	<b>PACE</b>	<b>PACENET</b>	<b>REFER TO:</b>
<b>DEMOGRAPHIC DATA</b>			
Total enrolled for 2009	152,419	193,781	Tables 4.2, A and B
% Participating	83.5%	80.0%	Tables 4.2, A and B
Avg. age for enrolled	79.4 yrs.	77.9 yrs.	Tables 4.2, A and B
Female, avg. age	80.0 yrs.	78.2 yrs.	
Male, avg. age	77.0 yrs.	77.3 yrs.	
% Female	80.1%	66.5%	Tables 4.2, A and B
% Own residence	54.1%	70.2%	Tables 4.2, A and B
% Rent	27.6%	18.7%	Tables 4.2, A and B
% Married	10.1%	40.4%	Tables 4.2, A and B
Avg. Income	\$11,808	\$21,369	Tables 4.2, A and B
% Cardholders in urban counties	42.0%	37.3%	Table 5.1
% Cardholders in rural counties	12.9%	13.6%	Table 5.1
<b>BENEFIT DATA</b>			
Avg. state share per enrolled cardholder	\$777	\$816	Tables 4.2, A and B
Avg. state share per participant	\$931	\$1,020	Tables 4.2, A and B
Avg. state share per copaid claim	\$22.65	\$29.50	Figure 2.1
2009 percent change in state share per claim	8.7% decrease	1.7% decrease	Figure 2.1, 2008 and 2009
Avg. claims per participant	41.1	38.6	Tables 4.2, A and B
Avg. number of therapeutic classes per participant	5.9	5.7	Tables 7.1, A and B
<b>UTILIZATION DATA (by date of payment)</b>			
Total claims	5,245,686	5,970,099	Tables 6.1 and 6.6
Avg. claims per cardholder	34.4	30.8	Tables 6.1 and 6.6
Avg. deductible claims per cardholder	-	7.9	Table 6.6
Avg. copaid claims per cardholder	-	22.9	Table 6.6
Generic utilization rate	64.3%	63.5%	Tables 6.2 and 6.6
<b>PAYMENT DATA</b>			
Total Program payout	\$118.46 M	\$158.05 M	Table 3.1
Avg. weekly Program payout	\$2.28 M	\$3.04 M	Table 3.1
Avg. annual Program payout per pharmacy	\$40,280	\$53,741	Tables 3.1 and 5.1
% Program payout to chain pharmacies	57.5%	58.6%	Tables 6.1 and 6.5



## **PENNSYLVANIA PHARMACEUTICAL ASSISTANCE CONTRACT FOR THE ELDERLY**

### **History**

The Pharmaceutical Assistance Contract for the Elderly (PACE) Program was enacted in November 1983, and implemented on July 1, 1984. Its purpose is to assist qualified state residents who are 65 years of age or older in paying for their prescription medications. The PACE legislation was amended in 1987 for reauthorization and, in 1992, for the manufacturers' rebate reauthorization and additional cost containment initiatives. The legislature expanded income eligibility for PACE on four occasions: 1985, 1991, 1996, and 2003. The 1996 legislation also created the PACE Needs Enhancement Tier (PACENET). In July 2001, Act 2001-77, the Pennsylvania Master Tobacco Settlement, increased PACENET income eligibility by \$1,000. Recognizing that the nominal increases in Social Security income were making enrollees ineligible for PACE, the legislature also created a limited PACE moratorium, effective January 1, 2001, until December 31, 2002, which permitted enrollees to remain in benefit even though their incomes exceeded the eligibility limits. Late in 2002, Act 2002-149 extended the moratorium for the PACE enrollment and expanded it to include the PACENET enrollment as well. While this moratorium expired on December 31, 2003, cardholders who were enrolled prior to the expiration, and had their eligibility periods extending into 2004, were permitted to remain in the Program until their eligibility end date.

In November 2003, Act 2003-37 enabled an unprecedented expansion for enrollment eligibility in the Programs, modified the \$500 annual PACENET deductible, and changed the PACE copay structure. The legislation raised the income limits for PACE to \$14,500 for individuals and \$17,700 for married couples; it boosted the income cap for PACENET to \$23,500 for single persons and to \$31,500 for married couples. With a \$480 deductible divided into monthly \$40 amounts, PACENET paid benefits after the first \$40 in prescription costs each month. Beginning in 2004, PACE and PACENET had a two-tiered prescription copayment structure. The PACE copayment became \$6 for generic drugs and \$9 for brand name products. The PACENET copayment remained at the original amounts of \$8 for generics and \$15 for brand name drugs. Act 37 required both Programs to adjust the copayments to reflect increasing drug prices over time.

Act 37 instituted federal upper limits (FUL) in the provider reimbursement formula and raised the dispensing fee fifty cents. The Program began to reimburse pharmacies the lesser of three prices: the Average Wholesale Price (AWP) minus 10%, plus a \$4.00 dispensing fee; the Usual and Customary charge to the cash-paying public; or, the most current FUL established in the Medicaid program, plus a \$4.00 dispensing fee. All payment methods include the subtraction of the cardholder's copayment.

The federal Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 created a new outpatient prescription drug benefit, Part D of Medicare. Prior to the full implementation of Medicare Part D and beginning in June 2004, low income, non-HMO, PACE enrollees (134,393 cardholders over 18 months) were auto-enrolled into the interim Medicare Drug Discount Card and Transitional Assistance Program. They received a discount card that allowed for \$600 per year in drug expenses in 2004 and again in 2005. Additional cardholders, estimated at 30,000, received this assistance through cards issued by their HMO. The PACE Program covered the Medicare drug card copayments for the auto-enrolled cardholders. The Medicare Transitional Assistance Program was a source of significant drug coverage for cardholders, with known savings in Program benefit payments of \$112 million for the auto-enrolled cardholders.

The Medicare Part D drug benefit began in January 2006. The PACE Program elected to be a qualified State Pharmacy Assistance Program which, along with the passage of state Act 111 in July 2006, allowed for the creation of PACE Plus Medicare. The successful launch of PACE Plus Medicare on September 1, 2006, saw thousands of cardholders take advantage of the features of both PACE and Medicare Part D. With the goal of providing seamless coverage, PACE Plus Medicare fills the coverage gaps encountered by cardholders in Medicare Part D, including deductibles, the doughnut hole phase, drugs excluded under MMA, drugs not in a plan's formulary, and copayment differentials between the Part D plan coverage and the PACE and PACENET copayments. PACE Plus pays the Medicare premiums for Part D coverage for PACE cardholders. Act 111 also eliminated the monthly deductible for PACENET cardholders. PACENET cardholders who choose to forego Part D coverage are now responsible for a monthly benchmark premium payment (\$32.59 in 2006; \$28.45 in 2007; \$26.59 in 2008; \$29.23 in 2009; \$32.09 in 2010; and, \$34.07 in 2011) to the Program. The benchmark premium payment remains lower than the prior \$40 per month deductible for the Program.

Act 111 recreated the PACE and PACENET moratoriums thereby permitting some 14,000 seniors to maintain their PACE or PACENET status despite disqualifying increases in their overall income due to Social Security cost-of-living increases. The PACE moratorium expired at the end of 2006; the PACENET moratorium continued through 2007. The Act revised provider reimbursement by adjusting the Average Wholesale Price formula from AWP minus 10% to AWP minus 12%, plus a \$4.00 dispensing fee.

Act 69 of 2008 recreated the PACE and PACENET moratoriums, thereby permitting 15,400 seniors to maintain their Program enrollment in 2010 despite disqualifying increases in their overall 2008 income due to Social Security cost-of-living increases.

PACE covers all medications requiring a prescription in the Commonwealth, as well as insulin, insulin syringes, and insulin needles, unless a manufacturer does not participate in the Manufacturers' Rebate Program. PACE does not cover experimental medications, medications for hair-loss or wrinkles, or any medication that can be purchased without a prescription. With appropriate documentation, PACE covers Drug Efficacy Study Implementation (DESI) medications. PACE requires generic substitution of brand multi-source products when an approved, Food and Drug Administration (FDA) A-rated generic is available. At the time of dispensing, a cardholder may encounter a prospective drug utilization review edit; PACE will not reimburse the prescription unless the pharmacist or physician documents the medical necessity for it. The Department of Aging recognizes the possibility of exceptional circumstances in connection with the application of therapeutic criteria and reimbursement edits. Appendix A contains a description of the PACE/PACENET medical exception process.

With the advent of PACE Plus, cardholders enrolled in Part D plans conform to the reimbursement limits established by the plans, some of which allow up to a ninety-day supply. Otherwise, cardholders not enrolled in a Part D Plan receive a thirty-day supply or 100 units (tablets or capsules) whichever is less. The Program guarantees reimbursement to the provider (including nearly 2,900 Pennsylvania pharmacies) within 21 days, paying interest on any unpaid balance after 21 days. Six types of providers dispense PACE/PACENET-funded prescriptions to cardholders. The majority of providers are either independent pharmacies or chain pharmacies. Other provider types include institutional pharmacies, nursing home pharmacies, mail order pharmacies, and dispensing physicians. All providers may offer mail order services if they are enrolled as a mail order pharmacy and if they follow specialized program requirements pertaining to record keeping and cardholder verification procedures.

Manufacturers for innovator products pay the Program a rebate similar to the federal “best price” Medicaid rebate. Generic manufacturers pay an 11% rebate based on the average manufacturer price (AMP). An inflation penalty applies to innovator products if annual price increases exceed the consumer price index. The inflation penalty rebate was discontinued for generic products at the end of 2006. Effective January 2010, the federal Medicaid flat rebate rate increased from 15.1% of the AMP to 23.1% and the generic rate increased from 11% to 13%.

### **Administration**

The Pennsylvania Department of Aging administers the PACE/PACENET Program. A contractor directly responsible to the Department assists in conducting many of the day-to-day operations. Four primary operation responsibilities of the Program are to process applications, reimburse providers for prescriptions, protect enrollees from adverse drug events, and obtain the most cost-efficient reimbursement possible for the Program. Administrative responsibilities include research and policy development, monitoring and evaluating operations and ensuring that the mandates of the Act and Program regulations are met. Activities in these areas include conducting audits of not only the providers, but also of the cardholders and the contracting agency. The Program routinely reviews medication utilization profiles of the cardholders and dispensing practices of the providers and physicians. The Department also evaluates the procedures used to implement the Program, identifies any trends which may be relevant for future administration, and carefully scrutinizes all expenditures.

The Department of Aging receives funds through restricted revenue accounts to serve as the administrative and fiscal agent for other Commonwealth-sponsored drug reimbursement programs. Pharmaceutical claims for the Chronic Renal Disease Program, Cystic Fibrosis Program, Spina Bifida Program, Metabolic Conditions Program, including Maple Syrup Urine Disease Program and the Phenylketonuria Program (all within the Department of Health), and the Special Pharmaceutical Benefits Program (Department of Public Welfare) are processed through the PACE/PACENET system. The program also adjudicates claims for two programs in the Department of Insurance, the Workers' Compensation Security Fund and the Pennsylvania Automobile Catastrophic Loss Benefits Continuation Fund. The PACE Program serves as the fiscal agent for the General Assistance Program (Department of Public Welfare), the Special Pharmaceutical Assistance Program, and the Chronic Renal Disease Program for the collection of rebates from pharmaceutical manufacturers.





# **SECTION 1**

# **PROGRAM RESEARCH HIGHLIGHTS**





## **HIGHLIGHTS OF CURRENT PACE/PACENET COLLABORATIVE RESEARCH AND EVALUATION PROJECTS (November 2010)**

### **TARGETING AND EMPOWERING PHYSICIANS TO AVERT INSTITUTIONALIZATION OF FRAIL ELDERLY (The PACE Program and the Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women's Hospital/Harvard Medical School)**

The Pennsylvania Department of Aging, in collaboration with the Harvard Medical School and the non-profit Independent Drug Information Service (iDiS) of Boston, uses trained drug education consultants to meet one-on-one with clinicians caring for a large number of patients enrolled in government-funded pharmacy programs. During these sessions, which began in 2005, the consultants provide objective, research-based information about the most effective drugs and non-medication therapeutic options for eight common chronic conditions. Beginning in 2008, the Department of Aging supported a parallel program in which consultants also began delivering three new educational modules to physicians who have high rates of nursing home admissions. These new modules focused on preventing the need for hospitalizations and institutionalizations due to cognitive impairment and associated behavioral problems, falls and mobility problems, and incontinence.

The falls and mobility module (661 office visits) reviews the risk factors for and consequences of falls; presents simple algorithms to screen for mobility problems and risk of falls in older, community dwelling patients; describes how to develop a targeted medical history and conduct an examination of persons at increased risk of falls; and reports on the community supports available to supplement physician interventions.

The cognitive impairment and associated behavioral problems module (682 visits) presents how to diagnose cognitive impairment and dementia in the elderly; defines an efficient diagnostic workup for finding treatable causes of memory loss; assesses drug treatment for cognitive impairment and its limitations; discusses how to respond to the behavioral problems in patients with dementia; and lists the adverse effects of drugs used in elderly patients with dementia, particularly the antipsychotics.

The module on incontinence (628 visits) includes practical strategies to screen for and diagnose urinary incontinence, and evaluates the available behavioral, pharmacological, and surgical approaches to its management.

Prior to the development of the long term living modules, insights gained from local area on agency interviews were added to the perspective of geriatricians and primary care physicians on the faculty at the Harvard Medical School, as well as the known, common problems which precipitate admission, especially preventable admission, of frail elderly into nursing homes. Taken together, this information helped identify the above three clinical areas which would be the most appropriate targets for the long term living focus in the academic detailing program.

For each topic in the academic detailing program, the iDiS staff developed print materials, trained the detailing staff and managed the intervention. The physician faculty determined the modules based upon common drugs used by and conditions affecting the elderly. For each module, drug educators distributed several different types of documents to physicians during face-to-face meetings including the following:

- comprehensive reviews of biomedical literature, known as evidence documents;

- distillations of key information to be used as the basis for the discussion between practitioner and the consultant, known as summary documents;
- patient or caregiver brochures that provide key information geared to the lay public, including resources for additional information and support;
- and, laminated, pocket-sized reference cards with tables for quick reference on treatment recommendations and drug efficacy.

In aggregate, these materials detail unbiased and balanced information useful to the physician, for example, which patient conditions warrant use of each drug, and clarify when more costly, brand-name drugs are more effective, and when less expensive generic or over-the-counter drugs may be equivalent or better. Materials can be found at [www.RxFacts.org](http://www.RxFacts.org).

Periodically, a survey measured physician satisfaction with the academic detailing visiting program. Elements receiving the highest agreement scores included:

“The program provides me with useful information about commonly used medications.”

“The content represents unbiased and balanced information about drugs.”

“My drug consultant is a well-informed source of evidence-based information about drugs I prescribe.”

“I would like to see this program continue.”

Drug consultants made nearly 2,000 visits in 2009, reaching a total number of visits of about 6,900 since October 2005.

Evaluation of two modules, non-steroidal anti-inflammatory drugs/coxib use and acid suppressing drugs, demonstrated that the program achieved significant reductions in the medications targeted.

### **TELEPHONE-BASED BEHAVIORAL HEALTH ASSESSMENT FOR SENIORS ON NEW PSYCHIATRIC MEDICATION (Behavioral Health Laboratory, University of Pennsylvania)**

Depression, anxiety, and dementia are prevalent in later life and lead to morbidity and disability, contributing to increased medical and nursing home service utilization and mortality. Many older adults who seek treatment for mental illness receive it in primary care, and nearly half of all antidepressants, sedatives, and hypnotics, as well as approximately 20% of all antipsychotics, are prescribed by primary care providers. An outcome of the effort to improve rates of treatment is the increased use of psychotropic medication, with increased use of medication for anxiety and depression in both primary care and specialty care. Recent findings question the value of antidepressants compared to placebo for mild to moderate depression severity. There is similar literature questioning the long term efficacy of anxiolytics for anxiety disorders or sleep disorders.

Results from the pilot program of care management services by the Behavioral Health Laboratory for PACE cardholders (begun in 2008) support the above concerns related to psychotropic medication prescribing in the elderly and also raise additional questions about off-label or inappropriate prescribing. Overall, 208 (47.4%) participants in the sample did not meet criteria for any mental health disorder, including 80 (55.9%) of those receiving anxiolytics. Just 6% met the criteria for anxiety disorders. The pilot found that older, community dwelling patients in the study received new psychotropic medications in excess of what might be expected based on their relatively low symptom burden. Many reported that the prescription was for a psychosocial stressor, while a number of others were unaware of the reason for the prescription.

The Behavioral Health Laboratory (BHL) has been effective in improving the management and treatment of mental health issues, which are closely linked to quality of life, morbidity, and mortality among older adults. The pilot study demonstrated the feasibility of delivering BHL services to PACE cardholders. The program is well suited to help reduce or delay the onset and progression of functional limitations, as well as provide information about and access to resources that enable independent living for longer periods of time.

As evidenced by the results, approximately 50% of cardholders are prescribed antidepressants or anxiolytics without significant evidence of a mental health disorder; however, they do report needs including social services, companionship, and managing low levels of distress, pain, or sleep complaints. There is room for an intervention, through psychosocial means, provider education, or collaborative care management, to reduce psychotropic prescribing in the PACE population, with the goals of minimizing risks from polypharmacy, as well as, leading to financial savings. Beginning in 2010, new project plans include an aggressive advertising campaign to a randomly selected group of primary care providers who treat a cluster of PACE cardholders to offer clinical telephone assessments to patients prior to initiating medication. The ad campaign would utilize direct-to-provider mailings, web assistance, and easy scheduling of an evaluation. The goal is to address the low level of symptoms through counseling and assistance with identified unmet physical and psychosocial needs, rather than prescribing medication, which has proven to be ineffective and associated with significant risks and costs in patients without significant disease. When primary care providers perceive patient distress and the telephone assessment reveals either a low level of symptoms or complaints that are not attributable to diagnosable psychiatric disorders, telephone-based interventions would be offered as a more appropriate alternative to pharmacotherapy. Recommendations for initiating medication would be reserved for patients reporting clinically significant mental health symptoms.

The clinical program has demonstrated an added value for cardholders and their prescribing physicians. New project aims include assigning individuals with clinically significant symptoms to minimal monitoring or monitoring with care management and social service support in order to determine whether the clinical services are impacting outcomes. Care management will include assessment and support for depression, sleep problems, anxiety, pain, and alcohol misuse.

For cardholders without significant symptoms, there are two aims: (1) a qualitative study of the individuals' understanding of the medication and their perceived benefit beyond the standard biomedical symptoms; (2) random assignment of individuals to monitoring alone or to monitoring combined with a discussion with the prescriber of continuing versus discontinuing the medication when symptoms are not present and addressing any other unmet needs.

Cardholders starting antipsychotics will receive an introductory letter that offers the possibility of caregiver support, given the high levels of impairment with this group. Individuals would be randomly assigned either to an initial assessment of symptoms and social needs with referral to appropriate community services or to the same level of service plus the telehealth educational program and continued monitoring of the individual for three months. The goal of this antipsychotic program component is to provide support and linkages to community-based services that address caregiver burden and promote successful management of the cardholder at home.

Over 18 months, approximately 1,000 older adults will enroll in the new program. Results from the pilot have been prepared for presentation and publication in 2010.

## **PREDICTORS AND HEALTH OUTCOMES OF MEDICATION ADHERENCE ACROSS MULTIPLE THERAPEUTIC CLASSES AMONG THE ELDERLY (The Medicine, Health, and Aging Project at Penn State University)**

Adherence to a medication regimen is generally defined as the extent to which patients take medications as prescribed by their health care provider. Medication non-adherence can reduce the effectiveness of any prescribed therapeutic regimen and may contribute to disease worsening, additional comorbidities, and death. The elderly are at high risk of medication non-adherence due to the likelihood of multiple chronic conditions for which medications are prescribed, such as hypertension, coronary artery disease, diabetes, and osteoporosis. Prior studies have identified predictors of medication non-adherence and have demonstrated adverse health outcomes associated with non-adherence. However, most prior work has focused on adherence within a single therapeutic class; few studies have examined medication adherence across multiple therapeutic classes. In order to gain a better understanding of the extent of non-adherence and its sequelae, this project examined adherence to multiple therapeutic classes and health outcomes associated with non-adherence in the PACE/PACENET population.

The primary goals of this research were to: 1) describe the prevalence of medication adherence/non-adherence within multiple commonly-used chronic therapeutic classes; 2) identify predictors of medication non-adherence across multiple therapeutic classes; and 3) evaluate the relationship between multiple class non-adherence and health outcomes.

Two studies were conducted to fulfill these research objectives. In Study 1, Descriptions of Medication Use and Factors Related to Medication Adherence, medication use status, medication adherence and medication-taking patterns for 15 therapeutic classes were described. Medication adherence levels were compared by demographic factors, therapeutic class, medication use patterns, medication use history, and specific measurement methods. The effects of potential predictors on medication non-adherence across multiple therapeutic classes were also assessed. In Study 2, Health Outcomes of Medication Non-Adherence, a cross-sectional study and a cohort study were conducted respectively to investigate the effects of medication non-adherence on hospitalization and mortality in a multiple therapeutic class setting.

The results of Study 1 showed that adherence rates for the 15 therapeutic classes ranged from 68% to 88%, and persistence rates ranged from 75% to 95%. The adherence rates for users of thyroid agents, calcium-channel blockers, and ARB/ACE medications were higher than those for other therapeutic classes. The adherence rates for users of oral antidiabetic drugs and other cardiovascular drugs fell in a second tier, followed by statins, Alzheimer's treatments, antidepressants, and proton pump inhibitors. Adherence rates were lowest for osteoporosis medications, overactive bladder medications, and diuretics. The results of Study 1 also suggest that race, medication use history, medication use pattern and specific therapeutic class were all significant predictors of medication non-adherence and non-persistence. For example, compared with other races, African-Americans were more likely to experience medication non-adherence and non-persistence. However, medication history and other demographic factors were also important predictors of non-adherence. The longer an older adult had used a medication, the more adherent or persistent the person was likely to be. While females and married persons generally had higher persistence rates, elderly with higher incomes in this sample were more likely to be non-persistent.

Results of Study 2 suggested an interaction effect between persistence and adherence level, as measured by the proportion of days covered (PDC). Results suggested that for persistent users, lower adherence levels were generally associated with a greater likelihood of

hospitalization, and higher mean numbers of hospitalization days. On the other hand, for non-persistent users, lower adherence levels were either unrelated to hospitalization and hospitalization days, or were associated with non-hospitalization and fewer hospitalization days, depending on the specific therapeutic class examined.

Study 2 also suggested significant relationships between non-persistence and all-cause mortality for ARB/ACE inhibitor medications (HR=1.39),  $\beta$ -blockers (HR=1.23), calcium-channel blockers (HR=1.15), statins (HR=1.29), overactive bladder drugs (HR=1.49) and thyroid agents (HR=1.56). The results also indicated a significant relationship between low adherence levels and mortality for  $\beta$ -blockers and cardiac glycosides, and barely significant relationships for oral antidiabetic drugs and osteoporosis medications.

In summary, this project provides important information regarding medication use patterns, prevalence of medication non-adherence, predictors of medication non-adherence, and health outcomes of medication non-adherence in a multiple medication class setting. In particular, this study identified several predictors for general medication non-adherence and demonstrated the independent effects of medication non-adherence for each therapeutic class on health outcomes. These results may help to guide the design of interventions aimed at improving medication adherence in the elderly. Results of this research have been published as a doctoral dissertation and will also be developed for scientific publication.

### **MEDICATION COMPREHENSION AND SAFETY IN OLDER ADULTS (Leonard Davis Institute of Health Economics, University of Pennsylvania School of Medicine)**

Medication adherence is a function of receiving, recalling and following instructions. Most research on medication errors emphasizes systems in hospital settings. However, out-of-hospital medication errors are more common. For community-dwelling patients, few systems exist to monitor drug administration and prevent medication errors at home. To understand medication-taking practices of older people in the community, this study surveyed nearly 5,000 cardholders who had filled a prescription for one of three drugs associated with a high risk of complications if not taken correctly: warfarin, digoxin, and phenytoin.

The results indicate that a substantial proportion of older adults do not recall receiving instructions on the use of their medications and do not take advantage of existing systems for organizing medications. In this study, 32% of subjects said that they had received no specific instructions about their medications, 35% said they had received instructions from their primary care provider, and 46% said they had received them from a pharmacist. The majority of patients who received instructions from their primary care provider received oral instructions, while the majority receiving instructions from a pharmacist received written instructions. New users were slightly more likely to report receiving instruction than chronic users. Patients on warfarin were more likely to report instructions than those on digoxin or phenytoin.

Only 24% reported being asked to bring in all of their medications to review with their physicians and 39% reported being asked about their use of over-the-counter and complementary therapies at their office visits.

Among warfarin users, 48% reported often or sometimes splitting their medication. This is especially disturbing given the fact that warfarin requires accurate dosing and even slight variations can increase risk of bleeding or clotting.

In terms of organizing medications, 54% of patients reported moving their medications from the pharmacy bottle to a pillbox with multiple compartments and filling the boxes themselves. However, 40% reported that they used no system at all.

The risk of warfarin-related hospitalizations is influenced by patient knowledge of medication instructions and by the number of medical and pharmaceutical care providers. A previous annual report reported findings from this study that indicated that patients receiving written instructions alone or written plus verbal instructions were associated with a reduced risk of bleeding events. The failure to report receiving instructions from health care providers does not necessarily mean that instructions were not given. However, if patients cannot recall receiving any instructions, it seems likely that even if instructions are being provided, the instructional system is inadequate.

These results point toward potential interventions that might reduce the risk of medication-related health problems in older people. Improved communication about safe medication use could be provided through physician offices or pharmacies, or through direct-to-patient education programs. Since the end of this study, Food and Drug Administration regulations require the distribution of a medication guide with all warfarin prescriptions. Medicare now provides a reimbursement mechanism for providers to counsel about medications. The Leonard Davis Institute released an Issue Brief in 2008 that summarizes this patient medication safety study ([www.upenn.edu./ldi](http://www.upenn.edu./ldi)).

### **ASSOCIATION BETWEEN STATIN USE AND INCIDENCE OF ATRIAL FIBRILLATION FOLLOWING HOSPITALIZATION FOR CORONARY ARTERY DISEASE (The Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women's Hospital/Harvard Medical School)**

This study demonstrated an association between statin use and a decrease in the incidence of atrial fibrillation (AF) after hospitalization for treatment of coronary artery disease. Evidence links inflammatory processes and AF. Research also suggests that statins possess antiarrhythmic properties and inhibit AF. This study sought to evaluate statin use and new onset AF by assembling data from the PACE Program, a similar program in New Jersey, and Medicare services data into a database of population-based medication use and health outcomes. Included in the database were the elements associated with hospitalizations for acute myocardial infarction or coronary revascularization from 1995 to 2004. The incidence of new AF was compared between two groups, those who were or were not prescribed statins within 1 month of hospital discharge after their cardiac event. Multivariable analysis controlling for demographic and clinical confounders indicated that statin use independently decreased the risk of developing new onset AF compared to nonusers. These findings lend support to the antiarrhythmic effects of statins and suggest another benefit for their use in patients with coronary artery disease, although a cause-and-effect relation was not confirmed. It is possible that the outcome of AF in this study represented a marker of coronary artery disease progression. However, most AF episodes in the study occurred in the community and did not require hospital admission, suggesting stability of patients' disease at the time of AF diagnosis. Analysis results were presented in *The American Journal of Cardiology* in 2010 ([www.AJConline.org](http://www.AJConline.org)).

**SECTION 2**

**FINANCIAL  
DATA  
BY DATE OF  
SERVICE**



**TABLE 2.1A  
HISTORICAL CLAIM AND EXPENDITURE DATA FOR PACE ENROLLED AND PARTICIPATING CARDHOLDERS  
BY SEMI-ANNUAL PERIOD BASED ON DATE OF SERVICE  
JANUARY 1991 - DECEMBER 2009**

SEMI-ANNUAL PERIOD	ENROLLED CARDHOLDERS	PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	CLAIMS PER		TOTAL EXPENDITURES	EXPENDITURES PER ENROLLED		EXPENDITURES PER PARTICIPATING		AVERAGE STATE SHARE PER CLAIM
				CARDHOLDER	PARTICIPATING CARDHOLDER		CARDHOLDER	CARDHOLDER	CARDHOLDER	CARDHOLDER	
JAN-JUN 1991	405,358	337,684	5,280,376	13.03	15.64	\$116,074,618	\$286.35	\$343.74	\$21.98		
JUL-DEC 1991	394,055	324,574	4,677,159	11.87	14.41	\$109,871,650	\$278.82	\$338.51	\$23.49		
JAN-JUN 1992	399,721	326,469	4,656,986	11.65	14.26	\$116,082,506	\$290.41	\$355.57	\$24.93		
JUL-DEC 1992	385,103	313,430	4,602,261	11.95	14.68	\$117,081,602	\$304.03	\$373.55	\$25.44		
JAN-JUN 1993	376,916	310,438	4,402,171	11.68	14.18	\$113,068,754	\$299.98	\$364.22	\$25.68		
JUL-DEC 1993	357,777	296,802	4,456,223	12.46	15.01	\$116,164,381	\$324.68	\$391.39	\$26.07		
JAN-JUN 1994	354,819	293,462	4,320,159	12.18	14.72	\$115,413,542	\$325.27	\$393.28	\$26.72		
JUL-DEC 1994	340,607	281,465	4,404,257	12.93	15.65	\$119,100,741	\$349.67	\$423.15	\$27.04		
JAN-JUN 1995	331,965	277,461	4,383,968	13.21	15.80	\$121,147,211	\$364.94	\$436.63	\$27.63		
JUL-DEC 1995	317,719	263,576	4,347,335	13.68	16.49	\$122,158,872	\$384.49	\$463.47	\$28.10		
JAN-JUN 1996	306,062	253,283	4,244,190	13.87	16.76	\$120,868,654	\$394.92	\$477.21	\$28.48		
JUL-DEC 1996	292,755	238,963	4,204,461	14.36	17.59	\$120,429,840	\$411.37	\$503.97	\$28.64		
JAN-JUN 1997	286,126	236,157	4,286,478	14.98	18.15	\$116,732,847	\$407.98	\$494.30	\$27.23		
JUL-DEC 1997	276,180	226,806	4,358,892	15.78	19.22	\$123,482,056	\$447.11	\$544.44	\$28.33		
JAN-JUN 1998	267,225	222,465	4,235,619	15.85	19.04	\$126,872,548	\$474.78	\$570.30	\$29.95		
JUL-DEC 1998	257,009	213,694	4,331,390	16.85	20.27	\$137,146,444	\$533.63	\$641.79	\$31.66		
JAN-JUN 1999	246,467	208,992	4,316,588	17.51	20.65	\$142,412,978	\$577.82	\$681.43	\$32.99		
JUL-DEC 1999	238,388	200,921	4,450,893	18.67	22.15	\$153,596,648	\$644.31	\$764.46	\$34.51		
JAN-JUN 2000	237,017	202,683	4,449,102	18.77	21.95	\$160,615,339	\$677.65	\$792.45	\$36.10		
JUL-DEC 2000	230,752	197,777	4,530,829	19.64	22.91	\$169,886,476	\$736.23	\$858.98	\$37.50		
JAN-JUN 2001	225,325	197,082	4,558,339	20.23	23.13	\$178,650,979	\$792.86	\$906.48	\$39.19		
JUL-DEC 2001	218,576	190,540	4,590,216	21.00	24.09	\$187,820,534	\$859.29	\$985.73	\$40.92		
JAN-JUN 2002	216,719	190,131	4,558,000	21.03	23.97	\$194,788,889	\$898.81	\$1,024.50	\$42.74		
JUL-DEC 2002	209,737	183,318	4,605,906	21.96	25.13	\$203,591,448	\$970.70	\$1,110.59	\$44.20		
JAN-JUN 2003	209,761	182,654	4,552,662	21.70	24.93	\$208,103,630	\$992.10	\$1,139.33	\$45.71		
JUL-DEC 2003	207,144	180,460	4,683,173	22.61	25.95	\$221,512,877	\$1,069.37	\$1,227.49	\$47.30		
JAN-JUN 2004	215,486	189,762	4,675,699	21.70	24.64	\$209,731,950	\$973.30	\$1,105.24	\$44.86		

**TABLE 2.1A  
HISTORICAL CLAIM AND EXPENDITURE DATA FOR PACE ENROLLED AND PARTICIPATING CARDHOLDERS  
BY SEMI-ANNUAL PERIOD BASED ON DATE OF SERVICE  
JANUARY 1991 - DECEMBER 2009**

SEMI-ANNUAL PERIOD	ENROLLED CARDHOLDERS	PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	CLAIMS PER		TOTAL EXPENDITURES	EXPENDITURES		AVERAGE STATE SHARE PER CLAIM
				ENROLLED CARDHOLDER	PARTICIPATING CARDHOLDER		PER ENROLLED CARDHOLDER	PER PARTICIPATING CARDHOLDER	
JUL-DEC 2004	209,237	183,970	4,639,594	22.17	25.22	\$178,165,448	\$851.50	\$968.45	\$38.40
JAN-JUN 2005	209,512	182,450	4,602,802	21.97	25.23	\$166,496,079	\$794.69	\$912.56	\$36.17
JUL-DEC 2005	203,956	177,667	4,628,809	22.70	26.05	\$208,631,707	\$1,022.93	\$1,174.29	\$45.07
JAN-JUN 2006	199,426	172,092	4,482,461	22.48	26.05	\$196,369,222	\$984.67	\$1,141.07	\$43.81
JUL-DEC 2006	194,884	164,174	4,071,755	20.89	24.80	\$126,433,882	\$648.76	\$770.12	\$31.05
JAN-JUN 2007	203,104	167,796	3,619,456	17.82	21.57	\$81,202,595	\$399.81	\$483.94	\$22.44
JUL-DEC 2007	183,839	150,273	3,487,882	18.97	23.21	\$98,984,305	\$538.43	\$658.70	\$28.38
JAN-JUN 2008	164,728	133,656	3,014,596	18.30	22.55	\$70,096,781	\$425.53	\$524.46	\$23.25
JUL-DEC 2008	160,802	125,319	2,878,017	17.90	22.97	\$76,070,500	\$473.07	\$607.01	\$26.43
JAN-JUN 2009	145,634	119,773	2,682,436	18.42	22.40	\$55,426,889	\$380.59	\$462.77	\$20.66
JUL-DEC 2009	141,988	114,169	2,546,781	17.94	22.31	\$63,035,614	\$443.95	\$552.13	\$24.75

20

SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY

NOTES: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS.  
ENROLLED CARDHOLDERS ARE THOSE ENROLLED FOR ANY PORTION OF THE REPORTED PERIOD.  
PARTICIPATING CARDHOLDERS ARE CARDHOLDERS WITH ONE OR MORE APPROVED CLAIMS DURING THE REPORTED PERIOD.


**TABLE 2.1B**  
**HISTORICAL CLAIM AND EXPENDITURE DATA FOR PACENET ENROLLED AND PARTICIPATING CARDHOLDERS**  
**BY SEMI-ANNUAL PERIOD BASED ON DATE OF SERVICE**  
**JULY 1996 - DECEMBER 2009**

<u>SEMI-ANNUAL PERIOD</u>	<u>ENROLLED CARDHOLDERS</u>	<u>PARTICI-PATING CARDHOLDERS</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER</u>		<u>TOTAL EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>	<u>EXPENDITURES PER PARTICIPATING CARDHOLDER</u>	<u>AVERAGE STATE SHARE PER CLAIM</u>
				<u>ENROLLED CARDHOLDER</u>	<u>PARTICI-PATING CARDHOLDER</u>				
JUL-DEC 1996	1,523	740	2,331	1.53	3.15	\$823	\$0.54	\$1.11	\$0.35
JAN-JUN 1997	9,063	6,369	75,721	8.35	11.89	\$592,426	\$65.37	\$93.02	\$7.82
JUL-DEC 1997	12,523	9,007	149,187	11.91	16.56	\$2,676,259	\$213.71	\$297.13	\$17.94
JAN-JUN 1998	18,053	12,683	175,085	9.70	13.80	\$2,909,397	\$161.16	\$229.39	\$16.62
JUL-DEC 1998	18,673	13,804	232,846	12.47	16.87	\$4,738,127	\$253.74	\$343.24	\$20.35
JAN-JUN 1999	22,272	16,649	263,010	11.81	15.80	\$5,519,395	\$247.82	\$331.52	\$20.99
JUL-DEC 1999	22,187	16,885	309,280	13.94	18.32	\$7,416,866	\$334.29	\$439.26	\$23.98
JAN-JUN 2000	25,739	19,762	339,481	13.19	17.18	\$8,371,658	\$325.25	\$423.62	\$24.66
JUL-DEC 2000	25,446	19,630	381,074	14.98	19.41	\$10,193,859	\$400.61	\$519.30	\$26.75
JAN-JUN 2001	29,522	22,146	412,077	13.96	18.61	\$11,255,086	\$381.24	\$508.22	\$27.31
JUL-DEC 2001	29,278	23,284	477,954	16.32	20.53	\$13,849,683	\$473.04	\$594.82	\$28.98
JAN-JUN 2002	35,508	27,594	540,878	15.23	19.60	\$16,333,097	\$459.98	\$591.91	\$30.20
JUL-DEC 2002	36,146	28,611	613,528	16.97	21.44	\$20,069,086	\$555.22	\$701.45	\$32.71
JAN-JUN 2003	39,263	31,011	644,800	16.42	20.79	\$21,627,367	\$550.83	\$697.41	\$33.54
JUL-DEC 2003	40,148	31,869	720,687	17.95	22.61	\$25,653,456	\$638.97	\$804.97	\$35.60
JAN-JUN 2004	93,861	72,605	1,305,266	13.91	17.98	\$48,958,319	\$521.60	\$674.31	\$37.51
JUL-DEC 2004	105,018	82,631	1,921,310	18.30	23.25	\$71,800,234	\$683.69	\$868.93	\$37.37
JAN-JUN 2005	123,399	94,979	2,176,264	17.64	22.91	\$81,372,126	\$659.42	\$856.74	\$37.39
JUL-DEC 2005	125,108	99,242	2,450,953	19.59	24.70	\$96,448,835	\$770.92	\$971.86	\$39.35
JAN-JUN 2006	134,715	108,462	2,708,710	20.11	24.97	\$100,473,823	\$745.83	\$926.35	\$37.09
JUL-DEC 2006	141,099	109,867	2,684,515	19.03	24.43	\$77,093,600	\$546.38	\$701.70	\$28.72
JAN-JUN 2007	162,966	127,001	2,630,629	16.14	20.71	\$59,094,943	\$362.62	\$465.31	\$22.46
JUL-DEC 2007	147,627	116,369	2,687,888	18.21	23.10	\$85,506,499	\$579.21	\$734.79	\$31.81
JAN-JUN 2008	176,161	136,910	2,950,988	16.75	21.55	\$68,072,714	\$386.42	\$497.21	\$23.07
JUL-DEC 2008	182,452	137,834	3,078,477	16.87	22.33	\$89,908,365	\$492.78	\$652.29	\$29.21
JAN-JUN 2009	177,553	140,328	2,963,530	16.69	21.12	\$66,833,671	\$376.42	\$476.27	\$22.55
JUL-DEC 2009	184,291	141,689	3,023,686	16.41	21.34	\$91,218,108	\$494.97	\$643.79	\$30.17

SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY


NOTES: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF SERVICE. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS. ENROLLED CARDHOLDERS ARE THOSE ENROLLED FOR ANY PORTION OF THE REPORTED PERIOD. PARTICIPATING CARDHOLDERS ARE CARDHOLDERS WITH ONE OR MORE APPROVED CLAIMS DURING THE REPORTED PERIOD.

**FIGURE 2.1**  
**PACE AND PACENET CLAIM DISTRIBUTION BY AMOUNT PAID PER CLAIM**  
**JANUARY - DECEMBER 2009**  
**(PACE N = 5,229,217; PACENET N = 4,466,438)**




SOURCE: PDA/CLAIMS HISTORY  
 NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET DEDUCTIBLE CLAIMS.

**FIGURE 2.2**  
**DISTRIBUTION OF PACE ANNUAL BENEFIT**  
**JANUARY - DECEMBER 2009**  
**N = 152,419**



SOURCE: PDA/CLAIMS HISTORY  
 NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS.

**FIGURE 2.3**  
**DISTRIBUTION OF PACENET ANNUAL BENEFIT**  
**JANUARY - DECEMBER 2009**  
**N = 193,781**




SOURCE: PDA/CLAIMS HISTORY  
 NOTE: DATA INCLUDE PACENET ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACE CLAIMS.

**TABLE 2.2**  
**PACE AND PACENET TOTAL PRESCRIPTION COST, EXPENDITURES, OFFSETS AND RECOVERIES**  
**JANUARY - DECEMBER 2009**

EXPENDITURES, RECOVERIES, OFFSETS	JAN - JUN	JUL - DEC	CY 2009	% OF TOTAL GROSS EXPENDITURES
<b>TOTAL PRESCRIPTION COST</b>	<b>\$ 360,309,460</b>	<b>\$ 366,425,660</b>	<b>\$ 726,735,120</b>	
<b>MEDICARE PART D PREMIUMS</b>	<b>15,261,572</b>	<b>24,461,280</b>	<b>39,722,852</b>	
<b>GROSS CLAIMS/PREMIUMS SUBTOTAL</b>	<b>375,571,032</b>	<b>390,886,940</b>	<b>766,457,972</b>	<b>97.2%</b>
<b>FHS CONTRACT</b>				
<b>OPERATIONS</b>	<b>7,032,825</b>	<b>7,998,090</b>	<b>15,030,915</b>	
<b>SPECIAL CLAIMS</b>	<b>1,093</b>	<b>550</b>	<b>1,643</b>	
<b>GROSS CONTRACT SUBTOTAL</b>	<b>7,033,918</b>	<b>7,998,640</b>	<b>15,032,558</b>	<b>1.9%</b>
<b>PDA ADMINISTRATION</b>				
<b>PERSONNEL</b>	<b>416,450</b>	<b>424,205</b>	<b>840,655</b>	
<b>OPERATIONS</b>	<b>46,000</b>	<b>46,698</b>	<b>92,698</b>	
<b>GROSS PDA ADMIN. SUBTOTAL</b>	<b>462,450</b>	<b>470,903</b>	<b>933,353</b>	<b>0.1%</b>
<b>OTHER ADMINISTRATION</b>				
<b>AUDITS</b>	<b>315,000</b>	<b>265,458</b>	<b>580,458</b>	
<b>MEDICAL ADVISOR</b>	<b>4,525</b>	<b>2,751</b>	<b>7,276</b>	
<b>THIRD PARTY RECOVERY</b>	<b>259,606</b>	<b>444,941</b>	<b>704,547</b>	
<b>GROSS OTHER ADMIN. SUBTOTAL</b>	<b>579,131</b>	<b>713,150</b>	<b>1,292,281</b>	<b>0.2%</b>
<b>BEHAVIORAL HEALTH INTERVENTIONS</b>	<b>301,814</b>	<b>178,398</b>	<b>480,212</b>	<b>0.1%</b>
<b>ENROLLMENT OUTREACH</b>	<b>1,678,583</b>	<b>1,238,237</b>	<b>2,916,820</b>	<b>0.4%</b>
<b>PRESCRIBER EDUCATION</b>	<b>750,167</b>	<b>664,434</b>	<b>1,414,601</b>	<b>0.2%</b>
<b>GROSS EXPENDITURES</b>	<b>386,377,095</b>	<b>402,150,702</b>	<b>788,527,797</b>	<b>100.0%</b>
<b>PRESCRIPTION COST OFFSETS</b>				
<b>PART D/OTHER PAYER OFFSETS</b>	<b>(188,434,876)</b>	<b>(164,956,736)</b>	<b>(353,391,612)</b>	<b>-44.8%</b>
<b>CARDHOLDER COPAYMENTS</b>	<b>(49,091,796)</b>	<b>(47,250,170)</b>	<b>(96,341,966)</b>	<b>-12.2%</b>
<b>TOTAL OFFSETS</b>	<b>(237,526,672)</b>	<b>(212,206,906)</b>	<b>(449,733,578)</b>	<b>-57.0%</b>
<b>RECOVERIES</b>				
<b>MANUFACTURER REBATES</b>	<b>(28,861,335)</b>	<b>(30,003,736)</b>	<b>(58,865,071)</b>	
<b>INCOME VERIFICATION / REVENUE MATCH</b>	<b>-</b>	<b>(3,477)</b>	<b>(3,477)</b>	
<b>ATTORNEY GENERAL COLLECTIONS</b>	<b>(1,440)</b>	<b>-</b>	<b>(1,440)</b>	
<b>THIRD-PARTY REIMBURSEMENTS</b>	<b>(6,479,692)</b>	<b>(10,829,777)</b>	<b>(17,309,469)</b>	
<b>COMBINED RECOVERIES</b>	<b>(35,342,467)</b>	<b>(40,836,990)</b>	<b>(76,179,457)</b>	
<b>PRIOR YEARS' REBATE REFUNDS</b>	<b>603,989</b>	<b>112,275</b>	<b>716,264</b>	
<b>NET RECOVERIES</b>	<b>(34,738,478)</b>	<b>(40,724,715)</b>	<b>(75,463,193)</b>	<b>-9.6%</b>
<b>NET EXPENDITURES</b>				
<b>STATE SHARE BEFORE RECOVERIES</b>	<b>122,782,788</b>	<b>154,218,754</b>	<b>277,001,542</b>	<b>35.1%</b>
<b>STATE SHARE AFTER RECOVERIES</b>	<b>88,044,310</b>	<b>113,494,039</b>	<b>201,538,349</b>	<b>25.6%</b>
<b>NET STATE SHARE SHARE EXPENDITURES</b>				
<b>AFTER OFFSETS AND RECOVERIES</b>	<b>\$ 114,111,945</b>	<b>\$ 149,219,081</b>	<b>\$ 263,331,026</b>	<b>33.4%</b>

NOTES: TABLE USES SAS201 REPORT FOR PRESCRIPTION COST DISTRIBUTION.  
REBATES (\$58.9 M) ARE 21.3% OF TOTAL STATE SHARE PRESCRIPTION DRUG COST (\$277.0 M).  
TOTAL PRESCRIPTION COST DOES NOT INCLUDE CLAIMS PROCESSED SOLELY BY THIRD PARTY COVERAGE.


**FIGURE 2.4**  
**PACE AND PACENET ENROLLMENT, CLAIMS, AND CLAIMS EXPENDITURES**  
**BY CALENDAR YEAR**  
**1988-2009**



Source: PACE Biannual Reports, 1988-1995; PACE Annual Reports, 1996-2009.


Notes: Enrollment figures represent the number of enrolled cardholders at the end of each reported calendar year. Recoveries include third party payments, manufacturers' rebate, and restitutions.

**FIGURE 2.5A**  
**PACE TOTAL ENROLLED AND PARTICIPATING CARDHOLDERS BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: END-OF-MONTH PACE ENROLLED TAKEN FROM MR-0-01A REPORT, PARTICIPATING TAKEN FROM CLAIMS HISTORY BASED ON DATE OF SERVICE

**FIGURE 2.5B**  
**PACENET TOTAL ENROLLED AND PARTICIPATING CARDHOLDERS BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: END-OF-MONTH PACE ENROLLED TAKEN FROM MR-0-01A REPORT, PARTICIPATING TAKEN FROM CLAIMS HISTORY BASED ON DATE OF SERVICE

**FIGURE 2.6A**  
**AVERAGE PRESCRIPTIONS PER PARTICIPATING PACE CARDHOLDER BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: PACE CLAIMS HISTORY (INCLUDES PACE PAID, ORIGINAL CLAIMS; EXCLUDES PACENET CLAIMS)  
 NOTE: PARTICIPATING CARDHOLDERS INCLUDE THOSE WITH ONE OR MORE CLAIMS IN A GIVEN MONTH, BASED ON DATE OF SERVICE.

**FIGURE 2.6B**  
**AVERAGE PRESCRIPTIONS PER PARTICIPATING PACENET CARDHOLDER BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: PACENET CLAIMS HISTORY (INCLUDES PACENET PAID, ORIGINAL CLAIMS; EXCLUDES PACE CLAIMS)  
 NOTE: PARTICIPATING CARDHOLDERS INCLUDE THOSE WITH ONE OR MORE CLAIMS IN A GIVEN MONTH, BASED ON DATE OF SERVICE.

**FIGURE 2.7A**  
**PACE AVERAGE STATE SHARE PER CLAIM BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: PACE CLAIMS HISTORY  
 NOTE: INCLUDES PAID; ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACENET CLAIMS.

**FIGURE 2.7B**  
**PACENET AVERAGE STATE SHARE PER COPAID CLAIM BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: PACENET CLAIMS HISTORY  
 NOTE: INCLUDES ONLY PACENET COPAID, ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACENET DEDUCTIBLE AND PACE CLAIMS.

**FIGURE 2.8A**  
**TOTAL PACE EXPENDITURE BY MONTH**  
**JANUARY 1999 - JANUARY 2010**




SOURCE: PACE CLAIMS HISTORY  
 NOTE: INCLUDES PAID, ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACENET CLAIMS.

**FIGURE 2.8B**  
**TOTAL PACENET EXPENDITURE BY MONTH**  
**JANUARY 1999 - JANUARY 2010**



SOURCE: PACENET CLAIMS HISTORY  
 NOTE: INCLUDES PACENET PAID; ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACE CLAIMS.

**FIGURE 2.9**  
**PACE AVERAGE WHOLESAL PRICE (AWP) AND AVERAGE MANUFACTURER'S PRICE (AMP)\***  
**BY QUARTER**  
**JANUARY 1997 - DECEMBER 2009**



\* DATA INCLUDE CLAIMS FOR NDC'S FOR WHICH REBATE AMP DATA ARE AVAILABLE FOR ANY QUARTER IN 1998-2009.  
 SOURCE: PACE CLAIMS HISTORY AND MANUFACTURERS' REBATE HISTORY



**SECTION 3**

**PROGRAM DATA  
BY DATE OF  
PAYMENT**



**TABLE 3.1**  
**PACE AND PACENET CLAIMS AND EXPENDITURES PAID BY FISCAL YEAR**  
**JULY 1984 - DECEMBER 2009**

SEMI-ANNUAL PERIOD	NUMBER OF WEEKS	PACE		AVERAGE STATE SHARE PER PROCESSED CLAIM *	NUMBER OF PROCESSED CLAIMS	PACENET		AVERAGE STATE SHARE PER PROCESSED CLAIM **
		NUMBER OF PROCESSED CLAIMS	EXPENDITURES			EXPENDITURES		
JUL-DEC 1984	26	2,101,419	\$20,714,685	\$9.86				
JAN-JUN 1985	26	3,475,440	\$36,579,102	\$10.53				
1 <sup>st</sup> YEAR TOTAL		5,576,859	\$57,293,787	\$10.27				
JUL-DEC 1985	26	4,372,468	\$50,616,334	\$11.58				
JAN-JUN 1986	26	4,966,536	\$61,368,193	\$12.36				
2 <sup>nd</sup> YEAR TOTAL		9,339,004	\$111,984,527	\$11.99				
JUL-DEC 1986	26	5,237,141	\$68,786,114	\$13.13				
JAN-JUN 1987	26	5,257,747	\$72,761,148	\$13.84				
3 <sup>rd</sup> YEAR TOTAL		10,494,888	\$141,547,262	\$13.49				
JUL-DEC 1987	27	5,515,827	\$80,237,477	\$14.55				
JAN-JUN 1988	25	5,440,743	\$84,469,697	\$15.53				
4 <sup>th</sup> YEAR TOTAL		10,956,570	\$164,707,174	\$15.03				
JUL-DEC 1988	27	6,055,327	\$99,192,197	\$16.38				
JAN-JUN 1989	26	5,937,088	\$103,781,619	\$17.48				
5 <sup>th</sup> YEAR TOTAL		11,992,415	\$202,973,816	\$16.93				
JUL-DEC 1989	26	5,709,497	\$106,600,899	\$18.67				
JAN-JUN 1990	26	5,544,295	\$110,848,137	\$19.99				
6 <sup>th</sup> YEAR TOTAL		11,253,792	\$217,449,036	\$19.32				
JUL-DEC 1990	26	5,352,797	\$112,293,188	\$20.98				
JAN-JUN 1991	26	5,453,044	\$117,814,625	\$21.61				
7 <sup>th</sup> YEAR TOTAL		10,805,841	\$230,107,813	\$21.29				
JUL-DEC 1991	26	5,073,452	\$115,304,410	\$22.73				
JAN-JUN 1992	26	4,816,750	\$115,596,910	\$24.00				
8 <sup>th</sup> YEAR TOTAL		9,890,202	\$230,901,320	\$23.35				
JUL-DEC 1992	26	4,724,142	\$115,980,339	\$24.55				
JAN-JUN 1993	26	4,403,096	\$108,876,491	\$24.73				
9 <sup>th</sup> YEAR TOTAL		9,127,238	\$224,856,830	\$24.64				
JUL-DEC 1993	26	4,729,097	\$118,778,523	\$25.12				
JAN-JUN 1994	26	4,341,896	\$111,401,456	\$25.66				
10 <sup>th</sup> YEAR TOTAL		9,070,993	\$230,179,979	\$25.38				
JUL-DEC 1994	26	4,721,702	\$122,294,905	\$25.90				
JAN-JUN 1995	27	4,228,653	\$111,136,630	\$26.28				
11 <sup>th</sup> YEAR TOTAL		8,950,355	\$233,431,535	\$26.08				
JUL-DEC 1995	26	4,895,160	\$131,701,547	\$26.90				
JAN-JUN 1996	26	4,443,096	\$121,066,818	\$27.25				
12 <sup>th</sup> YEAR TOTAL		9,338,256	\$252,768,365	\$27.07				
JUL-DEC 1996	26	4,334,551	\$119,612,179	\$27.60	540	\$23	\$0.04	
JAN-JUN 1997	26	4,523,225	\$116,697,725	\$25.80	74,647	\$586,350	\$7.85	
13 <sup>th</sup> YEAR TOTAL		8,857,776	\$236,309,904	\$26.68	75,187	\$586,373	\$7.80	
JUL-DEC 1997	26	4,546,360	\$121,880,844	\$26.81	150,263	\$2,680,675	\$17.84	
JAN-JUN 1998	26	4,497,031	\$126,776,785	\$28.19	171,797	\$2,860,833	\$16.65	
14 <sup>th</sup> YEAR TOTAL		9,043,391	\$248,657,629	\$27.50	322,060	\$5,541,508	\$17.21	
JUL-DEC 1998	26	4,504,394	\$134,229,706	\$29.80	233,277	\$4,737,561	\$20.31	
JAN-JUN 1999	26	4,220,448	\$139,246,165	\$32.99	256,109	\$5,410,383	\$21.13	
15 <sup>th</sup> YEAR TOTAL		8,724,842	\$273,475,871	\$31.34	489,386	\$10,147,944	\$20.74	

**TABLE 3.1**  
**PACE AND PACENET CLAIMS AND EXPENDITURES PAID BY FISCAL YEAR**  
**JULY 1984 - DECEMBER 2009**

SEMI-ANNUAL PERIOD	NUMBER OF WEEKS	PACE		AVERAGE STATE SHARE PER PROCESSED CLAIM *	NUMBER OF PROCESSED CLAIMS	PACENET		AVERAGE STATE SHARE PER PROCESSED CLAIM **
		NUMBER OF PROCESSED CLAIMS	EXPENDITURES			EXPENDITURES		
JUL-DEC 1999	26	4,456,680	\$153,781,999	\$34.51	310,165	\$7,421,422	\$23.93	
JAN-JUN 2000	26	4,453,977	\$160,846,800	\$36.11	339,250	\$8,389,295	\$24.73	
16 <sup>th</sup> YEAR TOTAL		8,910,657	\$314,628,799	\$35.31	649,415	\$15,810,717	\$24.35	
JUL-DEC 2000	26	4,538,814	\$170,118,213	\$37.48	382,379	\$10,200,170	\$26.68	
JAN-JUN 2001	26	4,536,651	\$177,830,053	\$39.20	420,529	\$11,319,858	\$26.92	
17 <sup>th</sup> YEAR TOTAL		9,075,465	\$347,948,266	\$38.34	802,908	\$21,520,028	\$26.80	
JUL-DEC 2001	26	4,635,934	\$189,489,307	\$40.87	480,559	\$13,924,106	\$28.97	
JAN-JUN 2002	26	4,554,962	\$194,745,251	\$42.75	542,321	\$16,348,022	\$30.14	
18 <sup>th</sup> YEAR TOTAL		9,190,896	\$384,234,558	\$41.81	1,022,880	\$30,272,128	\$29.59	
JUL-DEC 2002	26	4,615,282	\$203,947,092	\$44.19	615,169	\$20,100,929	\$32.68	
JAN-JUN 2003	26	4,554,809	\$208,208,623	\$45.71	644,320	\$21,608,906	\$33.54	
19 <sup>th</sup> YEAR TOTAL		9,170,091	\$412,155,715	\$44.95	1,259,489	\$41,709,835	\$33.12	
JUL-DEC 2003	26	4,688,095	\$221,734,037	\$47.30	722,537	\$25,698,628	\$35.57	
JAN-JUN 2004	26	4,581,399	\$205,908,844	\$44.94	1,268,014	\$47,385,206	\$37.37	
20 <sup>th</sup> YEAR TOTAL		9,269,494	\$427,642,881	\$46.13	1,990,551	\$73,083,834	\$36.72	
JUL-DEC 2004	26	4,646,945	\$178,347,082	\$38.38	1,922,663	\$71,852,034	\$37.37	
JAN-JUN 2005	26	4,613,122	\$166,886,748	\$36.18	2,178,944	\$81,479,300	\$37.39	
21 <sup>st</sup> YEAR TOTAL		9,260,067	\$345,233,830	\$37.28	4,101,607	\$153,331,334	\$37.38	
JUL-DEC 2005	26	4,632,516	\$208,781,508	\$45.07	2,451,200	\$96,468,947	\$39.36	
JAN-JUN 2006	26	4,484,886	\$196,409,910	\$43.79	2,708,585	\$100,489,805	\$37.10	
22 <sup>nd</sup> YEAR TOTAL		9,117,402	\$405,191,418	\$44.44	5,159,785	\$196,958,752	\$38.17	
JUL-DEC 2006	26	4,074,738	\$126,753,319	\$31.11	2,686,230	\$77,256,980	\$28.76	
JAN-JUN 2007	26	3,642,398	\$82,054,486	\$22.53	2,633,012	\$59,270,762	\$22.51	
23 <sup>rd</sup> YEAR TOTAL		7,717,136	\$208,807,805	\$27.06	5,319,242	\$136,527,742	\$25.67	
JUL-DEC 2007	26	3,491,014	\$99,077,033	\$28.38	2,688,584	\$85,271,656	\$31.72	
JAN-JUN 2008	26	3,015,416	\$70,145,582	\$23.26	2,947,413	\$67,641,825	\$22.95	
24 <sup>th</sup> YEAR TOTAL		6,506,430	\$169,222,615	\$26.01	5,635,997	\$152,913,481	\$27.13	
JUL-DEC 2008	26	2,882,322	\$76,213,073	\$26.44	3,082,226	\$89,890,137	\$29.16	
JAN-JUN 2009	26	2,682,436	\$55,426,889	\$20.66	2,963,530	\$66,833,671	\$22.55	
25 <sup>th</sup> YEAR TOTAL		5,564,758	\$131,639,962	\$23.66	6,045,756	\$156,723,808	\$25.92	
JUL-DEC 2009	26	\$2,546,781	\$63,035,614	\$24.75	3,023,686	\$91,218,108	\$30.17	
26 <sup>th</sup> YEAR-TO-DATE TOTAL		\$2,546,781	\$63,035,614	\$24.75	3,023,686	\$91,218,108	\$30.17	
CUMULATIVE TOTAL		229,751,599	\$6,266,386,311	\$27.27	35,897,949	\$1,086,345,591	\$30.26	

\* The State Share is the amount paid by the PACE Program for each claim. The State Share per processed claim does not reflect rebates from manufacturers, recoupments from insurance carriers, or audit disallowances received from providers and enrollees. The number of claims includes all original, debit, credit and void claims. Some claims, therefore, do not have a payment associated with them. The State Share per original, paid claim would be higher than the values shown on this table.

**Reimbursement formulas for PACE:**

**July 1, 1984 - June 1985:** The lesser of either the Average Wholesale Price (AWP) plus a \$2.50 dispensing fee or the Usual and Customary Charge (U&C), then subtracting a \$4.00 cardholder payment.

**July 1, 1985 - June 1991:** The lesser of either the Average Wholesale Price (AWP) plus a \$2.75 dispensing fee or the Usual and Customary Charge (U&C), then subtracting a \$4.00 cardholder payment.

**July 1, 1991 - November 21, 1996:** Same as above with copayment increased to \$6.00.

**November 22, 1996 - December 31, 2003:** The lesser of either the AWP minus 10% plus a \$3.50 dispensing fee, or the U&C, then subtracting a \$6.00 copayment.

**TABLE 3.1**  
**PACE AND PACENET CLAIMS AND EXPENDITURES PAID BY FISCAL YEAR**  
**JULY 1984 - DECEMBER 2009**

***Reimbursement formulas for PACE (continued):***

**January 1, 2004 - July 9, 2006:** The lesser of either AWP minus 10% plus a \$4.00 dispensing fee, or the U&C, or the Federal Upper Limit for generic product plus a \$4.00 dispensing fee, then subtracting a copayment of \$6.00 for generics and \$9.00 for brand products. The copayment can be adjusted annually.

**July 10, 2006 - Present:** The lesser of either AWP minus 12% plus a \$4.00 dispensing fee, or the U&C, or the Federal Upper Limit for a generic product plus a \$4.00 dispensing fee, then subtracting a copayment of \$6.00 for generics and \$9.00 for brand products. The copayment can be adjusted annually.

**June 2004 - December 2005:** Average PACE state share per claim reflects additional savings from the Transitional Assistance benefit for Medicare Discount Program cardholders.

**June 2004 - December 2009:** Average state share per claim reflects savings from Medicare Part D.

\*\* The State Share is the amount paid by the PACENET Program for each claim in the copayment phase. The State Share per processed claim does not reflect rebates from manufacturers, recoupments from insurance carriers, or audit disallowances received from providers and enrollees. The number of processed claims includes claims in the copay and deductible phases. Therefore, the State Share per copay phase claim would be higher than the values shown on this table.

***Reimbursement formulas for PACENET:***

**November 22, 1996 - December 31, 2003:** The lesser of either AWP minus 10% plus a \$3.50 dispensing fee, or the U&C, then subtracting a copayment of \$8.00 for generics and \$15 for brand products.

**January 1, 2004 - July 9, 2006:** The lesser of either AWP minus 10% plus a \$4.00 dispensing fee, or the U&C, or the Federal Upper Limit for generic product plus a \$4.00 dispensing fee, then subtracting a copayment of \$8.00 for generics and \$15.00 for brand products. The copayment can be adjusted annually.

**July 10, 2006 - Present:** The lesser of either AWP minus 12% plus a \$4.00 dispensing fee, or the U&C, or the Federal Upper Limit for a generic product plus a \$4.00 dispensing fee, then subtracting a copayment of \$8.00 for generics and \$15.00 for brand products. The copayment can be adjusted annually.

**June 2004 - December 2009:** Average state share per claim reflects savings from Medicare Part D.

SOURCE: PDA/MRW200-01 & MRM730-01

**TABLE 3.2A**  
**PACE HIGH EXPENDITURE AND HIGH VOLUME CLAIMS**  
**JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDITURES</u>	<u>RANK BY EXPENDITURE</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>	<u>RANK BY VOLUME</u>	<u>EXCLUSIVITY/PATENT</u>	<u>PRODUCT DESCRIPTION</u>
BRISTOL-MYERS SQUIBB	PLAVIX	75 MG	\$5,994,026.23	5.02	1	115,336	2.20	1	06/19	ANTIPLATELET AGENT
ASTRA ZENECA	NEXIUM	40 MG	\$4,280,410.37	3.59	2	61,285	1.17	2	05/20	GASTROINTESTINAL AGENT
EISAI	ARICEPT	10 MG	\$2,770,965.31	2.32	3	36,996	0.71	8	06/22	ALZHEIMER'S DISEASE TREATMENT
PFIZER	LIPITOR	20 MG	\$2,332,105.79	1.96	4	51,290	0.98	4	01/17	LIPID-LOWERING AGENT
BOEHRINGER INGELHEIM	SPIRIVA	18 MCG	\$1,905,149.78	1.60	5	32,701	0.62	12	03/23	RESPIRATORY AGENT
PFIZER	LIPITOR	10 MG	\$1,901,925.80	1.59	6	59,824	1.14	3	01/17	LIPID-LOWERING AGENT
WYETH	PANTOPRAZOLE SODIUM	40 MG	\$1,856,330.02	1.56	7	38,574	0.74	7	—	GASTROINTESTINAL AGENT
GLAXO SMITHKLINE	ADVAIR DISKUS	250/50 MCG	\$1,830,399.84	1.53	8	25,902	0.49	23	08/16	RESPIRATORY AGENT
PFIZER	CELEBREX	200 MG	\$1,658,281.46	1.39	9	30,321	0.58	15	04/18	ANTI-INFLAMMATORY/ANALGESIC
TAKEDA	PREVACID	30 MG	\$1,517,673.06	1.27	10	20,542	0.39	36	—	GASTROINTESTINAL AGENT
FOREST	NAMENDA	10 MG	\$1,514,996.33	1.27	11	23,073	0.44	29	04/15	ALZHEIMER'S DISEASE TREATMENT
PFIZER	LIPITOR	40 MG	\$1,385,332.16	1.16	12	30,440	0.58	14	01/17	LIPID-LOWERING AGENT
MERCK	ZETIA	10 MG	\$1,283,921.68	1.08	13	34,620	0.66	10	07/22	LIPID-LOWERING AGENT
EISAI	ARICEPT	5 MG	\$1,235,396.57	1.04	14	16,251	0.31	48	06/22	ALZHEIMER'S DISEASE TREATMENT
EISAI	ACIPHEX	20 MG	\$1,165,071.31	0.98	15	12,566	0.24	67	05/13	GASTROINTESTINAL AGENT
PFIZER	DETROL LA	4 MG	\$1,143,339.77	0.96	16	25,346	0.48	26	05/20	OVERACTIVE BLADDER TREATMENT
SANOFLAVENTIS	LANTUS SOLOSTAR	100 U/ML	\$1,081,656.75	0.91	17	21,959	0.42	33	12/23	DIABETES TREATMENT
WARNER CHILCOTT	ACTONEL	35 MG	\$1,077,891.65	0.90	18	29,325	0.56	17	02/19	OSTEOPOROSIS TREATMENT
ASTRA ZENECA	ARIMIDEX	1 MG	\$1,034,189.85	0.87	19	8,181	0.16	122	06/10	CHEMOTHERAPEUTIC AGENT
BOEHRINGER INGELHEIM	FLOWAX	0.4 MG	\$1,029,115.51	0.86	20	24,445	0.47	28	—	FOR PROSTATE HYPERPLASIA
MERCK	JANUVIA	100 MG	\$949,777.91	0.80	21	12,665	0.24	66	04/26	DIABETES TREATMENT
TAKEDA	ACTOS	30 MG	\$246,932.29	0.79	22	13,185	0.25	61	08/16	DIABETES TREATMENT
TEVA	PANTOPRAZOLE SODIUM	40 MG	\$921,296.32	0.77	23	17,892	0.34	43	—	GASTROINTESTINAL AGENT
MERCK	SINGULAIR	10 MG	\$917,663.39	0.77	24	22,591	0.43	32	08/12	RESPIRATORY AGENT
PFIZER	XALATAN	0.005%	\$913,241.86	0.77	25	27,949	0.53	19	03/11	GLAUCOMA TREATMENT
ROCHE	BONIVA	150 MG	\$846,725.00	0.71	26	17,509	0.33	45	05/23	OSTEOPOROSIS TREATMENT
FOREST	LEXAPRO	10 MG	\$840,193.63	0.70	27	25,882	0.49	24	02/23	ANTIDEPRESSANT
NOVARTIS	DIOVAN	160 MG	\$782,911.98	0.66	28	25,359	0.48	25	12/17	ANGIOTENSIN II RECEPTOR ANTAG.
TAKEDA	ACTOS	45 MG	\$753,721.81	0.63	29	9,694	0.18	100	08/16	DIABETES TREATMENT
ELI LILLY	FORTEO	250 MCG/ML	\$749,864.91	0.63	30	1,695	0.03	619	08/19	OSTEOPOROSIS TREATMENT

**TABLE 3.2A**  
**PACE HIGH EXPENDITURE AND HIGH VOLUME CLAIMS**  
**JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDITURES</u>	<u>RANK BY EXPENDITURE</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>	<u>RANK BY VOLUME</u>	<u>EXCLUSIVITY/ PATENT</u>	<u>PRODUCT DESCRIPTION</u>
ELI LILLY	EVISTA	60 MG	\$718,600.61	0.60	31	18,571	0.35	42	03/17	OSTEOPOROSIS TREATMENT
ABBOTT	TRICOR	145 MG	\$695,269.59	0.58	32	17,676	0.34	44	02/23	LIPID-LOWERING AGENT
TAKEDA	PREVACID	30 MG	\$641,881.58	0.54	33	8,583	0.16	114	—	GASTROINTESTINAL AGENT
GLAXO SMITHKLINE	ADVAIR DISKUS	500/50 MCG	\$638,186.24	0.54	34	7,094	0.14	139	08/16	RESPIRATORY AGENT
NOVARTIS	DIOVAN	80 MG	\$567,639.94	0.48	35	20,205	0.39	38	12/17	ANGIOTENSIN II RECEPTOR ANTAG.
ASTRA ZENECA	CRESTOR	10 MG	\$559,664.30	0.47	36	15,503	0.30	53	12/21	LIPID-LOWERING AGENT
BOEHRINGER INGELHEIM	AGGRENEX		\$554,383.53	0.46	37	9,980	0.19	94	01/17	ANTIPLATELET AGENT
ORTHO BIOTECH	PROCRIT	40000 U/ML	\$528,382.52	0.44	38	620	0.01	1258	—	HEMATOPOIETIC AGENT
TAKEDA	ACTOS	15 MG	\$512,288.88	0.43	39	10,701	0.20	83	08/16	DIABETES TREATMENT
PFIZER	LIPITOR	80 MG	\$501,673.57	0.42	40	10,829	0.21	82	01/17	LIPID-LOWERING AGENT
MERCK	VYTORIN	10/40 MG	\$476,914.97	0.40	41	10,989	0.21	78	04/17	LIPID-LOWERING AGENT
ASTRA ZENECA	CRESTOR	5 MG	\$473,668.31	0.40	42	11,534	0.22	76	12/21	LIPID-LOWERING AGENT
NOVARTIS	FEMARA	2.5 MG	\$470,748.94	0.39	43	3,676	0.07	300	06/11	CHEMOTHERAPEUTIC AGENT
BOEHRINGER INGELHEIM	COMBIVENT		\$466,623.47	0.39	44	13,345	0.25	60	06/15	RESPIRATORY AGENT
NOVARTIS	DIOVAN HCT	12.5 /1 MG	\$459,845.56	0.39	45	13,821	0.26	58	12/17	ANGIOTENSIN II RECEPTOR ANTAG.
NOVARTIS	DIOVAN	320 MG	\$451,571.63	0.38	46	12,919	0.25	64	12/17	ANGIOTENSIN II RECEPTOR ANTAG.
ASTELLAS	VESICARE	5 MG	\$442,752.28	0.37	47	8,010	0.15	127	11/18	OVERACTIVE BLADDER TREATMENT
MERCK	COZAAR	50 MG	\$438,631.20	0.37	48	11,988	0.23	69	—	ANGIOTENSIN II RECEPTOR ANTAG.
ORTHO BIOTECH	PROCRIT	20000 U/ML	\$428,554.74	0.36	49	881	0.02	990	—	HEMATOPOIETIC AGENT
ALLERGAN	RESTASIS	0.05%	\$417,000.37	0.35	50	5,431	0.10	189	05/14	DRY EYE TREATMENT
MYLAN	OMEPRAZOLE	20 MG	\$362,036.73	0.30	61	35,530	0.68	9	—	GASTROINTESTINAL AGENT
PAR	METAPROLOL SUCCINATE	50 GM	\$234,261.54	0.20	91	23,026	0.44	30	—	BETA BLOCKER
TEVA	ALENDRONATE SODIUM	70 GM	\$195,873.34	0.16	110	20,295	0.39	37	—	OSTEOPOROSIS TREATMENT
APOTEX	ALENDRONATE SODIUM	70 GM	\$130,092.21	0.11	165	16,060	0.31	50	—	OSTEOPOROSIS TREATMENT
TEVA	VITAMIN D	50,000 IU	\$90,171.33	0.08	229	19,495	0.37	39	—	VITAMIN SUPPLEMENT
UPSHER-SMITH	KLOR-CON M20	20 MEQ	\$55,510.50	0.05	328	17,018	0.32	46	—	ELECTROLYTE
TEVA	SIMVASTATIN	40 MG	\$47,993.73	0.04	363	27,280	0.52	22	—	LIPID-LOWERING AGENT
TEVA	SIMVASTATIN	20 MG	\$38,761.95	0.03	408	28,603	0.55	18	—	LIPID-LOWERING AGENT
WATSON	LORAZEPAM	0.5 MG	\$31,406.93	0.03	467	16,426	0.31	47	—	ANXIOLYTIC
MYLAN	LEVOTHYROXINE SODIUM	0.075 MG	\$28,554.98	0.02	492	25,152	0.48	27	—	THYROID REPLACEMENT

**TABLE 3.2A  
PACE HIGH EXPENDITURE AND HIGH VOLUME CLAIMS  
JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDI- TURES</u>	<u>RANK BY EXPENDI- TURE</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>	<u>RANK BY VOLUME</u>	<u>EXCLUSIVITY/ PATENT</u>	<u>PRODUCT DESCRIPTION</u>
MYLAN	AMLODIPINE BESYLATE	10 MG	\$25,079.24	0.02	533	21,271	0.41	35	—	CALCIUM CHANNEL BLOCKER
MYLAN	LEVOTHYROXINE SODIUM	0.05 MG	\$25,012.06	0.02	535	29,372	0.56	16	—	THYROID REPLACEMENT
MYLAN	AMLODIPINE BESYLATE	5 MG	\$24,994.94	0.02	538	30,448	0.58	13	—	CALCIUM CHANNEL BLOCKER
MYLAN	LEVOTHYROXINE SODIUM	0.10 MG	\$24,645.81	0.00	546	21,416	0.41	34	—	THYROID REPLACEMENT
COVIDIEN MALLINCKRODT	APAP/HYDROCODONE	500 MG/5	\$17,412.85	0.01	671	19,462	0.37	40	—	ANALGESIC NARCOTIC
MYLAN	METAPROLOL TARTRATE	25 MG	\$12,713.34	0.01	821	42,164	0.80	6	—	BETA BLOCKER
MYLAN	LEVOTHYROXINE SODIUM	0.025 MG	\$11,837.09	0.01	859	16,129	0.31	49	—	THYROID REPLACEMENT
LANNETT	DIGOXIN	0.125 MG	\$10,710.27	0.01	912	27,385	0.52	21	—	CARDIAC GLYCOSIDE
MYLAN	METAPROLOL TARTRATE	50 MG	\$5,303.89	0.00	1,427	34,058	0.65	11	—	BETA BLOCKER
MYLAN	FUROSEMIDE	40 MG	\$4,487.52	0.00	1,576	44,633	0.85	5	—	DIURETIC
MYLAN	FUROSEMIDE	20 MG	\$1,904.89	0.00	2,387	27,824	0.53	20	—	DIURETIC
TEVA	HYDROCHLOROTHIAZIDE	25 MG	\$67.46	0.00	6,284	19,252	0.37	41	—	DIURETIC
QUALITEST	HYDROCHLOROTHIAZIDE	25 MG	\$57.12	0.00	6,438	22,616	0.43	31	—	DIURETIC
	TOTAL		\$58,433,620.31	48.99		1,670,679	31.85			
	73 PRODUCTS									
	TOTAL		\$119,286,665.27	100.00		5,245,686	100.00			
	ALL PRODUCTS									

NOTES: PATENT AND EXCLUSIVITY EXPIRATION INFORMATION TAKEN FROM USPDI APPROVED DRUG PRODUCTS AND LEGAL REQUIREMENTS, VOLUME III, 25TH EDITION (2008).  
DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT FOR PACE ONLY, EXCLUDING PACENET.

SOURCE: PDA/CLAIMS HISTORY

**TABLE 3.2B  
PACENET HIGH EXPENDITURE AND HIGH VOLUME CLAIMS  
JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>CARDHOLDER EXPENDITURES</u>	<u>STATE SHARE EXPENDITURES</u>	<u>TOTAL EXPENDITURES</u>	<u>% OF TOTAL</u>	<u>RANK BY EXPEN- TURES</u>	<u>CLAIMS</u>	<u>% OF TOTAL</u>	<u>RANK BY VOLUME</u>
BRISTOL-MYERS SQUIBB	PLAVIX	75 MG	\$13,934,016.72	\$9,068,923.13	\$23,002,939.85	5.77	1	147,349	2.47	1
ASTRA ZENECA	NEXIUM	40 MG	\$6,565,784.05	\$4,939,276.35	\$11,505,060.40	3.14	2	62,933	1.05	2
EISAI	ARICEPT	10 MG	\$4,950,729.49	\$3,731,538.74	\$8,682,268.23	2.37	3	44,714	0.75	8
BOEHRINGER INGELHEIM	SPIRIVA	18 MCG	\$4,486,240.83	\$3,324,053.99	\$7,810,294.82	2.11	4	44,180	0.74	9
GLAXO SMITHKLINE	ADVAIR DISKUS	250/50 MCG	\$3,779,954.04	\$2,957,639.28	\$6,737,593.32	1.88	5	32,471	0.54	18
PFIZER	LIPITOR	20 MG	\$4,413,169.47	\$2,715,369.60	\$7,128,539.07	1.73	6	54,930	0.92	4
SANOFI-AVENTIS	LANTUS SOLOSTAR	100 U/ML	\$2,973,902.79	\$2,240,092.36	\$5,213,995.15	1.42	7	33,893	0.57	16
BOEHRINGER INGELHEIM	FLOMAX	0.4 MG	\$3,607,798.09	\$2,214,525.01	\$5,822,323.10	1.41	8	46,660	0.78	5
FOREST	NAMENDA	10 MG	\$2,648,287.17	\$2,099,861.75	\$4,748,148.92	1.33	9	29,142	0.49	22
PFIZER	CELEBREX	200 MG	\$2,464,965.12	\$1,989,207.95	\$4,454,173.07	1.26	10	31,835	0.53	19
MERCK	ZETIA	10 MG	\$2,736,012.05	\$1,925,526.94	\$4,661,538.99	1.22	11	43,103	0.72	10
PFIZER	LIPITOR	10 MG	\$3,589,370.65	\$1,910,646.80	\$5,500,017.45	1.21	12	60,852	1.02	3
WYETH	PANTOPRAZOLE SODIUM	40 MG	\$2,128,765.21	\$1,855,593.06	\$3,984,358.27	1.18	13	36,283	0.61	12
PFIZER	LIPITOR	40 MG	\$2,733,651.67	\$1,842,400.52	\$4,576,052.19	1.17	14	35,234	0.59	14
TAKEDA	PREVACID	30 MG	\$1,946,198.37	\$1,757,821.14	\$3,704,019.51	1.12	15	19,681	0.33	43
MERCK	JANUVIA	100 MG	\$1,611,046.54	\$1,622,139.92	\$3,233,186.46	1.03	16	17,057	0.29	52
ASTRA ZENECA	ARIMIDEX	1 MG	\$1,995,701.67	\$1,614,064.98	\$3,609,766.65	1.03	17	10,241	0.17	105
TAKEDA	ACTOS	30 MG	\$1,958,706.37	\$1,524,270.92	\$3,482,977.29	0.97	18	16,104	0.27	58
TAKEDA	ACTOS	45 MG	\$1,775,074.95	\$1,445,247.32	\$3,220,322.27	0.92	19	13,619	0.23	72
PFIZER	DETROL LA	4 MG	\$2,040,677.91	\$1,352,901.67	\$3,393,579.58	0.86	20	25,703	0.43	29
ESAI	ARICEPT	5 MG	\$1,864,258.55	\$1,292,782.10	\$3,157,040.65	0.82	21	16,143	0.27	56
ABBOTT	TRICOR	145 MG	\$1,810,544.71	\$1,216,475.65	\$3,027,020.36	0.77	22	24,589	0.41	32
MERCK	SINGULAIR	10 MG	\$1,750,164.92	\$1,214,288.23	\$2,964,453.15	0.77	23	24,895	0.42	31
ELI LILLY	FORTEO	250 MCG/ML	\$837,448.39	\$1,164,332.13	\$2,001,780.52	0.74	24	2,316	0.04	540
EISAI	ACIPHEX	20 MG	\$1,041,366.44	\$1,135,451.26	\$2,176,817.70	0.72	25	11,120	0.19	95
GLAXO SMITHKLINE	ADVAIR DISKUS	500/50 MCG	\$1,385,665.79	\$1,099,666.09	\$2,485,331.88	0.70	26	9,040	0.15	119
TEVA	PANTOPRAZOLE SODIUM	40 MG	\$1,123,166.41	\$1,065,716.55	\$2,188,882.96	0.68	27	19,893	0.33	41
PROCTER & GAMBLE	ACTONEL	35 MG	\$1,729,129.57	\$1,062,223.50	\$2,791,353.07	0.68	28	28,357	0.47	25
FOREST	LEXAPRO	10 MG	\$1,564,791.28	\$1,023,329.38	\$2,588,120.66	0.65	29	28,417	0.48	24
PFIZER	XALATAN	0.005%	\$1,363,865.36	\$897,936.53	\$2,261,801.89	0.57	30	29,692	0.50	21

**TABLE 3.2B**  
**PACENET HIGH EXPENDITURE AND HIGH VOLUME CLAIMS**  
**JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>CARDHOLDER</u> <u>EXPENDITURES</u>	<u>STATE</u> <u>SHARE</u> <u>EXPENDITURES</u>	<u>TOTAL</u> <u>EXPENDITURES</u>	<u>% OF</u> <u>TOTAL</u>	<u>RANK BY</u> <u>EXPENDI-</u> <u>TURES</u>	<u>CLAIMS</u>	<u>% OF</u> <u>TOTAL</u>	<u>RANK BY</u> <u>VOLUME</u>
ROCHE	BONIVA	150 MG	\$1,019,772.24	\$860,776.92	\$1,880,549.16	0.55	31	17,176	0.29	51
NOVARTIS	DIOVAN	160 MG	\$1,467,140.16	\$860,514.74	\$2,327,654.90	0.55	32	26,953	0.45	27
BOEHRINGER INGELHEIM	AGGRENOLX	10 MG	\$1,236,645.08	\$828,378.02	\$2,065,023.10	0.53	33	13,313	0.22	74
ASTRA ZENECA	CRESTOR	10 MG	\$1,433,152.36	\$827,739.66	\$2,260,892.02	0.53	34	19,397	0.32	44
NOVARTIS	FEMARA	2.5 MG	\$872,081.89	\$779,864.50	\$1,651,946.39	0.50	35	4,326	0.07	293
PFIZER	LIPITOR	80 MG	\$1,021,016.75	\$759,403.78	\$1,780,420.53	0.48	36	13,825	0.23	70
ELI LILLY	EVISTA	60 MG	\$1,380,507.97	\$749,466.01	\$2,129,973.98	0.48	37	18,697	0.31	45
BOEHRINGER INGELHEIM	COMBIVENT	40000 U/ML	\$1,220,849.60	\$743,771.94	\$1,964,621.54	0.47	38	15,149	0.25	62
ORTHO BIOTECH	PROCRIT	80 MG	\$730,004.96	\$738,925.51	\$1,468,930.47	0.47	39	876	0.01	1,101
NOVARTIS	DIOVAN	80 MG	\$1,120,868.40	\$678,927.54	\$1,799,795.94	0.43	40	23,035	0.39	35
TAKEDA	ACTOS	15 MG	\$1,050,121.21	\$673,599.06	\$1,723,720.27	0.43	41	11,876	0.20	88
TAKEDA	PREVACID	30 MG	\$763,859.65	\$629,662.46	\$1,393,522.11	0.40	42	7,830	0.13	142
MERCK	VYTORIN	10/40 MG	\$740,891.53	\$628,715.91	\$1,369,607.44	0.40	43	12,780	0.21	76
WYETH	EFFEXOR-XR	75 MG	\$785,476.41	\$601,905.43	\$1,387,381.84	0.38	44	8,575	0.14	127
ELI LILLY	CYMBALTA	60 MG	\$693,012.15	\$594,383.62	\$1,287,395.77	0.38	45	9,133	0.15	117
ASTRA ZENECA	CRESTOR	5 MG	\$882,878.41	\$590,408.27	\$1,473,286.68	0.38	46	12,871	0.22	75
GLAXOSMITHKLINE	AVODART	0.5 MG	\$800,431.27	\$559,318.87	\$1,359,750.14	0.36	47	12,458	0.21	81
GLAXOSMITHKLINE	ADVAIR DISKUS	100/50 MCG	\$843,719.42	\$557,135.90	\$1,400,855.32	0.35	48	8,374	0.14	132
MERCK	JANUVIA	50 MG	\$610,481.53	\$550,795.03	\$1,161,276.56	0.35	49	5,970	0.10	200
PROCTER & GAMBLE	ASACOL	400 mg	\$717,366.18	\$528,465.05	\$1,245,831.23	0.34	50	5,244	0.09	230
MYLAN	OMEPRAZOLE	20 MG	\$739,503.14	\$308,171.61	\$1,047,674.75	0.20	94	35,462	0.59	13
KREMERS URBAN	OMEPRAZOLE	20 MG	\$326,340.59	\$305,286.11	\$631,626.70	0.19	97	18,081	0.30	47
PAR	METOPROLOL SUCCINATE	50 MG	\$614,393.63	\$210,124.81	\$824,518.44	0.13	146	24,899	0.42	30
TEVA	ALENDRONATE SODIUM	70 MG	\$344,598.43	\$128,587.40	\$473,185.83	0.08	217	21,509	0.36	38
UPSHER-SMITH	KLOR-CON M20	20 MEQ	\$228,289.47	\$49,071.48	\$277,360.95	0.03	410	17,486	0.29	49
TEVA	VITAMIN D	50000 IU	\$172,352.32	\$42,717.90	\$215,070.22	0.03	447	19,767	0.33	42
KREMERS URBAN	ISOSORBIDE MONONITRATE	30 MG	\$179,492.97	\$41,181.46	\$220,674.43	0.03	457	17,521	0.29	48
TEVA	SIMVASTATIN	40 MG	\$444,493.66	\$28,992.91	\$473,486.57	0.02	554	34,122	0.57	15
TEVA	SIMVASTATIN	20 MG	\$423,949.99	\$18,300.79	\$442,250.78	0.01	717	33,391	0.56	17
MALLINCKRODT	APAP/HYDROCODONE	500/5 MG	\$150,772.36	\$12,496.23	\$163,268.59	0.01	897	22,735	0.38	36

**TABLE 3.2B**  
**PACENET HIGH EXPENDITURE AND HIGH VOLUME CLAIMS**  
**JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>CARDHOLDER</u> <u>EXPENDITURES</u>	<u>STATE</u> <u>SHARE</u> <u>EXPENDITURES</u>	<u>TOTAL</u> <u>EXPENDITURES</u>	<u>% OF</u> <u>TOTAL</u>	<u>RANK BY</u> <u>EXPENDI-</u> <u>TURES</u>	<u>CLAIMS</u>	<u>% OF</u> <u>TOTAL</u>	<u>RANK BY</u> <u>VOLUME</u>
MYLAN	AMLODIPINE BESYLATE	10 MG	\$294,861.92	\$11,086.33	\$305,948.25	0.01	958	22,441	0.38	37
MYLAN	LEVOTHYROXINE SODIUM	0.1 MG	\$175,945.65	\$9,410.32	\$185,355.97	0.01	1,079	21,282	0.36	39
MYLAN	LEVOTHYROXINE SODIUM	0.075 MG	\$195,650.21	\$9,134.16	\$204,784.37	0.01	1,095	24,441	0.41	33
MYLAN	LEVOTHYROXINE SODIUM	0.05 MG	\$219,527.10	\$7,864.30	\$227,391.40	0.00	1,199	28,995	0.49	23
MYLAN	AMLODIPINE BESYLATE	5 MG	\$373,584.35	\$6,235.10	\$379,819.45	0.00	1,365	31,527	0.53	20
LUPIN	LISINAPRIL	20 MG	\$150,314.99	\$2,554.96	\$152,869.95	0.00	2,113	17,243	0.29	50
LUPIN	LISINAPRIL	10 MG	\$139,310.74	\$2,142.86	\$141,453.60	0.00	2,307	18,677	0.31	46
LANNETT	DIGOXIN	0.125 MG	\$175,753.53	\$2,102.24	\$177,855.77	0.00	2,329	26,564	0.44	28
MYLAN	METOPROLOL TARTRATE	25 MG	\$271,785.19	\$1,894.49	\$273,679.68	0.00	2,443	45,933	0.77	6
MYLAN	FUROSEMIDE	40 MG	\$238,614.06	\$850.70	\$239,464.76	0.00	3,419	44,808	0.75	7
MYLAN	METOPROLOL TARTRATE	50 MG	\$208,914.47	\$615.92	\$209,530.39	0.00	3,821	36,539	0.61	11
MYLAN	FUROSEMIDE	20 MG	\$134,003.72	\$326.25	\$134,329.97	0.00	4,623	27,467	0.46	26
QUALITEST	HYDROCHLOROTHIAZIDE	25 MG	\$96,123.76	\$3.57	\$96,127.33	0.00	7,737	23,815	0.40	34
TEVA	HYDROCHLOROTHIAZIDE	25 MG	\$79,689.60	\$1.19	\$79,690.79	0.00	7,898	19,907	0.33	40
	TOTAL		\$112,578,997.60	\$78,244,614.16	\$190,823,611.76	49.74		1,882,916	31.54	
	74 PRODUCTS									
	TOTAL		\$241,336,546.51	\$157,305,361.62	\$398,641,908.13	100.00		5,970,099	100.00	
	ALL PRODUCTS									

NOTE: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF PAYMENT. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.  
SOURCE: PDA CLAIMS HISTORY

**TABLE 3.3  
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES  
2008-2009**

MANUFACTURER	PRODUCT	STRENGTH	2009				2008				PERCENT CHANGE: 2008-2009									
			EXPENDITURE	% CLAIMS	COST PER CLAIM	USERS	EXPENDITURE	% CLAIMS	COST PER CLAIM	USERS	CHANGE EXPENDITURE	% CHANGE CLAIMS	% CHANGE COST PER CLAIM	% CHANGE USERS						
<b>ANTI-INFECTIVE AGENTS</b>																				
ORTHO-MCNEIL	LEVAQUIN (LEVOFLOXACIN)	500 MG	\$230,127	9.6	5,994	4.4	\$38.39	4,842	8.8	\$338,160	11.4	8,708	5.6	\$38.83	6,875	11.0	-31.9	-31.2	-1.1	-29.6
VIROPHARMA, INC.	VANCOCIN HCL PULVULES	250 MG	\$220,187	9.1	257	0.1	\$656.76	155	0.2	\$315,695	10.7	311	0.2	\$1,014.78	171	0.2	-30.2	-17.4	-15.6	-9.4
SCHERING	AVELOX (MOXIFLOXACIN)	400 MG	\$169,369	7.0	3,950	2.9	\$42.88	3,199	5.8	\$192,172	6.5	5,177	3.3	\$37.12	4,162	6.6	-11.7	-23.7	15.7	-23.1
VIROPHARMA, INC.	VANCOCIN HCL PULVULES	125 MG	\$153,299	6.4	408	0.3	\$375.73	197	0.3	\$145,872	4.9	372	0.2	\$392.13	199	0.3	5.1	9.7	4.2	-1.0
AR SCIENTIFIC, INC.	QUALAQUIN (QUININE)	324 MG	\$143,595	5.9	1,741	1.2	\$82.48	368	0.6	\$173,880	5.9	2,271	1.4	\$76.57	504	0.8	-17.4	-23.3	7.7	-27.0
	ALL OTHER		\$1,477,420	61.7	122,903	90.8	\$12.02	51,899	94.8	\$1,779,201	60.4	136,674	89.0	\$13.02	58,579	93.7	-17.0	-10.1	-7.7	-11.4
	TOTAL		\$2,394,267	100.0	135,253	100.0	\$17.70	54,735	100.0	\$2,944,881	100.0	153,513	100.0	\$19.18	62,454	100.0	-18.7	-11.9	-7.7	-13.9
<b>AUTONOMIC DRUGS</b>																				
EISAI, INC.	ARICEPT (DONEPEZIL)	10 MG	\$2,770,965	31.3	36,996	20.2	\$72.93	6,294	17.5	\$2,957,003	31.2	40,546	20.5	\$72.93	6,294	17.5	-6.3	-8.8	2.7	-11.2
BOEHRINGER INGELHEIM	SPRIVA (TIOTROPIUM)	18 MCG	\$1,905,150	21.5	32,701	17.8	\$58.26	6,128	18.8	\$1,992,347	21.0	33,798	17.1	\$58.95	6,579	18.3	-4.4	-3.2	-1.2	-6.9
EISAI, INC.	ARICEPT (DONEPEZIL)	5 MG	\$1,235,397	13.9	16,251	8.8	\$74.21	3,783	10.5	\$1,286,293	13.5	17,333	8.7	\$74.21	3,783	10.5	-4.0	-6.2	2.4	-9.4
BOEHRINGER INGELHEIM	COMBIVENT (ALBUTEROL)	—	\$466,623	5.2	13,345	7.2	\$34.97	3,061	9.4	\$557,349	5.8	15,866	8.0	\$35.13	3,740	10.4	-16.3	-15.9	-0.5	-18.2
SCHERING	PROVENTIL HFA (ALBUTEROL)	0.09 MG	\$240,834	2.7	11,588	6.3	\$20.78	3,588	11.0	\$176,172	1.8	9,049	4.5	\$19.47	3,467	9.6	36.7	28.1	6.8	3.5
	ALL OTHER		\$2,215,438	25.0	72,194	39.4	\$30.69	19,469	59.8	\$2,500,388	26.4	81,041	41.0	\$30.85	21,653	60.2	-11.4	-10.9	-0.5	-10.1
	TOTAL		\$8,834,407	100.0	183,075	100.0	\$48.26	32,539	100.0	\$9,469,552	100.0	197,633	100.0	\$47.91	35,910	100.0	-6.7	-7.4	0.7	-9.4
<b>BLOOD FORMATION AND COAGULATION AGENTS</b>																				
ER SQUIBB	PLAVIX (CLOPIDOGREL)	75 MG	\$5,994,026	63.2	115,336	48.7	\$51.79	15,651	47.5	\$6,624,114	61.0	125,578	47.1	\$52.75	17,197	46.2	-9.5	-8.2	-1.5	-9.0
BOEHRINGER INGELHEIM	AGGRENOX (ASPIRIN/DIPIRYMADOLE)	25-200 MG	\$544,384	5.7	9,980	4.2	\$54.55	1,501	4.5	\$612,146	5.6	11,143	4.1	\$54.94	1,736	4.6	-11.1	-10.4	-0.7	-13.5
ORTHO BIOTECH	PROCRIT (EPOETIN)	40000 U	\$528,383	5.5	620	0.2	\$852.23	161	0.4	\$628,769	5.7	788	0.2	\$797.93	205	0.5	-16.0	-21.3	6.8	-21.5
ORTHO BIOTECH	PROCRIT (EPOETIN)	20000 U	\$428,555	4.5	881	0.3	\$486.44	228	0.6	\$527,180	4.8	1,115	0.4	\$472.81	309	0.8	-18.7	-21.0	2.9	-26.2
	ALL OTHER		\$172,061	1.8	765	0.3	\$224.92	185	0.5	\$215,281	1.9	864	0.3	\$249.17	234	0.6	-20.1	-11.5	9.7	-20.9
	TOTAL		\$1,807,093	19.0	109,133	46.1	\$16.56	17,532	53.2	\$2,250,248	20.7	126,783	47.6	\$17.75	20,207	54.3	-19.7	-13.9	-6.7	-13.2
	TOTAL		\$9,474,501	100.0	236,715	100.0	\$40.02	32,923	100.0	\$10,857,738	100.0	266,271	100.0	\$40.78	37,197	100.0	-12.7	-11.1	-1.8	-11.6
<b>CARDIAC DRUGS</b>																				
NOVARTIS	DIOVAN (VALSARTAN)	160 MG	\$782,912	5.4	25,359	2.1	\$30.87	3,786	3.8	\$867,536	4.3	28,348	2.0	\$30.60	4,322	3.8	-9.8	-10.5	0.9	-12.4
NOVARTIS	DIOVAN (VALSARTAN)	80 MG	\$567,640	3.9	20,205	1.7	\$28.09	3,089	3.1	\$671,269	3.4	24,662	1.8	\$27.22	3,752	3.3	-15.4	-18.1	3.2	-17.7
NOVARTIS	DIOVAN HCT	12.5 MG	\$459,846	3.1	13,821	1.1	\$33.27	1,959	1.9	\$539,347	2.7	16,510	1.2	\$32.67	2,345	2.0	-14.7	-16.3	1.8	-16.5
NOVARTIS	DIOVAN (VALSARTAN)	320 MG	\$451,572	3.1	12,919	1.0	\$34.95	1,830	1.8	\$428,323	2.1	12,534	0.9	\$34.17	1,865	1.6	5.4	3.1	2.3	-1.9
MERCK	COZAAR (LOSARTAN)	100 MG	\$438,631	3.0	11,988	1.0	\$36.59	1,612	1.6	\$515,082	2.6	13,172	0.9	\$39.10	1,847	1.6	-14.8	-9.0	-6.4	-12.7
	ALL OTHER		\$11,708,652	81.2	1,090,779	92.8	\$10.73	96,598	97.1	\$16,712,347	84.6	1,258,109	92.9	\$13.28	110,254	97.1	-29.9	-13.3	-19.2	-12.4
	TOTAL		\$14,409,252	100.0	1,175,071	100.0	\$12.26	99,483	100.0	\$19,733,904	100.0	1,353,335	100.0	\$14.58	113,526	100.0	-27.0	-13.2	-15.9	-12.5
<b>LIPID-LOWERING AGENTS</b>																				
PFIZER	LIPITOR (ATORVASTATIN)	20 MG	\$2,332,106	18.3	51,290	10.1	\$45.47	7,049	10.9	\$2,831,438	17.0	59,458	10.7	\$47.62	8,611	12.0	-17.6	-13.7	-4.5	-18.1
PFIZER	LIPITOR (ATORVASTATIN)	10 MG	\$1,901,926	14.9	59,824	11.8	\$31.79	7,797	12.0	\$2,408,541	14.4	73,097	13.1	\$32.95	10,029	14.0	-21.0	-18.2	-3.5	-22.3
PFIZER	LIPITOR (ATORVASTATIN)	40 MG	\$1,385,332	10.9	30,440	6.0	\$45.51	4,417	6.8	\$1,611,313	9.6	33,847	6.1	\$47.61	5,096	7.1	-14.0	-10.1	-4.4	-13.3
MERCK	ZETIA (EZETIMIBE)	10 MG	\$1,283,992	10.1	34,620	6.8	\$37.09	4,478	7.4	\$1,461,248	8.7	42,379	7.6	\$34.48	6,548	9.1	-12.1	-18.3	7.6	-27.0
ABBOTT	TRICOR (FENOFIBRATE)	145 MG	\$695,270	5.4	17,676	3.4	\$39.33	2,441	3.7	\$814,363	4.8	19,297	3.4	\$42.20	2,785	3.8	-14.6	-8.4	-6.8	-12.4
	ALL OTHER		\$5,086,232	40.0	311,493	61.6	\$16.33	45,732	70.8	\$7,503,745	45.1	325,745	58.8	\$23.04	48,116	67.1	-32.2	-4.4	-29.1	-5.0
	TOTAL		\$12,684,787	100.0	505,343	100.0	\$25.10	64,547	100.0	\$16,630,647	100.0	553,823	100.0	\$30.03	71,635	100.0	-23.7	-8.8	-16.4	-11.1

**TABLE 3.3  
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES  
2008-2009**

MANUFACTURER	PRODUCT	STRENGTH	2009				2008				PERCENT CHANGE: 2008-2009								
			EXPENDITURE	% CLAIMS	COST PER CLAIM	USERS	EXPENDITURE	% CLAIMS	COST PER CLAIM	USERS	CHANGE EXPENDITURE	% CHANGE CLAIMS	% CHANGE COST PER CLAIM	% CHANGE USERS					
<b>COX-2 INHIBITOR ANTI-INFLAMMATORY DRUGS</b>																			
PFIZER	CELEBREX (CELECOXIB)	200 MG	\$1,658,281	93.3	30,321	91.6	\$54.69	5,521	91.3	\$2,165,369	93.3	35,357	91.4	6,834	91.4	-23.4	-14.2	-10.7	-19.2
PFIZER	CELEBREX (CELECOXIB)	100 MG	\$118,673	6.6	2,721	8.2	\$43.61	627	10.3	\$152,023	6.5	3,286	8.4	741	9.9	-21.9	-17.2	-5.7	-15.4
PFIZER	CELEBREX (CELECOXIB)	50 MG	\$234	0.0	13	0.0	\$17.99	3	0.0	\$131	0.0	14	0.0	3	0.0	78.3	-7.1	92.0	0.0
PFIZER	CELEBREX (CELECOXIB)	400 MG	\$116	0.0	21	0.0	\$5.54	3	0.0	\$1,134	0.0	22	0.0	8	0.1	-89.7	-4.5	-89.3	-62.5
	TOTAL		\$1,777,304	100.0	33,076	100.0	\$121.83	6,154	100.0	\$2,318,657	100.0	38,679	100.0	7,470	100.0	-89.7	-4.5	-89.3	-62.5
<b>OTHER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS</b>																			
PFIZER	ARTHROTEC (DICLOFENAC)	75 MG	\$83,057	21.3	1,267	2.8	\$65.55	252	1.8	\$106,059	21.6	1,634	3.1	340	2.1	-21.7	-22.5	1.0	-25.9
ENDO	VOLTAREN GEL (DICLOFENAC)	1%	\$55,386	14.2	2,058	4.6	\$26.91	1,179	8.5	\$21,007	4.2	851	1.6	577	3.6	163.7	141.8	9.0	104.3
PFIZER	ARTHROTEC (DICLOFENAC)	50 MG	\$43,298	11.1	688	1.5	\$62.93	154	1.1	\$52,723	10.7	825	1.5	194	1.2	-17.9	-16.6	-1.5	-20.6
ENDO	VOLTAREN GEL (DICLOFENAC)	1%	\$29,131	7.4	940	2.1	\$30.99	631	4.5	\$0	0.0	0	0.0	0	0.0	—	—	—	—
TEVA	NABUMETONE	500 MG	\$15,247	3.9	1,130	2.5	\$13.49	328	2.3	\$19,742	4.0	1,208	2.3	363	2.3	-22.8	-6.5	-17.4	-9.6
	ALL OTHER		\$163,340	41.9	38,348	86.3	\$4.26	11,852	85.9	\$289,407	59.1	47,333	91.2	14,508	92.7	-43.6	-19.0	-30.3	-18.3
	TOTAL		\$389,460	100.0	44,431	100.0	\$8.77	13,786	100.0	\$488,939	100.0	51,851	100.0	15,648	100.0	-20.3	-14.3	-7.0	-9.9
<b>OPIATE AGONIST ANALGESICS</b>																			
PURDUE PHARMA L.P.	OXYCONTIN (OXYCODONE)	40 MG	\$203,846	9.5	1,015	0.7	\$200.83	215	0.6	\$220,583	9.3	1,186	0.7	241	0.6	-7.6	-14.4	8.0	-10.8
PURDUE PHARMA L.P.	OXYCONTIN (OXYCODONE)	20 MG	\$193,895	9.1	1,884	1.4	\$102.92	450	1.4	\$195,446	8.2	2,089	1.3	542	1.4	-0.8	-10.2	10.5	-17.0
PURDUE PHARMA L.P.	OXYCONTIN (OXYCODONE)	80 MG	\$144,928	6.8	418	0.3	\$346.72	71	0.2	\$155,326	6.5	429	0.2	95	0.2	-6.7	-2.6	-4.2	-25.3
PURDUE PHARMA L.P.	OXYCONTIN (OXYCODONE)	10 MG	\$109,759	5.1	2,071	1.5	\$53.00	645	2.0	\$89,904	3.7	1,883	1.2	590	1.6	22.1	10.0	11.0	9.3
PURDUE PHARMA L.P.	OXYCONTIN (OXYCODONE)	60 MG	\$81,459	3.8	206	0.1	\$395.43	39	0.1	\$17,711	0.7	59	0.0	22	0.0	359.9	249.2	31.7	77.3
	ALL OTHER		\$1,393,912	65.5	128,903	95.8	\$10.81	31,728	99.3	\$1,692,654	71.3	146,043	96.2	36,500	99.6	-17.6	-11.7	-6.7	-13.1
	TOTAL		\$2,127,799	100.0	134,497	100.0	\$15.82	31,947	100.0	\$2,371,624	100.0	151,699	100.0	36,624	100.0	-10.3	-11.3	1.2	-12.7
<b>ANTIDEPRESSANTS</b>																			
FOREST	LEXAPRO (ESCITALOPRAM)	10 MG	\$840,194	24.4	25,882	12.7	\$32.46	4,384	14.8	\$1,042,860	21.7	30,067	13.0	5,450	16.3	-19.4	-13.9	-6.4	-19.6
WYETH	EFFEXOR-XR (VENLAFAXINE)	75 MG	\$374,916	10.8	6,277	3.0	\$59.73	1,056	3.5	\$485,244	10.1	7,944	3.4	1,356	4.0	-22.7	-21.0	-2.2	-22.1
FOREST	LEXAPRO (ESCITALOPRAM)	20 MG	\$372,833	10.8	10,862	5.3	\$34.32	1,723	5.8	\$415,306	8.6	11,631	5.0	1,938	5.7	-10.2	-6.6	-3.9	-11.1
LILLY, ELI & CO.	CYMBALTA (DULOXETINE)	60 MG	\$364,447	10.5	6,384	3.1	\$57.09	1,108	3.7	\$412,410	8.6	6,756	2.9	1,177	3.5	-11.6	-5.5	-6.5	-5.9
LILLY, ELI & CO.	CYMBALTA (DULOXETINE)	30 MG	\$286,971	8.3	4,318	2.1	\$66.46	921	3.1	\$310,025	6.4	4,636	2.0	1,027	3.0	-7.4	-6.9	-0.6	-10.3
	ALL OTHER		\$1,200,583	34.9	149,187	73.5	\$8.05	23,529	79.7	\$2,118,025	44.2	168,958	73.4	26,409	79.0	-43.3	-11.7	-35.8	-10.9
	TOTAL		\$3,439,944	100.0	202,910	100.0	\$16.95	29,491	100.0	\$4,783,871	100.0	229,992	100.0	33,428	100.0	-28.1	-11.8	-18.5	-12.4
<b>ANTIPSYCHOTICS</b>																			
LILLY, ELI & CO.	ZYPREXA (OLANZAPINE)	2.5 MG	\$254,824	10.0	2,684	7.4	\$94.94	517	9.6	\$375,150	11.2	3,645	8.7	676	10.9	-32.1	-26.4	-7.8	-23.5
ASTRAZENECA LP	SEROQUEL (QUETIAPINE)	25 MG	\$253,127	10.0	5,622	15.6	\$45.02	1,154	21.6	\$286,104	8.6	6,591	15.8	1,343	21.8	-11.5	-14.7	3.7	-14.1
LILLY, ELI & CO.	ZYPREXA (OLANZAPINE)	5 MG	\$231,772	9.1	2,303	6.4	\$100.62	427	7.9	\$326,573	9.8	2,861	6.8	529	8.5	-29.0	-19.5	-11.9	-19.3
ER SQUIBB	ABILIFY (ARIPRAZOLE)	5 MG	\$220,650	8.7	1,285	3.5	\$171.71	275	5.1	\$179,775	5.4	1,100	2.6	268	4.3	22.7	16.8	5.1	2.6
ASTRAZENECA LP	SEROQUEL (QUETIAPINE)	50 MG	\$184,890	7.3	2,765	7.7	\$66.87	556	10.4	\$164,933	4.9	2,616	6.2	621	10.0	12.1	5.7	6.1	-10.5
	ALL OTHER		\$1,379,980	54.6	21,153	59.0	\$65.24	3,441	64.4	\$1,998,020	59.8	24,781	59.5	3,950	64.1	-30.6	-14.6	-18.7	-12.9
	TOTAL		\$2,525,195	100.0	35,812	100.0	\$70.51	5,339	100.0	\$3,320,555	100.0	41,594	100.0	6,159	100.0	-24.0	-13.9	-11.7	-13.8

**TABLE 3.3  
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES  
2008-2009**

MANUFACTURER	PRODUCT	STRENGTH	2009				2008				PERCENT CHANGE: 2008-2009									
			EXPENDITURE	% CLAIMS	COST PER CLAIM	USERS	EXPENDITURE	% CLAIMS	COST PER CLAIM	USERS	CHANGE EXPENDITURE	% CHANGE CLAIMS	% CHANGE COST PER CLAIM	% CHANGE USERS						
<b>ANXIOLYTICS, SEDATIVES, AND HYPNOTICS</b>																				
SEPRACOR, INC.	LUNESTA (ESZOPICLONE)	2 MG	\$204,491	14.0	2,964	1.6	\$68.99	583	1.9	\$263,425	8.8	3,519	1.7	\$74.86	782	2.3	-22.4	-15.8	-7.8	-25.4
SANOFI-AVENTIS	AMBIEN CR (ZOLPIDEM)	12.5 MG	\$124,272	8.5	2,390	1.3	\$52.00	418	1.3	\$126,958	4.2	2,582	1.2	\$49.17	524	1.5	-2.1	-7.4	5.7	-20.2
SANOFI-AVENTIS	AMBIEN CR (ZOLPIDEM)	6.25 MG	\$121,499	8.3	1,937	1.0	\$62.73	376	1.2	\$148,289	4.9	2,489	1.2	\$59.58	537	1.5	-18.1	-22.2	5.3	-30.0
COVIDIEN MALLINCKRODT	TEMAZEPAM	7.5 MG	\$112,270	7.6	462	0.2	\$243.01	170	0.5	\$14,489	0.4	78	0.0	\$185.75	51	0.1	674.9	492.3	30.8	233.3
COVIDIEN MALLINCKRODT	RESTORIL (TEMAZEPAM)	7.5 MG	\$79,076	5.4	297	0.1	\$266.25	118	0.3	\$173,873	5.8	933	0.4	\$186.36	296	0.8	-54.5	-68.2	42.9	-60.1
	ALL OTHER		\$818,166	56.0	175,747	95.6	\$4.66	29,157	97.5	\$2,256,696	75.6	193,503	95.2	\$11.66	32,706	96.8	-63.7	-9.2	-60.1	-10.9
	TOTAL		\$1,459,775	100.0	183,797	100.0	\$7.94	29,904	100.0	\$2,983,729	100.0	203,104	100.0	\$14.69	33,754	100.0	-51.1	-9.5	-45.9	-11.7
<b>EYE, EAR, NOSE AND THROAT PREPARATIONS</b>																				
PFIZER	XALATAN (LATANOPROST)	0.005%	\$913,242	18.6	27,949	17.1	\$32.68	4,687	14.4	\$1,033,802	19.1	32,786	18.5	\$31.53	5,563	15.5	-11.7	-14.8	3.6	-15.7
ALLERGAN	RESTASIS (CYCLOSPORINE)	0.05%	\$417,000	8.4	5,431	3.3	\$76.78	1,588	4.8	\$458,565	8.4	6,060	3.4	\$75.67	1,667	4.6	-9.1	-10.4	1.5	-5.9
ALLERGAN	LUMIGAN (BIMATOPROST)	2.5%	\$384,974	7.8	119,973	7.3	\$32.15	2,305	7.1	\$428,457	7.9	13,228	7.4	\$32.39	2,550	7.1	-10.1	-9.5	-0.7	-9.6
ALCON	TRAVATAN Z (TRAVOPROST)	0.004%	\$258,194	5.2	7,589	4.6	\$34.02	1,723	5.3	\$177,373	3.2	5,025	2.8	\$35.30	1,355	3.7	45.6	51.0	-3.6	27.2
ALCON	TRAVATAN (TRAVOPROST)	0.004%	\$214,761	4.3	6,537	4.0	\$32.85	1,400	4.3	\$272,526	5.0	8,098	4.5	\$33.65	1,901	5.3	-21.2	-19.3	-2.4	-26.4
	ALL OTHER		\$2,720,082	55.4	103,444	63.4	\$26.30	27,695	85.3	\$3,040,811	56.1	111,592	63.1	\$27.25	30,415	85.0	-10.5	-7.3	-3.5	-8.9
	TOTAL		\$4,908,252	100.0	162,923	100.0	\$30.13	32,436	100.0	\$5,411,535	100.0	176,789	100.0	\$30.61	35,770	100.0	-9.3	-7.8	-1.6	-9.4
<b>PROTON PUMP INHIBITOR ANTHULCER AGENTS</b>																				
ASTRAZENECA LP	NEXIUM (ESOMEPRAZOLE)	40 MG	\$4,280,410	32.1	61,285	22.5	\$69.84	8,997	21.7	\$5,213,322	29.7	69,184	23.4	\$75.35	10,674	23.3	-17.9	-11.4	-7.3	-15.7
WYETH	PANTOPRAZOLE SODIUM	40 MG	\$1,856,330	13.9	38,574	14.2	\$48.12	7,119	17.2	\$1,721,169	9.8	29,200	9.9	\$58.94	7,292	15.9	7.9	32.1	-18.4	-2.4
TAKEDA	PREVACID (LANSOPRAZOLE)	30 MG	\$1,517,673	11.4	20,542	7.5	\$73.88	3,621	8.7	\$0	0.0	0	0.0	\$0.00	0	0.0	—	—	—	—
EISAI, INC.	ACIPEX (RABEPRAZOLE)	20 MG	\$1,165,071	8.7	12,566	4.6	\$92.72	1,911	4.6	\$1,507,326	8.5	15,732	5.3	\$95.81	2,438	5.3	-22.7	-20.1	-3.2	-21.6
TEVA	PANTOPRAZOLE	40 MG	\$921,296	6.9	17,892	6.5	\$51.49	4,664	11.2	\$1,161,167	6.6	20,271	6.8	\$57.28	6,977	15.2	-20.7	-11.7	-10.1	-33.2
	ALL OTHER		\$3,558,066	26.7	120,599	44.4	\$29.51	25,551	61.8	\$7,930,200	45.2	160,108	54.3	\$49.53	31,600	69.1	-55.1	-24.7	-40.4	-19.1
	TOTAL		\$13,298,847	100.0	271,418	100.0	\$49.00	41,336	100.0	\$17,533,185	100.0	294,495	100.0	\$59.54	45,677	100.0	-24.2	-7.8	-17.7	-12.1
<b>OTHER ANTI-ULCER AGENTS &amp; MISC. GI DRUGS</b>																				
PROCTER & GAMBLE	ASACOL (MESALAMINE)	400 MG	\$295,620	42.2	3,848	10.0	\$76.82	549	6.7	\$309,902	43.3	4,520	10.5	\$68.56	634	7.1	-4.6	-14.9	12.1	-13.4
AXCAN SCANDIPHARM	CARAFATE (SUCRALFATE)	1 GM	\$71,216	10.1	1,331	3.4	\$53.51	473	5.7	\$67,692	9.4	1,490	3.4	\$45.43	489	5.5	5.2	-10.7	17.8	-3.3
SHIRE US, INC.	LIALDA (MESALAMINE)	1.2 GM	\$53,757	7.6	377	0.9	\$142.59	64	0.7	\$28,691	4.0	215	0.5	\$133.45	40	0.4	87.4	75.3	6.9	60.0
TAKEDA	KAPIDEX (DEXLANSOPRAZOLE)	60 MG	\$46,034	6.5	571	1.4	\$80.62	204	2.4	\$0	0.0	0	0.0	\$0.00	0	0.0	—	—	—	—
SHIRE US, INC.	PENTASA (MESALAMINE)	500 MG	\$36,314	5.1	325	0.8	\$111.73	53	0.6	\$45,463	6.3	428	0.9	\$106.22	61	0.6	-20.1	-24.1	5.2	-13.1
	ALL OTHER		\$197,302	28.1	31,932	83.1	\$6.18	7,058	86.3	\$263,096	36.8	36,312	84.5	\$7.25	7,800	88.4	-25.0	-12.1	-14.7	-9.5
	TOTAL		\$700,243	100.0	38,384	100.0	\$18.24	8,170	100.0	\$714,843	100.0	42,965	100.0	\$16.64	8,818	100.0	-2.0	-10.7	9.6	-6.9
<b>ANTIDIABETIC AGENTS</b>																				
SANOFI-AVENTIS	LANTUS (INSULIN)	100 U	\$1,081,657	11.8	21,959	7.0	\$49.26	4,253	13.9	\$1,043,872	10.3	22,145	6.2	\$47.14	4,360	12.6	3.6	-0.8	4.5	-2.5
MERCK	JANUVIA (SITAGLIPTIN)	100 MG	\$949,778	10.4	12,665	4.0	\$74.99	1,953	6.4	\$906,598	9.0	11,288	3.2	\$80.32	1,897	5.5	4.8	12.2	-6.6	3.0
TAKEDA	ACTOS (PIOGLITAZONE)	30 MG	\$946,932	10.3	13,185	4.2	\$71.82	1,964	6.4	\$1,152,298	11.4	15,679	4.4	\$73.49	2,446	7.1	-17.8	-15.9	-2.3	-19.7
TAKEDA	ACTOS (PIOGLITAZONE)	45 MG	\$753,722	8.2	9,694	3.1	\$77.75	1,386	4.5	\$946,094	9.3	11,990	3.4	\$78.91	1,687	4.9	-20.3	-19.1	-1.5	-17.8
TAKEDA	ACTOS (PIOGLITAZONE)	15 MG	\$512,229	5.6	10,701	3.4	\$47.87	1,627	5.3	\$566,745	5.6	12,151	3.4	\$46.64	1,921	5.5	-9.6	-11.9	2.6	-15.3
	ALL OTHER		\$4,866,771	53.4	243,478	78.1	\$19.99	28,290	92.9	\$5,455,198	54.1	278,594	79.1	\$19.58	32,030	93.1	-10.8	-12.6	2.1	-11.7
	TOTAL		\$9,111,089	100.0	311,682	100.0	\$29.93	30,440	100.0	\$10,070,805	100.0	351,847	100.0	\$28.62	34,370	100.0	-9.5	-11.4	2.1	-11.0

**TABLE 3.3  
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES  
2008-2009**

MANUFACTURER	PRODUCT	STRENGTH	2009			2008			PERCENT CHANGE: 2008-2009			
			EXPENDITURE	% CLAIMS	COST PER CLAIM	EXPENDITURE	% CLAIMS	COST PER CLAIM	CHANGE EXPENDITURE	% CHANGE CLAIMS	% CHANGE COST PER CLAIM	% CHANGE USERS
<b>OTHER HORMONES AND SYNTHETIC AGENTS</b>												
GLAXOSMITHKLINE	ADVAIR DISKUS 250/50 (FLUTICASONE)	250-50 MCG	\$1,830,400	40.6	\$70.67	\$2,060,578	40.2	\$77.17	-11.2	-3.0	-8.4	-7.4
GLAXOSMITHKLINE	ADVAIR DISKUS 500/50 (FLUTICASONE)	500-50 MCG	\$638,186	14.1	\$89.96	\$751,673	14.6	\$99.96	-15.1	-5.7	-10.0	-7.6
GLAXOSMITHKLINE	ADVAIR DISKUS 100/50 (FLUTICASONE)	100-50 MCG	\$367,638	8.1	\$55.30	\$471,575	9.2	\$60.55	-22.0	-14.6	-8.7	-14.6
ASTRAZENECA LP	SYMBICORT (BUDESONIDE)		\$167,957	3.7	\$71.14	\$101,129	1.9	\$86.14	66.1	101.1	-17.4	92.8
GLAXOSMITHKLINE	FLOVENT HFA (FLUTICASONE)	0.11 MG	\$128,260	2.8	\$44.57	\$166,319	3.2	\$49.05	-22.9	-15.1	-9.1	-15.9
ALL OTHER			\$1,375,326	30.5	\$5.55	\$1,573,163	30.6	\$5.62	-12.6	-11.6	-1.1	-10.3
TOTAL			\$4,507,768	100.0	\$15.41	\$5,124,438	100.0	\$15.69	-12.0	-10.4	-1.8	-9.5
<b>OSTEOPOROSIS DRUGS</b>												
PROCTER & GAMBLE	ACTONEL (RISEDRONATE)	35 MG	\$1,077,892	21.5	\$36.76	\$1,515,621	22.6	\$35.19	-28.9	-31.9	4.5	-32.4
ROCHE LABORATORIES	BONIVA (IBANDRONATE)	150 MG	\$846,725	16.9	\$48.36	\$952,277	14.2	\$49.60	-11.1	-8.8	-2.5	-13.9
LILLY, ELI & CO.	FORTEO (TERIPARATIDE)	250 MCG	\$749,865	15.0	\$442.40	\$53,585	0.8	\$510.33	1299.4	1514.3	-13.3	270.9
LILLY, ELI & CO.	EVISTA (RALOXIFENE)	60 MG	\$718,601	14.3	\$38.69	\$917,467	13.7	\$39.63	-21.7	-19.8	-2.4	-21.3
PROCTER & GAMBLE	ACTONEL (RISEDRONATE)	150 MG	\$370,964	7.4	\$43.60	\$78,089	1.1	\$48.56	375.1	429.2	-10.2	156.2
ALL OTHER			\$1,226,616	24.5	\$16.82	\$3,161,349	47.3	\$33.91	-61.2	-21.8	-50.4	-19.6
TOTAL			\$4,990,662	100.0	\$33.60	\$6,678,389	100.0	\$37.03	-25.3	-17.6	-9.3	-17.0
<b>ALL OTHER DRUGS</b>												
FOREST	NAMENDA (MEMANTINE)	10 MG	\$1,514,996	6.8	\$65.66	\$1,670,294	6.3	\$67.16	-9.3	-7.2	-2.2	-7.6
PFIZER	DETROL LA (TOLTERODINE)	4 MG	\$1,143,340	5.1	\$45.09	\$1,406,564	5.3	\$48.91	-18.7	-11.8	-7.8	-17.3
ASTRAZENECA LP	ARIMDEX (ANASTROZOLE)	1 MG	\$1,034,190	4.6	\$126.41	\$1,034,171	3.9	\$116.92	0.0	-7.5	8.1	-7.9
BOEHRINGER INGELHEIM	FLOMAX (TAMSULOSIN)	0.4 MG	\$1,029,116	4.6	\$42.10	\$939,582	3.5	\$36.52	9.5	-5.0	15.3	-6.4
MERCK	SINGULAIR (MONTelukAST)	10 MG	\$917,663	4.1	\$40.62	\$1,024,019	3.8	\$41.23	-10.4	-9.0	-1.5	-12.0
ALL OTHER			\$16,613,808	74.6	\$15.87	\$20,281,439	76.9	\$17.08	-18.1	-11.9	-4.5	-11.5
TOTAL			\$22,253,113	100.0	\$19.35	\$26,356,070	100.0	\$20.27	-15.6	-11.6	-4.5	-11.5
<b>TOTAL (ALL CATEGORIES)</b>			\$119,286,665	100.0	\$22.74	\$147,793,363	100.0	\$24.99	-19.3	-11.3	-9.0	-11.7

DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT FOR PACE ONLY, EXCLUDING PACENET. THERAPEUTIC CLASSES ARE BASED ON THE AMERICAN HOSPITAL FORMULARY SERVICE (AHFS) CLASSIFICATION SYSTEM, AS PROVIDED BY RED BOOK (SEE APPENDIX B).

**TABLE 3.4**  
**PACE AND PACENET NUMBER AND PERCENT OF EXPENDITURES AND CLAIMS BY MANUFACTURER**  
**JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>ASSOCIATED NDC LABELER CODES</u>	<u>RANK BY EXPENDITURE</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDITURES</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>
PFIZER	00009, 00013, 00025, 00049, 00069, 00071, 59762, 63010	1	\$29,592,598.19	10.7%	856,698	7.6%
ASTRA ZENECA	00186, 00310	2	\$19,887,072.38	7.2%	310,691	2.8%
NOVARTIS	00028, 00067, 00078, 00083, 00185, 00781, 53905, 58768, 66521, 66685	3	\$18,273,472.59	6.6%	787,150	7.0%
BRISTOL-MYERS SQUIBB	00003, 00015, 00056, 00072, 00087, 59772, 63653, 66733	4	\$17,587,387.45	6.4%	338,561	3.0%
MERCK	00006, 66582	5	\$16,375,290.73	5.9%	342,961	3.1%
GLAXOSMITHKLINE	00007, 00029, 00145, 00173, 14168, 19515, 59366, 63032, 65726, 66203	6	\$14,460,815.46	5.2%	228,712	2.0%
BOEHRINGER INGELHEIM	00054, 00597	7	\$14,044,265.48	5.1%	316,745	2.8%
TAKEDA	00300, 64764	8	\$12,292,600.38	4.4%	154,446	1.4%
EISAI	58063, 62856	9	\$11,478,811.66	4.2%	138,294	1.2%
LILLY	00002, 00777	10	\$10,043,596.23	3.6%	136,807	1.2%
TEVA	00093, 00172, 00182, 00555, 00575, 00703, 38245, 50111, 51285, 55953, 57844, 59310, 68546	11	\$8,990,859.93	3.3%	1,322,747	11.8%
FOREST	00258, 00456, 00785	12	\$7,597,588.51	2.7%	174,302	1.6%
WYETH	00005, 00008, 00046, 00206	13	\$6,899,381.18	2.5%	144,236	1.3%
SANOFI-AVENTIS	00024, 00039, 00066, 00068, 00075, 00088, 00955	14	\$6,675,441.57	2.4%	92,790	0.8%

**TABLE 3.4  
PACE AND PACENET NUMBER AND PERCENT OF EXPENDITURES AND CLAIMS BY MANUFACTURER  
JANUARY - DECEMBER 2009**

<u>MANUFACTURER</u>	<u>ASSOCIATED NDC LABELER CODES</u>	<u>RANK BY EXPENDITURE</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDITURES</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>
ABBOTT	00074, 57599, 60598	15	\$5,660,758.86	2.0%	123,534	1.1%
MYLAN	00378, 15330, 51079, 62794	16	\$5,209,906.60	1.9%	1,414,270	12.6%
JOHNSON & JOHNSON	00045, 00062, 10147, 17314, 50458, 50580, 57894, 59676, 68669	17	\$5,069,607.62	1.8%	52,420	0.5%
NOVO NORDISK	00169	18	\$4,896,972.74	1.8%	79,944	0.7%
PROCTER & GAMBLE	00149	19	\$3,866,377.74	1.4%	87,063	0.8%
AMGEN USA INC	55513, 58406	20	\$3,723,614.68	1.3%	6,925	0.1%
ALLERGAN	00023, 11980, 60758	21	\$3,628,623.82	1.3%	95,121	0.8%
DAIICHI-SANKYO	63395, 65597	22	\$3,089,306.57	1.1%	89,439	0.8%
SCHERING-PLOUGH	00052, 00085, 59930	23	\$2,739,671.54	1.0%	100,824	0.9%
ALCON	00065, 00299, 00998, 61314	24	\$2,666,763.87	1.0%	97,887	0.9%
ROCHE	00004	25	\$2,195,081.05	0.8%	37,861	0.3%
TOTAL, TOP 25 MANUFACTURERS			\$236,945,866.83	85.7%	7,530,428	67.1%
TOTAL, ALL OTHER MANUFACTURERS			\$39,646,160.06	14.3%	3,685,357	32.9%
TOTAL, ALL MANUFACTURERS			\$276,592,026.89	100.0%	11,215,785	100.0%

SOURCE: PDA CLAIMS HISTORY

NOTES: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

MANUFACTURER DATA ARE SUMMARIZED BY THE FIRST FIVE DIGITS OF THE 11-DIGIT NATIONAL DRUG CODE, I.E., LABELER CODE.

**TABLE 3.5  
MANUFACTURERS' REBATE CASH RECEIPTS  
BY QUARTER/YEAR BILLED AND BY FISCAL YEAR RECEIVED  
JANUARY 1991 - DECEMBER 2009**

QUARTER/YEAR BILLED	91-92 THROUGH 01-02 RECEIPTS	RECEIPTS												TOTAL	
		02-03	03-04	04-05	05-06	06-07	07-08	08-09	09-10	YTD	RECEIPTS	RECEIPTS	RECEIPTS		
JAN-DEC 1991	\$22,767,522	(\$14,702)	(\$2,038)	\$0	\$0	\$0	\$0	\$20,846	\$0	\$0	\$0	\$0	\$0	\$0	\$22,771,828
JAN-DEC 1992	\$33,085,338	\$34,972	\$4,219	\$0	\$0	\$0	\$0	\$19,211	\$0	\$0	\$0	\$0	\$0	\$0	\$33,143,739
JAN-DEC 1993	\$31,596,853	\$401,990	\$5,661	\$0	\$0	\$0	\$0	\$12,634	\$0	\$0	\$0	\$0	\$0	\$0	\$32,017,138
JAN-DEC 1994	\$30,654,918	\$7,377	\$3,868	\$0	\$0	\$248	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$30,666,411
JAN-DEC 1995	\$32,651,754	(\$100,326)	\$91,350	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$32,642,779
JAN-DEC 1996	\$31,367,617	(\$43,469)	\$42,279	\$0	\$0	\$0	\$0	\$2,285	\$0	\$0	\$0	\$0	\$0	\$0	\$31,368,712
JAN-DEC 1997	\$38,690,297	\$64,988	\$29,634	\$1,537	\$1,552	\$0	\$0	\$12,686	\$0	\$0	\$0	\$0	\$0	\$0	\$38,803,897
JAN-DEC 1998	\$48,862,313	\$31,412	(\$33,567)	\$1,473	\$1,788	\$0	\$0	\$12,158	\$0	\$0	\$0	\$0	\$0	\$157	\$48,875,735
JAN-DEC 1999	\$52,153,079	(\$166,284)	\$85,243	\$217,717	\$217,671	\$0	\$0	\$1,280	\$0	\$0	\$0	\$0	\$0	\$26,070	\$52,542,980
JAN-DEC 2000	\$58,857,801	(\$447,591)	(\$616,680)	\$1,007,093	\$823	\$0	\$0	\$186,718	\$0	\$0	\$0	\$0	\$0	\$0	\$58,988,164
JAN-DEC 2001	\$57,939,445	\$1,288,679	(\$386,926)	(\$519,910)	(\$78,055)	\$18	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$58,243,252
JAN-DEC 2002	\$10,339,259	\$60,830,701	\$288,842	\$3,927,461	\$443,563	\$3,115	\$4,075	\$4,075	\$1,070	\$1,058	\$1,058	\$1,058	\$1,058	\$1,058	\$75,839,143
JAN-DEC 2003	\$0	\$5,050,874	\$73,444,391	\$17,745,590	\$7,358,829	(\$2,733,936)	\$2,140	\$2,140	\$67,452	\$1,069	\$1,069	\$1,069	\$1,069	\$1,069	\$100,936,409
JAN-MAR 2004	\$0	\$0	\$11,482,655	\$16,273,577	\$660,588	\$361,277	\$462,584	\$462,584	\$7,666	\$643	\$643	\$643	\$643	\$643	\$29,248,990
APR-JUN 2004	\$0	\$0	\$0	\$29,708,534	\$2,063,356	\$425,464	\$188,281	\$188,281	\$32,065	\$931	\$931	\$931	\$931	\$931	\$32,418,631
JUL-SEP 2004	\$0	\$0	\$0	\$28,671,294	\$1,572,262	\$551,444	(\$520,986)	(\$520,986)	\$14,806	\$1,009	\$1,009	\$1,009	\$1,009	\$1,009	\$30,289,830
OCT-DEC 2004	\$0	\$0	\$0	\$24,735,007	\$6,899,320	\$313,698	\$41,201	\$41,201	\$2,869	\$35,663	\$35,663	\$35,663	\$35,663	\$35,663	\$32,027,759
JAN-MAR 2005	\$0	\$0	\$0	\$12,450,103	\$23,322,157	\$260,308	\$260,308	(\$540,632)	(\$2,924)	(\$25,946)	(\$25,946)	(\$25,946)	(\$25,946)	(\$25,946)	\$35,463,066
APR-JUN 2005	\$0	\$0	\$0	\$0	\$30,831,573	\$281,060	\$281,060	\$16,745	\$36,015	\$10,549	\$10,549	\$10,549	\$10,549	\$10,549	\$31,175,942
JUL-SEP 2005	\$0	\$0	\$0	\$0	\$33,196,236	\$519,425	\$519,425	\$252,481	(\$55,958)	(\$36,897)	(\$36,897)	(\$36,897)	(\$36,897)	(\$36,897)	\$33,875,287
OCT-DEC 2005	\$0	\$0	\$0	\$0	\$32,485,824	\$410,268	\$410,268	(\$781,153)	\$85,373	(\$23,102)	(\$23,102)	(\$23,102)	(\$23,102)	(\$23,102)	\$32,177,210
JAN-MAR 2006	\$0	\$0	\$0	\$0	\$25,420,400	\$10,542,899	\$10,542,899	\$205,139	\$89,446	\$8,886	\$8,886	\$8,886	\$8,886	\$8,886	\$36,266,771
APR-JUN 2006	\$0	\$0	\$0	\$0	\$0	\$34,205,769	\$34,205,769	(\$187,686)	\$358,043	\$10,026	\$10,026	\$10,026	\$10,026	\$10,026	\$34,386,152
JUL-SEP 2006	\$0	\$0	\$0	\$0	\$0	\$33,499,014	\$33,499,014	\$821,162	(\$206,715)	\$58,295	\$58,295	\$58,295	\$58,295	\$58,295	\$34,171,757
OCT-DEC 2006	\$0	\$0	\$0	\$0	\$0	\$13,179,308	\$13,179,308	\$809,776	\$58,917	\$43,691	\$43,691	\$43,691	\$43,691	\$43,691	\$14,091,692
JAN-MAR 2007	\$0	\$0	\$0	\$0	\$0	\$6,579,637	\$6,579,637	\$10,042,696	(\$35,052)	\$258,805	\$258,805	\$258,805	\$258,805	\$258,805	\$16,846,086
APR-JUN 2007	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$14,327,483	\$60,246	\$289,402	\$289,402	\$289,402	\$289,402	\$289,402	\$14,677,131
JUL-SEP 2007	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$19,514,578	(\$136)	\$354,921	\$354,921	\$354,921	\$354,921	\$354,921	\$19,869,363
OCT-DEC 2007	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$19,182,687	\$337,938	\$429,302	\$429,302	\$429,302	\$429,302	\$429,302	\$19,949,927
JAN-MAR 2008	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$13,551,772	\$3,140,495	\$349,888	\$349,888	\$349,888	\$349,888	\$349,888	\$17,042,155
APR-JUN 2008	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,971,639	\$307,754	\$307,754	\$307,754	\$307,754	\$307,754	\$13,279,393
JUL-SEP 2008	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$16,829,532	\$358,329	\$358,329	\$358,329	\$358,329	\$358,329	\$17,187,861
OCT-DEC 2008	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$19,258,030	\$591,908	\$591,908	\$591,908	\$591,908	\$591,908	\$19,849,938
JAN-MAR 2009	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$11,782,455	\$1,540,945	\$1,540,945	\$1,540,945	\$1,540,945	\$1,540,945	\$13,323,400
APR-JUN 2009	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,501,708	\$12,501,708	\$12,501,708	\$12,501,708	\$12,501,708	\$12,501,708
JUL-SEP 2009	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,905,452	\$12,905,452	\$12,905,452	\$12,905,452	\$12,905,452	\$12,905,452
TOTAL	\$448,966,196	\$66,938,621	\$84,438,932	\$134,219,475	\$164,397,888	\$98,399,018	\$77,660,160	\$64,841,475	\$30,003,719	\$1,169,865,485	\$1,169,865,485	\$1,169,865,485	\$1,169,865,485	\$1,169,865,485	\$1,169,865,485

SOURCE: PDA CHECK RECEIPTS AS REPORTED ON STATE STATUS REPORT FOR WEEK ENDING DECEMBER 26, 2009.

**SECTION 4**

**CARDHOLDER  
UTILIZATION  
DATA**



**TABLE 4.1  
PACE AND PACENET CARDHOLDER ENROLLMENTS BY QUARTER**

**PACE**

		<b>JULY 1984 - JUNE 1988</b>		
	<b><u>QUARTER</u></b>	<b><u>NEWLY ENROLLED *</u></b>	<b><u>% OF NEWLY ENROLLED</u></b>	<b><u>CUMULATIVE ENROLLMENTS</u></b>
FIRST	JUL-SEP 1984	273,001	100.0	273,001
PROGRAM	OCT-DEC 1984	23,561	7.9	296,562
YEAR	JAN-MAR 1985	20,941	6.6	317,503
	APR-JUN 1985	69,436	17.9	386,939
SECOND	JUL-SEP 1985	38,750	10.0	389,177
PROGRAM	OCT-DEC 1985	20,522	5.0	409,699
YEAR	JAN-MAR 1986	18,770	4.4	428,469
	APR-JUN 1986	17,367	3.9	445,836
THIRD	JUL-SEP 1986	23,595	5.6	420,776
PROGRAM	OCT-DEC 1986	14,982	3.4	435,758
YEAR	JAN-MAR 1987	18,130	4.0	453,888
	APR-JUN 1987	18,853	4.0	472,741
FOURTH	JUL-SEP 1987	26,133	5.9	439,967
PROGRAM	OCT-DEC 1987	10,432	2.3	450,399
YEAR	JAN-MAR 1988	13,429	2.9	463,828
	APR-JUN 1988	13,944	2.9	477,772

**PACE**

		<b>JULY 1988 - JUNE 1996</b>		
	<b><u>QUARTER</u></b>	<b><u>CUMULATIVE NEWLY ENROLLED</u></b>	<b><u>% OF NEWLY ENROLLED</u></b>	<b><u>ENROLLMENT AT END OF QUARTER**</u></b>
FIFTH	JUL-SEP 1988	15,990	3.6	443,518
PROGRAM	OCT-DEC 1988	26,069	5.7	454,428
YEAR	JAN-MAR 1989	41,866	9.1	460,232
	APR-JUN 1989	57,406	12.7	451,547
SIXTH	JUL-SEP 1989	9,847	2.2	438,834
PROGRAM	OCT-DEC 1989	17,787	4.2	426,822
YEAR	JAN-MAR 1990	30,278	7.1	424,120
	APR-JUN 1990	40,169	9.8	408,493
SEVENTH	JUL-SEP 1990	6,714	1.7	394,821
PROGRAM	OCT-DEC 1990	26,742	6.9	384,854
YEAR	JAN-MAR 1991	37,239	9.7	383,792
	APR-JUN 1991	46,020	12.4	371,592
EIGHTH	JUL-SEP 1991	8,657	2.3	370,654
PROGRAM	OCT-DEC 1991	17,529	4.7	373,365
YEAR	JAN-MAR 1992	31,581	8.4	375,697
	APR-JUN 1992	44,986	12.2	369,919
NINTH	JUL-SEP 1992	7,115	2.0	355,319
PROGRAM	OCT-DEC 1992	13,436	3.9	347,371
YEAR	JAN-MAR 1993	29,556	8.4	353,309
	APR-JUN 1993	41,397	12.1	341,361
TENTH	JUL-SEP 1993	6,658	2.0	334,757
PROGRAM	OCT-DEC 1993	11,519	3.5	331,338
YEAR	JAN-MAR 1994	20,162	6.2	324,160
	APR-JUN 1994	33,967	10.4	325,090
ELEVENTH	JUL-SEP 1994	7,091	2.3	312,413
PROGRAM	OCT-DEC 1994	11,167	3.6	307,231
YEAR	JAN-MAR 1995	22,732	7.3	311,450
	APR-JUN 1995	31,995	10.5	304,153
TWELFTH	JUL-SEP 1995	5,382	1.8	298,732
PROGRAM	OCT-DEC 1995	8,278	2.9	289,919
YEAR	JAN-MAR 1996	16,146	5.6	290,460
	APR-JUN 1996	22,518	8.1	279,397

**TABLE 4.1**  
**PACE AND PACENET CARDHOLDER ENROLLMENTS BY QUARTER**  
**JULY 1996 - DECEMBER 2009**

		<u>PACE</u>			<u>PACENET</u>		
	<u>QUARTER</u>	<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER**</u>	<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER</u>
THIRTEENTH PROGRAM YEAR	JUL-SEP 1996	4,127	1.5	267,049			
	OCT-DEC 1996	9,332	3.6	260,678	1,523	100.0	1,523
	JAN-MAR 1997	23,797	8.6	275,607	5,771	100.0	5,771
	APR-JUN 1997	30,602	11.6	264,414	9,088	100.0	9,088
FOURTEENTH PROGRAM YEAR	JUL-SEP 1997	4,536	1.8	257,291	1,949	17.7	11,037
	OCT-DEC 1997	8,694	3.5	250,671	3,801	29.5	12,889
	JAN-MAR 1998	16,693	6.6	251,915	5,710	48.5	11,771
	APR-JUN 1998	22,838	9.3	245,553	7,419	53.8	13,802
FIFTEENTH PROGRAM YEAR	JUL-SEP 1998	4,375	1.8	237,753	879	5.8	15,213
	OCT-DEC 1998	8,042	3.5	230,722	1,504	9.4	15,964
	JAN-MAR 1999	14,744	6.4	231,049	3,216	19.9	16,164
	APR-JUN 1999	20,672	9.1	227,041	4,722	27.2	17,372
SIXTEENTH PROGRAM YEAR	JUL-SEP 1999	4,086	1.8	221,535	761	4.2	18,195
	OCT-DEC 1999	7,981	3.7	217,103	1,510	8.1	18,655
	JAN-MAR 2000	18,146	8.2	220,896	4,169	21.6	19,298
	APR-JUN 2000	25,583	11.8	217,140	6,125	30.1	20,375
SEVENTEENTH PROGRAM YEAR	JUL-SEP 2000	5,061	2.4	213,041	1,032	4.9	21,223
	OCT-DEC 2000	10,283	4.9	208,227	2,034	9.3	21,781
	JAN-MAR 2001	19,041	9.1	208,299	4,610	20.8	22,167
	APR-JUN 2001	24,932	12.0	207,193	6,603	28.9	22,875
EIGHTEENTH PROGRAM YEAR	JUL-SEP 2001	3,877	1.9	204,839	1,710	6.9	24,929
	OCT-DEC 2001	7,907	4.0	199,898	3,132	12.1	25,873
	JAN-MAR 2002	16,319	8.2	199,719	6,931	23.3	29,692
	APR-JUN 2002	22,742	11.4	198,629	9,938	32.7	30,346
NINETEENTH PROGRAM YEAR	JUL-SEP 2002	3,490	1.8	191,935	1,378	4.6	29,980
	OCT-DEC 2002	6,925	3.7	188,566	2,476	8.2	30,356
	JAN-MAR 2003	13,384	7.0	190,697	5,516	17.5	31,464
	APR-JUN 2003	21,287	10.9	194,961	9,654	29.7	32,520
TWENTIETH PROGRAM YEAR	JUL-SEP 2003	4,467	2.4	187,914	2,299	6.8	33,855
	OCT-DEC 2003	8,106	4.4	185,143	3,737	10.9	34,314
	JAN-MAR 2004	21,568	10.8	200,130	37,246	51.4	72,474
	APR-JUN 2004	28,312	14.3	197,600	43,224	49.7	87,007
TWENTY-FIRST PROGRAM YEAR	JUL-SEP 2004	4,222	2.2	194,488	7,598	8.1	94,002
	OCT-DEC 2004	6,717	3.5	191,669	15,186	15.3	99,572
	JAN-MAR 2005	13,536	7.0	193,946	25,934	28.2	92,035
	APR-JUN 2005	19,467	10.2	190,273	35,063	34.2	102,622
TWENTY-SECOND PROGRAM YEAR	JUL-SEP 2005	3,935	2.1	187,696	6,301	5.9	107,240
	OCT-DEC 2005	9,001	4.8	188,495	15,579	13.3	116,755
	JAN-MAR 2006	14,476	7.6	190,654	25,774	20.8	123,687
	APR-JUN 2006	23,477	12.5	187,311	42,841	33.4	128,212
TWENTY-THIRD PROGRAM YEAR	JUL-SEP 2006	2,084	1.1	184,106	3,182	2.5	127,978
	OCT-DEC 2006	5,269	2.9	179,240	11,330	8.5	132,764
	JAN-MAR 2007	8,687	4.8	182,332	19,571	14.6	134,018
	APR-JUN 2007	11,621	6.5	178,746	26,974	19.7	136,805
TWENTY-FOURTH PROGRAM YEAR	JUL-SEP 2007	2,143	1.2	174,824	3,940	2.8	138,701
	OCT-DEC 2007	4,477	2.8	158,560	8,642	5.5	157,874
	JAN-MAR 2008	6,956	4.5	155,547	19,078	11.9	160,227
	APR-JUN 2008	9,712	6.3	155,026	29,033	17.2	169,043

**TABLE 4.1**  
**PACE AND PACENET CARDHOLDER ENROLLMENTS BY QUARTER**  
**JULY 1996 - DECEMBER 2009**

		<u>PACE</u>			<u>PACENET</u>		
<u>QUARTER</u>		<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER**</u>	<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER</u>
TWENTY-FIFTH	JUL-SEP 2008	2,321	1.5	150,074	6,087	3.6	170,931
PROGRAM	OCT-DEC 2008	4,873	3.4	141,712	11,833	6.8	173,460
YEAR	JAN-MAR 2009	6,838	6.7	101,470	17,435	10.5	165,925
	APR-JUN 2009	8,521	6.3	134,590	23,075	13.8	167,488
TWENTY-SIXTH	JUL-SEP 2009	1,848	1.4	133,248	6,469	3.8	170,994
PROGRAM	OCT-DEC 2009	2,654	2.0	131,002	13,898	8.2	169,270
YEAR							

\* THE NEWLY ENROLLED NUMBER IS CALCULATED AS A TOTAL FOR THE QUARTER.

\*\* ENROLLMENT AT END OF QUARTER REPRESENTS THE ENROLLMENT REPORTED ON THE LAST DAY OF THE QUARTER (I.E., 131,002 PACE CARDHOLDERS AND 169,270 PACENET CARDHOLDERS ON THE FILE ON DECEMBER 31, 2009).

SOURCE: PDA/MR-0-01A/CARDHOLDER FILE

**TABLE 4.2A**  
**PACE CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES**  
**BY DEMOGRAPHIC CHARACTERISTICS**  
**JANUARY - DECEMBER 2009**

	TOTAL ENROLLED CARDHOLDERS	TOTAL PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	PERCENT OF TOTAL CLAIMS	CLAIMS PER PARTICIPATING CARDHOLDER	TOTAL EXPENDITURES	STATE SHARE PER PARTICIPATING CARDHOLDER	PERCENT OF ALL EXPENDITURES
TOTAL	152,419	127,307	5,229,217	100.0	41.1	\$118,462,504	\$930.53	100.0
SEX								
FEMALE	122,145	104,731	4,404,007	84.2	42.1	\$99,319,247	\$948.33	83.8
MALE	30,274	22,576	825,210	15.8	36.6	\$19,143,256	\$847.95	16.2
AGE								
65-69 YEARS	19,101	14,072	478,563	9.2	34.0	\$11,959,563	\$849.88	10.1
70-74 YEARS	25,579	20,929	847,219	16.2	40.5	\$19,511,023	\$932.25	16.5
75-79 YEARS	30,541	25,899	1,100,681	21.0	42.5	\$24,865,167	\$960.08	21.0
80-84 YEARS	34,543	29,886	1,303,980	24.9	43.6	\$29,106,507	\$973.92	24.6
85 YEARS OR OVER	42,655	36,521	1,498,774	28.7	41.0	\$33,020,243	\$904.14	27.9
RESIDENCE TYPE								
OWN	82,477	69,244	2,771,573	53.0	40.0	\$65,533,237	\$946.41	55.3
RENT	42,133	34,603	1,432,335	27.4	41.4	\$29,585,473	\$855.00	25.0
NURSING HOME/ PERSONAL CARE HOME	3,354	2,710	150,560	2.9	55.6	\$4,006,672	\$1,478.48	3.4
LIVE WITH RELATIVE	13,603	11,567	507,108	9.7	43.8	\$11,941,370	\$1,032.37	10.1
OTHER	8,975	7,659	312,475	6.0	40.8	\$6,076,767	\$793.42	5.1
MISSING	1,877	1,524	55,166	1.1	36.2	\$1,318,985	\$865.48	1.1
MARITAL STATUS								
SINGLE OR WIDOWED	116,905	98,674	4,105,351	78.5	41.6	\$91,806,275	\$930.40	77.5
MARRIED	15,387	12,377	473,452	9.1	38.3	\$11,007,539	\$889.35	9.3
DIVORCED	14,986	12,086	472,616	9.0	39.1	\$10,997,562	\$909.94	9.3
MARRIED, LIVING SEPARATELY	5,141	4,170	177,798	3.4	42.6	\$4,651,129	\$1,115.38	3.9

**TABLE 4.2A**  
**PACE CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES**  
**BY DEMOGRAPHIC CHARACTERISTICS**  
**JANUARY - DECEMBER 2009**

ETHNIC ORIGIN	TOTAL ENROLLED CARDHOLDERS	TOTAL PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	PERCENT OF TOTAL CLAIMS	CLAIMS PER PARTICIPATING CARDHOLDER	TOTAL EXPENDITURES	STATE SHARE PER PARTICIPATING CARDHOLDER	PERCENT OF ALL EXPENDITURES
WHITE	128,941	110,087	4,667,236	89.3	42.4	\$103,822,043	\$943.09	87.6
AFRICAN-AMERICAN	13,536	10,220	333,069	6.4	32.6	\$8,435,243	\$825.37	7.1
AMERICAN INDIAN	174	128	4,495	0.1	35.1	\$109,219	\$853.27	0.1
HISPANIC	1,821	1,319	45,735	0.9	34.7	\$987,329	\$748.54	0.8
ASIAN	854	609	18,011	0.3	29.6	\$648,845	\$1,065.43	0.5
OTHER	746	526	15,723	0.3	29.9	\$504,950	\$959.98	0.4
MISSING	6,347	4,418	144,948	2.8	32.8	\$3,954,874	\$895.17	3.3
<b>INCOME - SINGLE</b>								
\$0-\$2,999	4,055	2,306	93,715	1.8	40.6	\$2,366,232	\$1,026.12	2.0
\$3,000-\$5,999	3,811	2,962	108,567	2.1	36.7	\$2,332,821	\$787.58	2.0
\$6,000-\$8,999	14,431	11,700	432,576	8.3	37.0	\$10,219,007	\$873.42	8.6
\$9,000-\$11,999	43,349	36,172	1,445,530	27.6	40.0	\$30,902,556	\$854.32	26.1
\$12,000-\$14,000	48,296	41,373	1,752,525	33.5	42.4	\$39,120,751	\$945.56	33.0
\$14,001-\$14,500	16,472	14,510	649,638	12.4	44.8	\$15,613,674	\$1,076.06	13.2
MORATORIUM	6,618	5,907	273,214	5.2	46.3	\$6,899,924	\$1,168.09	5.8
<b>INCOME - MARRIED</b>								
\$0-\$2,999	250	105	3,851	0.1	36.7	\$116,561	\$1,110.10	0.1
\$3,000-\$5,999	242	178	6,225	0.1	35.0	\$168,051	\$944.11	0.1
\$6,000-\$8,999	688	552	22,462	0.4	40.7	\$662,391	\$1,199.98	0.6
\$9,000-\$11,999	1,328	1,057	41,377	0.8	39.1	\$1,166,647	\$1,103.73	1.0
\$12,000-\$14,999	3,357	2,690	98,969	1.9	36.8	\$2,567,360	\$954.41	2.2
\$15,000-\$17,200	5,453	4,373	166,601	3.2	38.1	\$3,583,798	\$819.53	3.0
\$17,201-\$17,700	2,526	2,108	84,145	1.6	39.9	\$1,779,640	\$844.23	1.5
MORATORIUM	1,543	1,314	49,822	1.0	37.9	\$963,090	\$732.95	0.8

SOURCE: PDA/CLAIMS HISTORY, CARDHOLDER FILE  
 NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE; EXCLUDE PACENET CLAIMS.

**TABLE 4.2B  
 PACENET CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES  
 BY DEMOGRAPHIC CHARACTERISTICS  
 JANUARY - DECEMBER 2009**

	TOTAL ENROLLED CARDHOLDERS	TOTAL PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	% OF TOTAL CLAIMS	CLAIMS PER PARTICIPANT	TOTAL EXPENDITURES	TOTAL CARDHOLDER EXPENDITURES	CARDHOLDER SHARE (%) OF TOTAL EXPENDITURES	STATE SHARE (%) OF TOTAL EXPENDITURES	STATE SHARE PER PARTICIPATING CARDHOLDER	% OF STATE SHARE EXPENDITURES
TOTAL	193,781	155,002	5,987,216	100.0	38.6	\$401,318,645	\$243,266,867	60.6	39.4	\$1,019.68	100.0
SEX											
FEMALE	128,778	107,246	4,323,281	72.2	40.3	\$283,925,110	\$172,132,619	60.6	39.4	\$1,042.39	70.7
MALE	65,003	47,756	1,663,935	27.8	34.8	\$117,393,536	\$71,134,248	60.6	39.4	\$968.66	29.3
AGE											
65-69 YEARS	30,685	22,669	742,920	12.4	32.8	\$56,150,333	\$34,019,981	60.6	39.4	\$1,543.71	14.0
70-74 YEARS	37,685	29,944	1,150,537	19.2	38.4	\$81,506,895	\$49,065,967	60.2	39.8	\$1,083.39	20.5
75-79 YEARS	43,155	34,921	1,375,492	23.0	39.4	\$92,784,917	\$56,180,119	60.5	39.5	\$1,048.22	23.2
80-84 YEARS	42,744	34,877	1,398,722	23.4	40.1	\$91,090,037	\$55,169,599	60.6	39.4	\$1,029.92	22.7
85 YEARS OR OVER	39,512	32,591	1,319,545	22.0	40.5	\$79,786,465	\$48,831,201	61.2	38.8	\$949.81	19.6
RESIDENCE TYPE											
OWN	135,966	107,310	3,964,436	66.2	36.9	\$267,072,751	\$162,323,990	60.8	39.2	\$976.13	66.3
RENT	36,152	29,388	1,196,609	20.0	40.7	\$78,766,506	\$47,887,447	60.8	39.2	\$1,050.74	19.5
NURSING HOME/ PERS. CARE HOME	4,199	3,496	197,250	3.3	56.4	\$12,110,431	\$7,185,485	59.3	40.7	\$1,408.74	3.1
LIVE WITH RELATIVE	9,609	8,289	362,114	6.0	43.7	\$25,569,308	\$14,959,795	58.5	41.5	\$1,279.95	6.7
OTHER	5,923	4,920	206,277	3.4	41.9	\$13,731,931	\$8,451,876	61.5	38.5	\$1,073.18	3.3
MISSING	1,932	1,599	60,530	1.0	37.9	\$4,067,719	\$2,458,274	60.4	39.6	\$1,006.53	1.0
MARITAL STATUS											
SINGLE OR WIDOWED	100,624	82,820	3,340,923	55.8	40.3	\$218,217,460	\$132,121,105	60.5	39.5	\$1,039.56	54.5
MARRIED	78,243	60,521	2,203,565	36.8	36.4	\$151,359,737	\$92,450,275	61.1	38.9	\$973.37	37.3
DIVORCED	12,017	9,378	349,837	5.8	37.3	\$25,391,267	\$14,954,678	58.9	41.1	\$1,112.88	6.6
MARRIED, LIVING SEPARATELY	2,897	2,283	92,891	1.6	40.7	\$6,350,182	\$3,740,809	58.9	41.1	\$1,142.96	1.7
ETHNIC ORIGIN											
WHITE	168,858	136,923	5,410,537	90.4	39.5	\$360,589,714	\$218,827,838	60.7	39.3	\$1,035.34	89.7
AFRICAN-AMERICAN	9,222	6,890	224,826	3.8	32.6	\$15,989,207	\$9,260,585	57.9	42.1	\$976.58	4.3
AMERICAN INDIAN	145	117	4,035	0.1	34.5	\$326,036	\$187,750	57.6	42.4	\$1,181.93	0.1
HISPANIC	1,223	947	32,481	0.5	34.3	\$2,135,147	\$828,771	61.2	38.8	\$875.15	0.5
ASIAN	569	418	12,012	0.2	28.7	\$989,977	\$509,137	51.4	48.6	\$1,150.33	0.3
OTHER	1,205	837	24,529	0.4	29.3	\$1,729,194	\$1,077,186	62.3	37.7	\$778.98	0.4
MISSING	12,559	8,870	278,796	4.7	31.4	\$19,559,371	\$12,097,995	61.9	38.1	\$841.19	4.7


**TABLE 4.2B  
 PACENET CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES  
 BY DEMOGRAPHIC CHARACTERISTICS  
 JANUARY - DECEMBER 2009**

INCOME - SINGLE	TOTAL ENROLLED CARDHOLDERS	TOTAL PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	% OF TOTAL CLAIMS	TOTAL PARTICIPATING CLAIMS	TOTAL EXPENDITURES	TOTAL CARDHOLDER EXPENDITURES	CARDHOLDER SHARE (%) OF TOTAL EXPENDITURES	STATE SHARE (%) OF TOTAL EXPENDITURES	% OF STATE SHARE EXPENDITURES
\$14,501 - \$17,000	40,873	34,099	1,381,822	23.1	40.5	\$88,315,171	\$55,052,127	62.3	37.7	21.0
\$17,001 - \$20,000	40,914	33,376	1,347,304	22.5	40.4	\$89,246,569	\$52,913,607	59.3	40.7	23.0
\$20,001 - \$23,500	31,400	25,025	972,050	16.2	38.8	\$66,835,846	\$39,582,588	59.2	40.8	17.2
MORATORIUM	2,351	1,981	82,475	1.4	41.6	\$5,561,322	\$3,268,269	58.8	41.2	1.5
<b>INCOME - MARRIED</b>										
\$17,701 - \$20,200	8,645	6,815	251,255	4.2	36.9	\$16,512,146	\$11,656,237	70.6	29.4	3.1
\$20,201 - \$23,000	14,596	11,307	424,113	7.1	37.5	\$28,255,843	\$17,691,398	62.6	37.4	6.7
\$23,001 - \$26,000	17,609	13,588	498,085	8.3	36.7	\$33,896,715	\$20,045,621	59.1	40.9	8.8
\$26,001 - \$29,000	18,251	14,063	498,861	8.3	35.5	\$35,182,209	\$20,910,839	59.4	40.6	9.0
\$29,001 - \$31,500	16,933	12,957	460,128	7.7	35.5	\$32,539,598	\$19,249,351	59.2	40.8	8.4
MORATORIUM	2,209	1,791	71,123	1.2	39.7	\$4,973,226	\$2,896,829	58.2	41.8	1.3


SOURCE: PDA/CLAIMS HISTORY, CARDHOLDER FILE  
 NOTE: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF SERVICE. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.

**FIGURE 4.1A**  
**PERCENT OF ENROLLED PACE CARDHOLDERS**  
**BY INCOME AND MARITAL STATUS**  
**JANUARY - DECEMBER 2009**  
**(TOTAL N = 152,419)**

**SINGLE**  
**N=137,032**




**MARRIED**  
**N=15,387**




**FIGURE 4.1B**  
**PERCENT OF ENROLLED PACENET CARDHOLDERS**  
**BY INCOME AND MARITAL STATUS**  
**JANUARY - DECEMBER 2009**  
**(TOTAL N = 193,781)**

**SINGLE**  
**N=115,538**



**MARRIED**  
**N=78,243**



**TABLE 4.3  
OTHER PRESCRIPTION INSURANCE COVERAGE OF PACE AND PACENET ENROLLED CARDHOLDERS  
JANUARY - DECEMBER 2009**

<b>A. PACE</b>	<b>PACE ENROLLED CARDHOLDERS</b>		<b>PACE CLAIMS</b>		<b>STATE SHARE EXPENDITURES</b>	
	<u>NUMBER</u>	<u>% OF TOTAL</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER ENROLLED CARDHOLDER</u>	<u>TOTAL STATE SHARE EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>
OTHER PRESCRIPTION COVERAGE IDENTIFIED	144,252	94.6%	5,130,627	35.6	\$114,041,645	\$790.57
MEDICARE PART D COVERAGE	133,026	87.3%	4,681,318	35.2	\$91,108,481	\$684.89
NON MEDICARE PART D COVERAGE	11,226	7.4%	449,309	40.0	\$22,933,164	\$2,042.86
NO OTHER KNOWN PRESCRIPTION COVERAGE	8,167	5.4%	98,590	12.1	\$4,420,859	\$541.31
TOTAL PACE ENROLLED	152,419	100.0%	5,229,217	34.3	\$118,462,504	\$777.22

<b>B. PACENET</b>	<b>PACENET ENROLLED CARDHOLDERS</b>		<b>PACENET CLAIMS</b>		<b>STATE SHARE EXPENDITURES</b>	
	<u>NUMBER</u>	<u>% OF TOTAL</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER ENROLLED CARDHOLDER</u>	<u>TOTAL STATE SHARE EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>
OTHER PRESCRIPTION COVERAGE IDENTIFIED	175,638	90.6%	5,828,021	33.2	\$152,321,068	\$867.24
MEDICARE PART D COVERAGE	156,227	80.6%	5,306,165	34.0	\$129,339,487	\$827.89
NON MEDICARE PART D COVERAGE	19,411	10.0%	521,856	26.9	\$22,981,580	\$1,183.95
NO OTHER KNOWN PRESCRIPTION COVERAGE	18,143	9.4%	159,195	8.8	\$5,730,711	\$315.86
TOTAL PACENET ENROLLED	193,781	100.0%	5,987,216	30.9	\$158,051,779	\$815.62

SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY

NOTES: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE. SOME CARDHOLDERS WERE ENROLLED IN BOTH PROGRAMS FOR SOME PORTION OF THE YEAR. NOT ALL CARDHOLDERS WITH IDENTIFIED R<sub>x</sub> INSURANCE HAD ACTIVE THIRD PARTY COVERAGE FOR DRUGS REIMBURSED BY PACE AT THE TIME OF DISPENSING.

**TABLE 4.4**  
**PART D CARDHOLDER ENROLLMENT, PARTICIPATION, AND EXPENDITURES**  
**JANUARY - DECEMBER 2009**


	PACE	PACENET	TOTAL
<b>Enrolled Cardholders</b>			
Part D, Auto-Enrolled	77,206	73,426	149,539
Part D, Not Auto-Enrolled	55,842	82,857	137,596
Not Enrolled in Part D	19,371	37,498	56,460
Total PACE/PACENET Enrolled	152,419	193,781	343,595
<b>Participating Cardholders</b>			
Part D, Auto-Enrolled	69,817	68,714	137,567
Part D, Not Auto-Enrolled	44,418	66,594	110,200
Not Enrolled in Part D	13,072	19,694	32,522
Total Participating Cardholders	127,307	155,002	280,289
<b>Claims</b>			
Part D, Auto-Enrolled	2,994,637	3,012,627	6,007,264
Part D, Not Auto-Enrolled	1,686,806	2,293,973	3,980,779
Not Enrolled in Part D	547,774	680,616	1,228,390
Total Claims	5,229,217	5,987,216	11,216,433
<b>Claims Per Enrollee</b>			
Part D, Auto-Enrolled	38.79	41.03	40.17
Part D, Not Auto-Enrolled	30.21	27.69	28.93
Not Enrolled in Part D	28.28	18.15	21.76
All PACE/PACENET Enrolled	34.31	30.90	32.64
<b>State Share Expenditures</b>			
Part D, Auto-Enrolled	\$57,281,614	\$69,591,973	\$126,873,586
Part D, Not Auto-Enrolled	\$33,831,960	\$59,770,092	\$93,602,052
Not Enrolled in Part D	\$27,348,930	\$28,689,714	\$56,038,644
All PACE/PACENET Enrolled	\$118,462,504	\$158,051,779	\$276,514,282
<b>State Share Per Claim</b>			
Part D, Auto-Enrolled	\$19.13	\$23.10	\$21.12
Part D, Not Auto-Enrolled	\$20.06	\$26.06	\$23.51
Not Enrolled in Part D	\$49.93	\$42.15	\$45.62
All PACE/PACENET Enrolled	\$22.65	\$26.40	\$24.65
<b>Total Cardholder Expenditures</b>			
Part D, Auto-Enrolled	\$16,278,052	\$34,843,801	\$51,121,853
Part D, Not Auto-Enrolled	\$9,386,232	\$22,378,390	\$31,764,622
Not Enrolled in Part D	\$3,729,095	\$9,609,291	\$13,338,386
All PACE/PACENET Enrolled	\$29,393,379	\$66,831,482	\$96,224,861
<b>Cardholder Share Per Claim</b>			
Part D, Auto-Enrolled	\$5.44	\$11.57	\$8.51
Part D, Not Auto-Enrolled	\$5.56	\$9.76	\$7.98
Not Enrolled in Part D	\$6.81	\$14.12	\$10.86
All PACE/PACENET Enrolled	\$5.62	\$11.16	\$8.58
<b>TPL Share</b>			
Part D, Auto-Enrolled	\$109,842,025	\$90,977,261	\$200,819,287
Part D, Not Auto-Enrolled	\$65,720,123	\$81,824,377	\$147,544,500
Not Enrolled in Part D	\$1,406,354	\$3,633,747	\$5,040,101
All PACE/PACENET Enrolled	\$176,968,503	\$176,435,385	\$353,403,888

**TABLE 4.4**  
**PART D CARDHOLDER ENROLLMENT, PARTICIPATION, AND EXPENDITURES**  
**JANUARY - DECEMBER 2009**

	PACE	PACENET	TOTAL
TPL Share Per Claim			
Part D, Auto-Enrolled	\$36.68	\$30.20	\$33.43
Part D, Not Auto-Enrolled	\$38.96	\$35.67	\$37.06
Not Enrolled in Part D	\$2.57	\$5.34	\$4.10
All PACE/PACENET Enrolled	\$33.84	\$29.47	\$31.51
Total Expenditures (State, Cardholder, TPL)			
Part D, Auto-Enrolled	\$183,401,691	\$195,413,035	\$378,814,726
Part D, Not Auto-Enrolled	\$108,938,315	\$163,972,858	\$272,911,173
Not Enrolled in Part D	\$32,484,379	\$41,932,752	\$74,417,131
All PACE/PACENET Enrolled	\$324,824,385	\$401,318,645	\$726,143,031
Part D LIS Status Among Auto-Enrolled			
Full LIS	27,328	2,329	29,585
Partial LIS	5,785	3,203	8,940
No LIS	44,093	67,894	111,014
Total Auto-Enrolled Cardholders	77,206	73,426	149,539
Part D LIS Status Among Other Part D Enrolled			
Full LIS	19,753	3,105	22,786
Partial LIS	3,800	2,930	6,697
No LIS	32,289	76,822	108,113
Total Other Part D Enrolled Cardholders	55,842	82,857	137,596

Notes: Auto-enrolled cardholders include individuals who were auto-enrolled by PACE/PACENET into Part D plans for 2009. The expenditure totals shown are based only on claims that were recorded in the PACE/PACENET claim adjudication system. There may be additional prescription expenditures that were not submitted to PACE/PACENET.

**FIGURE 4.2**  
**PACE GENERIC UTILIZATION RATES BY QUARTER**  
**DECEMBER 1988 - DECEMBER 2009**



SOURCE: PDAMONTHLY COST CONTAINMENT REPORT



# **SECTION 5**

# **COUNTY DATA**



**TABLE 5.1  
NUMBER AND PERCENT OF PACE AND PACENET CARDHOLDERS  
AND NUMBER OF PROVIDERS BY COUNTY  
JANUARY - DECEMBER 2009**

COUNTY	NUMBER OF PACE ENROLLED CARDHOLDERS	NUMBER OF PACENET ENROLLED CARDHOLDERS	TOTAL NUMBER ENROLLED*	% OF TOTAL	NUMBER OF PARTICIPATING CARDHOLDERS	NUMBER OF PROVIDERS	TYPE OF COUNTY	STATE SHARE	PACE CLAIMS	PACENET CLAIMS	PACE STATE SHARE	PACENET STATE SHARE
PENNSYLVANIA	152,419	193,781	343,595	100.0	280,289	2,941	ALL COUNTIES	\$276,514,282	5,229,217	5,987,216	\$118,462,504	\$158,051,779
ADAMS	1,034	1,520	2,531	0.7	2,138	18	RURAL	\$1,901,461	37,327	50,833	\$752,063	\$1,149,398
ALLEGHENY	14,621	17,788	32,192	9.4	26,052	308	URBAN	\$25,398,300	484,735	514,592	\$10,852,654	\$14,545,646
ARMSTRONG	1,046	1,375	2,406	0.7	1,914	17	RURAL	\$1,765,278	30,376	35,527	\$712,880	\$1,052,397
BEAVER	2,329	3,586	5,872	1.7	4,772	42	URBAN	\$4,828,393	84,804	112,561	\$1,752,026	\$3,076,367
BEDFORD	1,109	1,384	2,480	0.7	2,000	19	RURAL	\$2,119,870	37,308	40,652	\$941,346	\$1,178,524
BERKS	3,743	6,089	9,762	2.8	8,006	64	SUBURBAN	\$7,142,959	131,876	189,582	\$2,539,075	\$4,603,884
BLAIR	2,319	3,235	5,503	1.6	4,522	40	SUBURBAN	\$4,628,503	90,549	108,680	\$1,815,937	\$2,812,567
BRADFORD	1,192	1,388	2,556	0.7	2,057	17	RURAL	\$1,701,512	34,856	40,087	\$750,608	\$950,905
BUCKS	3,954	5,556	9,442	2.7	7,709	130	URBAN	\$11,125,964	145,381	183,490	\$4,930,344	\$6,195,620
BUTLER	1,829	2,651	4,447	1.3	3,610	43	SEMIRURAL	\$3,480,161	66,483	78,742	\$1,465,716	\$2,014,445
CAMBRIA	2,901	3,611	6,472	1.9	5,242	36	SUBURBAN	\$4,946,879	92,226	100,013	\$2,057,575	\$2,889,304
CAMERON	80	162	241	0.1	190	3	SEMIRURAL	\$135,863	2,048	4,158	\$39,759	\$96,104
CARBON	1,296	1,665	2,929	0.9	2,450	15	SUBURBAN	\$2,087,064	48,985	51,284	\$915,269	\$1,171,795
CENTRE	919	1,459	2,363	0.7	1,939	32	SUBURBAN	\$1,588,173	34,125	45,493	\$588,837	\$999,336
CHESTER	2,475	3,183	5,611	1.6	4,571	93	SUBURBAN	\$5,334,402	85,804	95,316	\$2,398,300	\$2,936,102
CLARION	593	1,032	1,607	0.5	1,316	14	RURAL	\$1,201,706	18,379	30,069	\$442,320	\$759,386
CLEARFIELD	1,527	2,192	3,680	1.1	3,057	18	RURAL	\$2,837,062	59,475	74,597	\$1,120,756	\$1,716,306
CLINTON	711	1,015	1,704	0.5	1,407	8	SEMIRURAL	\$1,102,643	27,856	31,934	\$489,007	\$613,636
COLUMBIA	1,364	1,737	3,064	0.9	2,563	16	SEMIRURAL	\$2,202,136	53,160	56,407	\$1,003,331	\$1,198,806
CRAWFORD	1,306	1,932	3,211	0.9	2,527	19	RURAL	\$1,938,369	41,125	52,221	\$779,889	\$1,158,480
CUMBERLAND	1,859	2,977	4,795	1.4	4,023	68	SUBURBAN	\$3,789,263	70,283	98,067	\$1,381,122	\$2,408,141
DAUPHIN	2,073	2,704	4,739	1.4	3,812	56	URBAN	\$3,259,383	70,267	80,688	\$1,341,033	\$1,918,350
DELAWARE	4,344	5,352	9,632	2.8	7,731	137	URBAN	\$9,912,344	145,331	162,205	\$4,521,754	\$5,390,589
ELK	502	1,027	1,516	0.4	1,302	8	SEMIRURAL	\$1,190,714	17,674	35,770	\$363,022	\$827,692
ERIE	3,014	4,768	7,731	2.3	6,130	59	URBAN	\$5,536,118	102,147	138,352	\$2,046,008	\$3,490,110
FAYETTE	2,671	3,168	5,808	1.7	4,680	44	SEMIRURAL	\$4,223,804	86,232	86,728	\$1,875,553	\$2,348,251
FOREST	107	149	253	0.1	193	2	RURAL	\$146,939	3,035	4,276	\$46,490	\$100,448
FRANKLIN	1,445	2,132	3,551	1.0	2,957	24	SEMIRURAL	\$2,853,548	58,192	77,284	\$1,109,641	\$1,743,907
FULTON	216	313	526	0.2	428	3	RURAL	\$372,976	8,047	11,116	\$127,863	\$245,112
GREENE	480	529	1,002	0.3	814	9	RURAL	\$631,051	15,164	15,883	\$271,987	\$359,064

**TABLE 5.1  
NUMBER AND PERCENT OF PACE AND PACENET CARDHOLDERS  
AND NUMBER OF PROVIDERS BY COUNTY  
JANUARY - DECEMBER 2009**

COUNTY	NUMBER OF PACE ENROLLED CARDHOLDERS	NUMBER OF PACENET ENROLLED CARDHOLDERS	TOTAL NUMBER ENROLLED*	% OF TOTAL	NUMBER OF PARTICIPATING CARDHOLDERS	NUMBER OF PROVIDERS	TYPE OF COUNTY	STATE SHARE	PACE CLAIMS	PACENET CLAIMS	PACE STATE SHARE	PACENET STATE SHARE
HUNTINGDON	740	1,050	1,775	0.5	1,430	9	RURAL	\$1,252,716	25,482	32,031	\$523,962	\$728,753
INDIANA	1,127	1,492	2,601	0.8	2,138	19	RURAL	\$2,148,254	41,356	49,085	\$929,256	\$1,218,998
JEFFERSON	914	1,310	2,203	0.6	1,862	13	SEMIURURAL	\$1,817,791	33,402	43,437	\$678,648	\$1,139,143
JUNIATA	365	568	926	0.3	789	5	RURAL	\$863,209	15,677	23,314	\$325,183	\$538,026
LACKAWANNA	4,866	5,068	9,867	2.9	8,493	77	URBAN	\$8,712,304	183,681	175,892	\$4,280,751	\$4,431,553
LANCASTER	3,981	6,708	10,605	3.1	8,717	93	SUBURBAN	\$7,979,884	142,662	221,821	\$2,884,741	\$5,095,143
LAWRENCE	1,674	2,407	4,052	1.2	3,331	24	SEMIURURAL	\$2,993,166	59,329	72,557	\$1,118,388	\$1,874,777
LEBANON	1,432	2,106	3,493	1.0	2,796	23	SEMIURURAL	\$2,468,915	52,020	66,901	\$930,538	\$1,538,376
LEHIGH	3,041	4,408	7,383	2.1	6,157	61	URBAN	\$5,585,126	109,569	138,635	\$2,246,508	\$3,338,618
LUZERNE	8,198	8,368	16,429	4.8	13,900	99	SUBURBAN	\$13,315,079	311,474	282,328	\$6,383,336	\$6,931,742
LYCOMING	1,829	2,605	4,402	1.3	3,640	27	SUBURBAN	\$3,102,182	66,386	83,206	\$1,144,349	\$1,957,833
MCKEAN	681	962	1,631	0.5	1,337	13	SEMIURURAL	\$1,233,471	23,737	32,359	\$457,642	\$775,828
MERCER	1,673	2,874	4,511	1.3	3,568	32	SUBURBAN	\$3,606,592	55,569	80,656	\$1,294,223	\$2,312,369
MIFFLIN	982	1,550	2,515	0.7	2,164	11	RURAL	\$2,143,977	46,972	62,373	\$810,409	\$1,333,568
MONROE	1,437	1,835	3,244	0.9	2,612	35	RURAL	\$2,448,833	46,870	56,446	\$967,097	\$1,481,736
MONTGOMERY	5,173	6,930	12,025	3.5	9,846	203	URBAN	\$12,617,646	180,404	213,956	\$5,361,046	\$7,256,601
MONTOUR	236	313	545	0.2	451	6	SEMIURURAL	\$382,799	8,097	10,959	\$133,409	\$249,391
NORTHAMPTON	3,518	5,467	8,909	2.6	7,510	69	SUBURBAN	\$6,891,396	129,352	188,212	\$2,506,977	\$4,384,420
NORTHUMBERLAND	2,526	2,725	5,202	1.5	4,413	24	SEMIURURAL	\$3,972,764	109,932	92,475	\$1,967,618	\$2,005,146
PERRY	544	778	1,311	0.4	1,106	10	RURAL	\$1,091,227	18,997	24,018	\$445,323	\$645,904
PHILADELPHIA	20,674	16,061	36,548	10.6	28,261	361	URBAN	\$31,898,141	568,971	453,085	\$17,242,115	\$14,656,026
PIKE	510	672	1,174	0.3	934	12	RURAL	\$784,531	15,807	17,613	\$355,782	\$428,750
POTTER	328	432	753	0.2	586	4	RURAL	\$427,930	10,738	13,152	\$164,691	\$263,238
SCHUYLKILL	4,115	4,311	8,353	2.4	7,000	32	SEMIURURAL	\$5,828,755	147,359	134,407	\$2,751,823	\$3,076,932
SNYDER	495	729	1,212	0.4	1,032	13	RURAL	\$919,964	20,120	25,808	\$364,208	\$555,757
SOMERSET	1,706	2,081	3,753	1.1	3,122	16	RURAL	\$3,211,985	58,834	61,744	\$1,402,870	\$1,809,115
SULLIVAN	144	175	317	0.1	252	2	RURAL	\$195,090	4,611	4,775	\$90,793	\$104,297
SUSQUEHANNA	734	824	1,539	0.4	1,239	8	RURAL	\$1,092,213	22,860	23,434	\$481,658	\$610,556
TIOGA	731	942	1,659	0.5	1,323	10	RURAL	\$1,172,203	26,129	28,718	\$434,701	\$737,502
UNION	465	741	1,192	0.3	1,030	10	SEMIURURAL	\$887,272	20,038	25,968	\$365,956	\$521,316

**TABLE 5.1  
NUMBER AND PERCENT OF PACE AND PACENET CARDHOLDERS  
AND NUMBER OF PROVIDERS BY COUNTY  
JANUARY - DECEMBER 2009**


COUNTY	NUMBER OF PACE CARDHOLDERS	NUMBER OF PACENET ENROLLED CARDHOLDERS	TOTAL NUMBER ENROLLED*	% OF TOTAL	NUMBER OF PARTICIPATING CARDHOLDERS	NUMBER OF PROVIDERS	TYPE OF COUNTY	STATE SHARE	PACE CLAIMS	PACENET CLAIMS	PACE STATE SHARE	PACENET STATE SHARE
VENANGO	714	1,247	1,938	0.6	1,524	14	SEMIRURAL	\$1,409,850	23,047	36,230	\$472,078	\$937,772
WARREN	425	813	1,228	0.4	942	10	SEMIRURAL	\$809,858	11,944	22,293	\$269,726	\$540,132
WASHINGTON	2,755	3,706	6,405	1.9	5,202	47	SUBURBAN	\$4,744,842	88,521	107,262	\$1,886,151	\$2,858,691
WAYNE	797	957	1,744	0.5	1,444	12	RURAL	\$1,267,721	29,253	29,938	\$587,775	\$679,947
WESTMORELAND	5,427	7,623	12,966	3.8	10,592	87	SUBURBAN	\$9,266,641	180,314	214,527	\$3,674,345	\$5,592,296
WYOMING	472	532	997	0.3	816	10	RURAL	\$732,800	18,899	18,247	\$338,691	\$394,109
YORK	3,931	6,732	10,562	3.1	8,618	78	SUBURBAN	\$7,854,318	137,554	212,747	\$2,757,572	\$5,096,746

\* TOTAL NUMBER ENROLLED IS AN UNDUPLICATED COUNT OF CARDHOLDERS, SOME OF WHOM MAY HAVE BEEN ENROLLED IN BOTH PROGRAMS DURING THE YEAR.


SOURCE: PDA/CARDHOLDER FILE; CLAIMS HISTORY  
NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE.

**FIGURE 5.1**  
**PACE AND PACENET CARDHOLDER, CLAIM, AND PROVIDER INFORMATION**  
**BY COUNTY TYPE**  
**JANUARY - DECEMBER 2009**


**PENNSYLVANIA SENIOR  
 CITIZEN POPULATION**  
**N = 1,919,165**




**PARTICIPATING  
 CARDHOLDERS**  
**N = 280,289**




**ENROLLED  
 CARDHOLDERS**  
**N = 343,595**




**TOTAL CLAIMS**  
**N = 11,216,433**



**PENNSYLVANIA COUNTIES**  
**N = 67**



**PACE PROVIDERS**  
**N = 2,941**



SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY, AND 2000 CENSUS COUNTS  
 NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE.





# **SECTION 6**

# **PROVIDER DATA**



**TABLE 6.1  
PACE CLAIMS AND EXPENDITURES BY PROVIDER TYPE  
JANUARY - DECEMBER 2009**

PROVIDER TYPE	PROVIDERS		CLAIMS		EXPENDITURES		PERCENT OF CLAIMS REDUCED TO AWP-12%+\$4.00						
	JAN - JUNE NO.	JULY - DEC NO.	JAN - JUNE %	JULY - DEC %	JAN - JUNE AMOUNT	JULY - DEC AMOUNT	JAN - JUNE %	JULY - DEC %					
INDEPENDENT PHARMACIES	971	982	34.1	34.3	967,308	900,438	35.4	38.4	\$21,927,403	\$23,775,480	38.2	23.9	24.7
DISPENSING PHYSICIANS	9	9	0.3	0.3	55	51	0.0	0.0	\$4,539	\$1,108	0.0	0.0	2.0
INSTITUTIONAL PHARMACIES	26	27	0.9	0.9	13,196	12,853	0.5	0.6	\$321,166	\$336,375	0.5	39.0	37.3
CHAIN PHARMACIES	1,773	1,774	62.2	61.9	1,631,859	1,536,485	60.5	57.4	\$32,715,618	\$35,834,187	57.6	16.8	16.7
NURSING HOME PHARMACIES	53	55	1.9	1.9	74,872	71,687	2.8	2.6	\$1,456,965	\$1,728,248	2.8	23.0	27.9
MAIL ORDER PHARMACIES	19	20	0.7	0.7	17,979	18,903	0.7	1.1	\$604,342	\$581,236	0.9	12.7	14.0
TOTAL	2,851	2,867	100.0	100.0	2,705,269	2,540,417	100.0	100.0	\$57,030,032	\$62,256,633	100.0	19.6	20.0

SOURCE: PDA/PS-0-100, CLAIMS HISTORY  
NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS.

**TABLE 6.2  
PACE CLAIMS VOLUME BY PRODUCT AND PROVIDER TYPE  
JANUARY - DECEMBER 2009**

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		TOTAL	
	JAN - JUNE NO.	JULY - DEC NO.	JAN - JUNE NO.	JULY - DEC NO.	JAN - JUNE NO.	JULY - DEC NO.	JAN - JUNE NO.	JULY - DEC NO.
	%	%	%	%	%	%	%	%
INDEPENDENT PHARMACIES	327,470	301,608	32,887	31,740	606,951	567,090	967,308	900,438
	33.9	33.5	3.4	3.5	62.8	63.0	100.0	100.0
DISPENSING PHYSICIANS	37	28	0	0	18	23	55	51
	67.3	54.9	0.0	0.0	32.7	45.1	100.0	100.0
INSTITUTIONAL PHARMACIES	3,938	3,528	746	804	8,512	8,521	13,196	12,853
	29.8	27.5	5.7	6.3	64.5	66.3	100.0	100.0
CHAIN PHARMACIES	522,047	489,387	49,997	49,089	1,059,815	998,009	1,631,859	1,536,485
	32.0	31.9	3.1	3.2	65.0	65.0	100.0	100.0
NURSING HOME PHARMACIES	21,973	20,469	2,034	1,707	50,865	49,511	74,872	71,687
	29.4	28.6	2.7	2.4	67.9	69.1	100.0	100.0
MAIL ORDER PHARMACIES	6,400	6,249	686	908	10,893	11,746	17,979	18,903
	35.6	33.1	3.8	4.8	60.6	62.1	100.0	100.0
TOTAL	881,865	821,269	86,350	84,248	1,737,054	1,634,900	2,705,269	2,540,417
	32.6	32.3	3.2	3.3	64.2	64.4	100.0	100.0

SOURCE: PDA/PS-0-100, CLAIMS HISTORY  
NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS.

**TABLE 6.3  
PACE EXPENDITURES BY PRODUCT AND PROVIDER TYPE  
JANUARY - DECEMBER 2009**

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		TOTAL	
	JAN - JUNE AMOUNT	JULY - DEC AMOUNT	JAN - JUNE AMOUNT	JULY - DEC AMOUNT	JAN - JUNE AMOUNT	JULY - DEC AMOUNT	JAN - JUNE AMOUNT	JULY - DEC AMOUNT
	%	%	%	%	%	%	%	%
INDEPENDENT PHARMACIES	\$16,174,320	\$18,105,107	\$1,347,427	\$1,608,714	\$4,405,655	\$4,061,659	\$21,927,403	\$23,775,480
	73.8	76.2	6.1	6.8	20.1	17.1	100.0	100.0
DISPENSING PHYSICIANS	\$4,370	\$1,057	\$0	\$0	\$169	\$51	\$4,539	\$1,108
	96.3	95.4	0.0	0.0	3.7	4.6	100.0	100.0
INSTITUTIONAL PHARMACIES	\$226,257	\$241,216	\$20,527	\$25,495	\$74,381	\$69,664	\$321,166	\$336,375
	70.4	71.7	6.4	7.6	23.2	20.7	100.0	100.0
CHAIN PHARMACIES	\$25,083,660	\$28,104,540	\$1,854,603	\$2,236,655	\$5,777,356	\$5,492,993	\$32,715,618	\$35,834,188
	76.7	78.4	5.7	6.2	17.7	15.3	100.0	100.0
NURSING HOME PHARMACIES	\$1,062,940	\$1,341,864	\$74,800	\$73,087	\$319,225	\$313,296	\$1,456,965	\$1,728,247
	73.0	77.6	5.1	4.2	21.9	18.1	100.0	100.0
MAIL ORDER PHARMACIES	\$533,807	\$487,389	\$21,899	\$34,264	\$48,636	\$59,582	\$604,342	\$581,235
	88.3	83.9	3.6	5.9	8.0	10.3	100.0	100.0
TOTAL	\$43,085,353	\$48,281,173	\$3,319,256	\$3,978,215	\$10,625,423	\$9,997,245	\$57,030,032	\$62,256,633
	75.5	77.6	5.8	6.4	18.6	16.1	100.0	100.0

SOURCE: PDA/PS-0-100, CLAIMS HISTORY  
NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS.

**TABLE 6.4**  
**AVERAGE STATE SHARE PER PACE CLAIM BY PRODUCT AND PROVIDER TYPE**  
**JANUARY - DECEMBER 2009**

<u>PROVIDER TYPE</u>	<u>BRAND SINGLE-SOURCE</u>		<u>BRAND MULTI-SOURCE</u>		<u>GENERIC</u>		<u>AVERAGE FOR ALL TYPES</u>	
	<u>JAN - JUNE</u>	<u>JULY - DEC</u>	<u>JAN - JUNE</u>	<u>JULY - DEC</u>	<u>JAN - JUNE</u>	<u>JULY - DEC</u>	<u>JAN - JUNE</u>	<u>JULY - DEC</u>
INDEPENDENT PHARMACIES	\$49.39	\$60.03	\$40.97	\$50.68	\$7.26	\$7.16	\$22.67	\$26.40
DISPENSING PHYSICIANS	\$118.10	\$37.74	\$0.00	\$0.00	\$9.39	\$2.22	\$82.52	\$21.72
INSTITUTIONAL PHARMACIES	\$57.45	\$68.37	\$27.52	\$31.71	\$8.74	\$8.18	\$24.34	\$26.17
CHAIN PHARMACIES	\$48.05	\$57.43	\$37.09	\$45.56	\$5.45	\$5.50	\$20.05	\$23.32
NURSING HOME PHARMACIES	\$48.37	\$65.56	\$36.77	\$42.82	\$6.28	\$6.33	\$19.46	\$24.11
MAIL ORDER PHARMACIES	\$83.41	\$77.99	\$31.92	\$37.74	\$4.46	\$5.07	\$33.61	\$30.75
ALL PROVIDER TYPES	\$48.86	\$58.79	\$38.44	\$47.22	\$6.12	\$6.11	\$21.08	\$24.51

SOURCE: PDA/PS-0-100, CLAIMS HISTORY  
NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS.

**TABLE 6.5  
PACENET CLAIMS AND EXPENDITURES BY PROVIDER TYPE  
JANUARY - DECEMBER 2009**

PROVIDER TYPE	PROVIDERS		CLAIMS				EXPENDITURES				% OF TOTAL EXPENDITURES
	ENROLLED	PARTICIPATING	DEDUCTIBLE CLAIMS <sup>1</sup>	COPAID CLAIMS	TOTAL CLAIMS	% OF CLAIMS	CARDHOLDER EXPENDITURES	OTHER PAYER EXPENDITURES	STATE SHARE EXPENDITURES	TOTAL EXPENDITURES	
INDEPENDENT PHARMACIES	1,132	1,014	527,260	1,564,046	2,091,306	35.0	\$23,607,426	\$59,302,942	\$57,059,898	\$139,970,267	35.1
DISPENSING PHYSICIANS	59	9	22	80	102	0.0	\$1,204	\$27,807	\$8,296	\$37,307	0.0
INSTITUTIONAL PHARMACIES	31	27	3,887	15,776	19,663	0.3	\$213,200	\$586,609	\$601,636	\$1,401,445	0.4
CHAIN PHARMACIES	1,898	1,796	944,814	2,665,941	3,610,755	60.5	\$39,823,718	\$102,376,266	\$92,209,820	\$234,409,803	58.8
NURSING HOME PHARMACIES	68	55	34,554	131,188	165,742	2.8	\$1,608,522	\$4,206,759	\$3,873,376	\$9,688,657	2.4
MAIL ORDER PHARMACIES	30	21	13,731	68,800	82,531	1.4	\$1,414,199	\$8,167,895	\$3,552,336	\$13,134,430	3.3
TOTAL (ALL PROVIDERS)	3,218	2,922	1,524,268	4,445,831	5,970,099	100.0	\$66,668,269	\$174,668,278	\$157,305,362	\$398,641,908	100.0

<sup>1</sup>IN 2009, THE MONTHLY PACENET DEDUCTIBLE WAS CHANGED TO \$29.23 TO COINCIDE WITH THE REGIONAL MEDICARE PART D PREMIUM BENCHMARK. PACENET CARDHOLDERS WHO ARE NOT ENROLLED IN PART D ARE REQUIRED TO PAY THE BENCHMARK AMOUNT PRIOR TO ANY PACENET CLAIM COVERAGE.

SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

**TABLE 6.6  
PACENET CLAIMS VOLUME BY PHASE OF COVERAGE<sup>1</sup>, PRODUCT TYPE, AND PROVIDER TYPE  
JANUARY - DECEMBER 2009**

**DEDUCTIBLE PHASE CLAIMS**

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		TOTAL (ALL PRODUCTS)	
	NO.	%	NO.	%	NO.	%	NO.	%
INDEPENDENT PHARMACIES	188,730	35.8	17,838	3.4	320,692	60.8	527,260	100.0
DISPENSING PHYSICIANS	12	54.6	0	0.0	10	45.5	22	100.0
INSTITUTIONAL PHARMACIES	1,152	29.6	235	6.1	2,500	64.3	3,887	100.0
CHAIN PHARMACIES	304,226	32.2	27,245	2.9	613,343	64.9	944,814	100.0
NURSING HOME PHARMACIES	11,053	32.0	918	2.7	22,583	65.4	34,554	100.0
MAIL ORDER PHARMACIES	5,584	40.7	501	3.7	7,646	55.7	13,731	100.0
TOTAL (ALL PROVIDERS)	510,757	33.5	46,737	3.1	966,774	63.4	1,524,268	100.0

**COPAYMENT PHASE CLAIMS**

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		TOTAL (ALL PRODUCTS)	
	NO.	%	NO.	%	NO.	%	NO.	%
INDEPENDENT PHARMACIES	537,957	34.4	51,687	3.3	974,402	62.3	1,564,046	100.0
DISPENSING PHYSICIANS	53	66.3	1	1.3	26	32.5	80	100.0
INSTITUTIONAL PHARMACIES	4,557	28.9	874	5.5	10,345	65.6	15,776	100.0
CHAIN PHARMACIES	882,273	33.1	79,895	3.0	1,703,773	63.9	2,665,941	100.0
NURSING HOME PHARMACIES	38,885	29.6	3,402	2.6	88,901	67.8	131,188	100.0
MAIL ORDER PHARMACIES	21,575	31.4	2,308	3.4	44,917	65.3	68,800	100.0
TOTAL (ALL PROVIDERS)	1,485,300	33.4	138,167	3.1	2,822,364	63.5	4,445,831	100.0

<sup>1</sup>IN 2009, THE MONTHLY PACENET DEDUCTIBLE WAS CHANGED TO \$29.23 TO COINCIDE WITH THE REGIONAL MEDICARE PART D PREMIUM BENCHMARK. PACENET CARDHOLDERS WHO ARE NOT ENROLLED IN PART D ARE REQUIRED TO PAY THE BENCHMARK AMOUNT PRIOR TO ANY PACENET CLAIM COVERAGE. THE DEDUCTIBLE AND COPAYMENT PHASES DIFFER IN THE TYPES OF CLAIMS SUBMITTED. LOW-PRICED PRESCRIPTIONS FOR WHICH THE TOTAL PRICE IS LESS THAN THE \$8 OR \$15 COPAY ARE NOT NECESSARILY SUBMITTED DURING THE COPAYMENT PHASE, BUT MAY BE SUBMITTED DURING THE DEDUCTIBLE PHASE TO SATISFY THE DEDUCTIBLE. GENERIC UTILIZATION RATES MAY THEREFORE BE HIGHER IN THE DEDUCTIBLE PHASE DUE TO THE OVER-REPRESENTATION OF LOW-PRICED GENERIC CLAIMS.

SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

**TABLE 6.7**  
**PACENET EXPENDITURES BY PHASE OF COVERAGE, PRODUCT TYPE, AND PROVIDER TYPE**  
**JANUARY - DECEMBER 2009**

**A. DEDUCTIBLE PHASE CLAIMS<sup>1</sup>**

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		ALL PRODUCTS	
	AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
<b>INDEPENDENT PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$5,491,883	60.4	\$418,728	4.6	\$3,185,103	35.0	\$9,095,714	100.0
OTHER PAYER EXPENDITURES	\$13,534,443	82.9	\$763,767	4.7	\$2,032,865	12.5	\$16,331,075	100.0
STATE SHARE EXPENDITURES	\$7,441,692	80.2	\$537,183	5.8	\$1,300,751	14.0	\$9,279,626	100.0
TOTAL EXPENDITURES	\$26,468,018	76.3	\$1,719,678	5.0	\$6,518,718	18.8	\$34,706,414	100.0
<b>DISPENSING PHYSICIANS</b>								
CARDHOLDER EXPENDITURES	\$266	80.1	\$0	0.0	\$66.00	19.9	\$331.00	100.0
OTHER PAYER EXPENDITURES	\$10,505	99.3	\$0	0.0	\$79.00	0.8	\$10,584.00	100.0
STATE SHARE EXPENDITURES	\$578	98.4	\$0	0.0	\$10.00	1.6	\$587.00	100.0
TOTAL EXPENDITURES	\$11,348	98.7	\$0	0.0	\$154.00	1.3	\$11,502.00	100.0
<b>INSTITUTIONAL PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$38,743	49.9	\$5,469	7.1	\$33,372	43.0	\$77,584	100.0
OTHER PAYER EXPENDITURES	\$60,087	82.9	\$4,130	5.7	\$8,274	11.4	\$72,491	100.0
STATE SHARE EXPENDITURES	\$62,764	78.0	\$3,889	4.8	\$13,802	17.2	\$80,455	100.0
TOTAL EXPENDITURES	\$161,594	70.1	\$13,487	5.9	\$55,447	24.1	\$230,528	100.0
<b>CHAIN PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$9,255,697	60.4	\$673,333	4.4	\$5,387,251	35.2	\$15,316,281	100.0
OTHER PAYER EXPENDITURES	\$20,462,991	79.0	\$1,055,739	4.1	\$4,395,458	17.0	\$25,914,188	100.0
STATE SHARE EXPENDITURES	\$12,922,672	82.5	\$907,822	5.8	\$1,835,960	11.7	\$15,666,454	100.0
TOTAL EXPENDITURES	\$42,641,359	74.9	\$2,636,894	4.6	\$11,618,669	20.4	\$56,896,922	100.0
<b>NURSING HOME PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$291,898	58.5	\$19,429	3.9	\$187,709	37.6	\$499,036	100.0
OTHER PAYER EXPENDITURES	\$810,932	77.4	\$47,916	4.6	\$189,182	18.1	\$1,048,030	100.0
STATE SHARE EXPENDITURES	\$367,744	78.2	\$26,612	5.7	\$76,219	16.2	\$470,575	100.0
TOTAL EXPENDITURES	\$1,470,575	72.9	\$93,956	4.7	\$453,110	22.5	\$2,017,641	100.0
<b>MAIL ORDER PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$214,423	67.4	\$13,706	4.3	\$90,230	28.3	\$318,359	100.0
OTHER PAYER EXPENDITURES	\$1,272,967	91.4	\$37,846	2.7	\$81,252	5.8	\$1,392,065	100.0
STATE SHARE EXPENDITURES	\$670,139	92.7	\$21,460	3.0	\$30,980	4.3	\$722,579	100.0
TOTAL EXPENDITURES	\$2,157,529	88.7	\$73,012	3.0	\$202,463	8.3	\$2,433,004	100.0
<b>TOTAL (ALL PROVIDERS)</b>								
CARDHOLDER EXPENDITURES	\$15,292,910	60.4	\$1,130,665	4.5	\$8,883,731	35.1	\$25,307,306	100.0
OTHER PAYER EXPENDITURES	\$36,151,925	80.8	\$1,909,397	4.3	\$6,707,110	15.0	\$44,768,432	100.0
STATE SHARE EXPENDITURES	\$21,465,588	81.9	\$1,496,965	5.7	\$3,257,721	12.4	\$26,220,274	100.0
TOTAL EXPENDITURES	\$72,910,423	75.7	\$4,537,027	4.7	\$18,848,562	19.6	\$96,296,012	100.0

<sup>1</sup>IN 2009, THE MONTHLY PACENET DEDUCTIBLE WAS CHANGED TO \$29.23 TO COINCIDE WITH THE REGIONAL MEDICARE PART D BENCHMARK PREMIUM. STATE SHARE EXPENDITURES FOR DEDUCTIBLE CLAIMS ARE ONLY INCURRED FOR TRANSITION CLAIMS WHICH COMPLETE THE \$29.23 MONTHLY DEDUCTIBLE ACCUMULATION. FOR THESE CLAIMS, THE CARDHOLDER PAYS THE OUTSTANDING DEDUCTIBLE AMOUNT AND A COPAYMENT, WHILE PACENET COVERS THE REMAINING COST, IF ANY, OF THE PRESCRIPTION.

SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

**TABLE 6.7**  
**PACENET EXPENDITURES BY PHASE OF COVERAGE, PRODUCT TYPE, AND PROVIDER TYPE**  
**JANUARY - DECEMBER 2009**

**B. COPAYMENT PHASE CLAIMS**

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		ALL PRODUCTS	
	AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
<b>INDEPENDENT PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$7,885,849	54.3	\$689,134	4.75	\$5,936,728	40.9	\$14,511,711	100.0
OTHER PAYER EXPENDITURES	\$33,155,819	77.2	\$2,066,242	4.81	\$7,749,807	18.0	\$42,971,868	100.0
STATE SHARE EXPENDITURES	\$37,365,808	78.2	\$2,901,077	6.07	\$7,513,388	15.7	\$47,780,273	100.0
TOTAL EXPENDITURES	\$78,407,476	74.5	\$5,656,454	5.37	\$21,199,922	20.1	\$105,263,852	100.0
<b>DISPENSING PHYSICIANS</b>								
CARDHOLDER EXPENDITURES	\$705	80.8	\$15	1.72	\$153	17.5	\$873	100.0
OTHER PAYER EXPENDITURES	\$16,680	96.8	\$98	0.57	\$446	2.6	\$17,224	100.0
STATE SHARE EXPENDITURES <sup>1</sup>	\$7,579	98.3	\$2	0.03	\$127	1.7	\$7,708	100.0
TOTAL EXPENDITURES	\$24,964	96.7	\$115	0.45	\$725	2.8	\$25,804	100.0
<b>INSTITUTIONAL PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$65,303	48.2	\$11,209	8.27	\$59,105	43.6	\$135,617	100.0
OTHER PAYER EXPENDITURES	\$408,656	79.5	\$21,048	4.09	\$84,415	16.4	\$514,119	100.0
STATE SHARE EXPENDITURES	\$417,886	80.2	\$22,929	4.4	\$80,366	15.4	\$521,181	100.0
TOTAL EXPENDITURES	\$891,845	76.2	\$55,187	4.71	\$223,886	19.1	\$1,170,918	100.0
<b>CHAIN PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$13,460,445	54.9	\$1,106,537	4.52	\$9,940,455	40.6	\$24,507,437	100.0
OTHER PAYER EXPENDITURES	\$56,826,069	74.3	\$3,189,436	4.17	\$16,446,573	21.5	\$76,462,078	100.0
STATE SHARE EXPENDITURES	\$61,897,782	80.9	\$4,657,586	6.08	\$9,987,998	13.1	\$76,543,366	100.0
TOTAL EXPENDITURES	\$132,184,297	74.5	\$8,953,558	5.04	\$36,375,026	20.5	\$177,512,881	100.0
<b>NURSING HOME PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$550,800	49.6	\$43,621	3.93	\$515,064	46.4	\$1,109,485	100.0
OTHER PAYER EXPENDITURES	\$2,281,924	72.2	\$134,890	4.27	\$741,915	23.5	\$3,158,729	100.0
STATE SHARE EXPENDITURES	\$2,600,309	76.4	\$199,253	5.86	\$603,239	17.7	\$3,402,801	100.0
TOTAL EXPENDITURES	\$5,433,033	70.8	\$377,764	4.92	\$1,860,218	24.3	\$7,671,015	100.0
<b>MAIL ORDER PHARMACIES</b>								
CARDHOLDER EXPENDITURES	\$613,884	56.0	\$45,875	4.19	\$436,080	39.8	\$1,095,839	100.0
OTHER PAYER EXPENDITURES	\$5,391,331	79.6	\$177,673	2.62	\$1,206,826	17.8	\$6,775,829	100.0
STATE SHARE EXPENDITURES	\$2,499,572	88.3	\$114,082	4.03	\$216,102	7.6	\$2,829,757	100.0
TOTAL EXPENDITURES	\$8,504,787	79.5	\$337,630	3.15	\$1,859,008	17.4	\$10,701,425	100.0
<b>TOTAL (ALL PROVIDERS)</b>								
CARDHOLDER EXPENDITURES	\$22,576,987	54.6	\$1,896,391	4.58	\$16,887,584	40.8	\$41,360,962	100.0
OTHER PAYER EXPENDITURES	\$98,080,478	75.5	\$5,589,387	4.3	\$26,229,981	20.2	\$129,899,846	100.0
STATE SHARE EXPENDITURES	\$104,788,937	79.9	\$7,894,930	6.02	\$18,401,221	14.0	\$131,085,088	100.0
TOTAL EXPENDITURES	\$225,446,401	74.6	\$15,380,708	5.09	\$61,518,786	20.4	\$302,345,896	100.0

<sup>1</sup>IN 2009, THE MONTHLY PACENET DEDUCTIBLE WAS CHANGED TO \$29.23 TO COINCIDE WITH THE REGIONAL MEDICARE PART D BENCHMARK PREMIUM. STATE SHARE EXPENDITURES FOR DEDUCTIBLE CLAIMS ARE ONLY INCURRED FOR TRANSITION CLAIMS WHICH COMPLETE THE \$29.23 MONTHLY DEDUCTIBLE ACCUMULATION. FOR THESE CLAIMS, THE CARDHOLDER PAYS THE OUTSTANDING DEDUCTIBLE AMOUNT AND A COPAYMENT, WHILE PACENET COVERS THE REMAINING COST, IF ANY, OF THE PRESCRIPTION.

SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

**TABLE 6.8**  
**AVERAGE CARDHOLDER AND STATE SHARE COST PER PACENET CLAIM**  
**BY PHASE OF COVERAGE, PRODUCT TYPE, AND PROVIDER TYPE**  
**JANUARY - DECEMBER 2009**

PROVIDER TYPE	<u>DEDUCTIBLE PHASE<sup>1</sup></u>				<u>COPAYMENT PHASE</u>			
	BRAND SINGLE- SOURCE	BRAND MULTI- SOURCE	GENERIC	TOTAL	BRAND SINGLE- SOURCE	BRAND MULTI- SOURCE	GENERIC	TOTAL
<b>INDEPENDENT PHARMACIES</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$29.10	\$23.47	\$9.93	\$17.25	\$14.66	\$13.33	\$6.09	\$9.28
AVERAGE OTHER PAYER SHARE	\$71.71	\$42.82	\$6.34	\$30.97	\$61.63	\$39.98	\$7.95	\$27.47
AVERAGE STATE SHARE	\$39.43	\$30.11	\$4.06	\$17.60	\$69.46	\$56.13	\$7.71	\$30.55
AVERAGE TOTAL RX COST	\$140.24	\$96.41	\$20.33	\$65.82	\$145.75	\$109.44	\$21.76	\$67.30
<b>DISPENSING PHYSICIANS</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$22.13	\$0.00	\$6.58	\$15.06	\$13.30	\$15.00	\$5.87	\$10.91
AVERAGE OTHER PAYER SHARE	\$875.41	\$0.00	\$7.89	\$481.08	\$314.71	\$98.21	\$17.14	\$215.29
AVERAGE STATE SHARE	\$48.14	\$0.00	\$0.96	\$26.69	\$143.01	\$2.00	\$4.90	\$96.36
AVERAGE TOTAL RX COST	\$945.67	\$0.00	\$15.43	\$522.83	\$471.02	\$115.21	\$27.90	\$322.56
<b>INSTITUTIONAL PHARMACIES</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$33.63	\$23.27	\$13.35	\$19.96	\$14.33	\$12.83	\$5.71	\$8.60
AVERAGE OTHER PAYER SHARE	\$52.16	\$17.57	\$3.31	\$18.65	\$89.68	\$24.08	\$8.16	\$32.59
AVERAGE STATE SHARE	\$54.48	\$16.55	\$5.52	\$20.70	\$91.70	\$26.23	\$7.77	\$33.04
AVERAGE TOTAL RX COST	\$140.27	\$57.39	\$22.18	\$59.31	\$195.71	\$63.14	\$21.64	\$74.22
<b>CHAIN PHARMACIES</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$30.42	\$24.71	\$8.78	\$16.21	\$15.26	\$13.85	\$5.83	\$9.19
AVERAGE OTHER PAYER SHARE	\$67.26	\$38.75	\$7.17	\$27.43	\$64.41	\$39.92	\$9.65	\$28.68
AVERAGE STATE SHARE	\$42.48	\$33.32	\$2.99	\$16.58	\$70.16	\$58.30	\$5.86	\$28.71
AVERAGE TOTAL RX COST	\$140.16	\$96.78	\$18.94	\$60.22	\$149.82	\$112.07	\$21.35	\$66.59
<b>NURSING HOME PHARMACIES</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$26.41	\$21.16	\$8.31	\$14.44	\$14.16	\$12.82	\$5.79	\$8.46
AVERAGE OTHER PAYER SHARE	\$73.37	\$52.20	\$8.38	\$30.33	\$58.68	\$39.65	\$8.35	\$24.08
AVERAGE STATE SHARE	\$33.27	\$28.99	\$3.38	\$13.62	\$66.87	\$58.57	\$6.79	\$25.94
AVERAGE TOTAL RX COST	\$133.05	\$102.35	\$20.06	\$58.39	\$139.72	\$111.04	\$20.92	\$58.47
<b>MAIL ORDER PHARMACIES</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$38.40	\$27.36	\$11.80	\$23.19	\$28.45	\$19.88	\$9.71	\$15.93
AVERAGE OTHER PAYER SHARE	\$227.97	\$75.54	\$10.63	\$101.38	\$249.89	\$76.98	\$26.87	\$98.49
AVERAGE STATE SHARE	\$120.01	\$42.83	\$4.05	\$52.62	\$115.86	\$49.43	\$4.81	\$41.13
AVERAGE TOTAL RX COST	\$386.38	\$145.73	\$26.48	\$177.19	\$394.20	\$146.29	\$41.39	\$155.54
<b>TOTAL (ALL PROVIDERS)</b>								
AVERAGE CARDHOLDER SHARE <sup>2</sup>	\$29.94	\$24.19	\$9.19	\$16.60	\$15.20	\$13.73	\$5.98	\$9.30
AVERAGE OTHER PAYER SHARE	\$70.78	\$40.85	\$6.94	\$29.37	\$66.03	\$40.45	\$9.29	\$29.22
AVERAGE STATE SHARE	\$42.03	\$32.03	\$3.37	\$17.20	\$70.55	\$57.14	\$6.52	\$29.48
AVERAGE TOTAL RX COST	\$142.75	\$97.08	\$19.50	\$63.18	\$151.79	\$111.32	\$21.80	\$68.01

<sup>1</sup>IN 2009, THE MONTHLY PACENET DEDUCTIBLE WAS CHANGED TO \$29.23 TO COINCIDE WITH THE REGIONAL MEDICARE PART D BENCHMARK PREMIUM. STATE SHARE EXPENDITURES FOR DEDUCTIBLE CLAIMS ARE ONLY INCURRED FOR TRANSITION CLAIMS WHICH COMPLETE THE \$29.23 MONTHLY DEDUCTIBLE ACCUMULATION. FOR THESE CLAIMS, THE CARDHOLDER PAYS THE OUTSTANDING DEDUCTIBLE AMOUNT AND A COPAYMENT, WHILE PACENET COVERS THE REMAINING COST, IF ANY, OF THE PRESCRIPTION.

<sup>2</sup>THE CARDHOLDER SHARE INCLUDES THE DEDUCTIBLE PAYMENTS, COPAYMENTS, AND GENERIC DIFFERENTIAL PAYMENTS IF BRAND IS CHOSEN OVER GENERIC. THE CARDHOLDER SHARE DURING THE COPAYMENT PHASE MAY THEREFORE EXCEED THE \$8 OR \$15 COPAYMENT.

SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.



**SECTION 7**

**THERAPEUTIC  
CLASS DATA  
AND  
DRUG UTILIZATION  
REVIEW DATA**



**TABLE 7.1A  
NUMBER AND PERCENT OF PACE CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS  
BY THERAPEUTIC CLASS  
JANUARY - DECEMBER 2009**

THERAPEUTIC CLASS <sup>1</sup>	TOTAL	% OF	TOTAL	% OF	CARD-	% OF	ANNUAL COST	
	CLAIMS	TOTAL	EXPENDITURE	TOTAL	HOLDERS WITH ANY CLAIMS	PARTICIPATING CARDHOLDERS	(PERSONS WITH CLAIMS IN CLASS)	COST (ALL ENROLLED) <sup>2</sup>
ANTI-INFEKTIVE AGENTS	134,284	2.6%	\$2,378,677.59	2.0%	53,678	42.2%	\$44.31	\$15.61
QUINOLONES	29,986	0.6%	\$615,519.47	0.5%	20,230	15.9%	\$30.43	\$4.04
CEPHALOSPORINS	15,302	0.3%	\$83,168.51	0.1%	10,838	8.5%	\$7.67	\$0.55
ANTINEOPLASTIC AGENTS	27,750	0.5%	\$3,242,592.38	2.7%	4,885	3.8%	\$663.79	\$21.27
AUTONOMIC DRUGS	183,184	3.5%	\$8,849,768.49	7.5%	31,708	24.9%	\$279.10	\$58.06
ANTICHOLINERGICS	46,539	0.9%	\$2,123,708.46	1.8%	9,685	7.6%	\$219.28	\$13.93
ADRENERGIC AGENTS	60,339	1.2%	\$1,597,083.39	1.3%	15,375	12.1%	\$103.88	\$10.48
BLOOD FORMATION & COAGULATION AGENTS	236,065	4.5%	\$9,408,981.57	7.9%	31,770	25.0%	\$296.16	\$61.73
CARDIOVASCULAR DRUGS	1,801,267	34.4%	\$28,225,005.26	23.8%	105,836	83.1%	\$266.69	\$185.18
CARDIAC DRUGS	1,169,540	22.4%	\$14,292,213.76	12.1%	95,192	74.8%	\$150.14	\$93.77
ANGIOTENSION RECEPTOR BLOCKERS	227,405	4.3%	\$7,522,148.15	6.3%	27,310	21.5%	\$275.44	\$49.35
ACE INHIBITORS	225,368	4.3%	\$496,767.22	0.4%	34,687	27.2%	\$14.32	\$3.26
CARDIAC GLYCOSIDES	48,484	0.9%	\$19,478.48	0.0%	7,755	6.1%	\$2.51	\$0.13
ANTIARRHYTHMIC AGENTS	14,241	0.3%	\$287,467.21	0.2%	2,578	2.0%	\$111.51	\$1.89
BETA BLOCKERS	357,938	6.8%	\$1,981,329.65	1.7%	52,825	41.5%	\$37.51	\$13.00
CALCIUM CHANNEL BLOCKERS	279,572	5.3%	\$3,321,156.82	2.8%	39,478	31.0%	\$84.13	\$21.79
LIPID-LOWERING AGENTS	504,706	9.7%	\$12,605,913.28	10.6%	62,127	48.8%	\$202.91	\$82.71
HYPOTENSIVE AGENTS	45,404	0.9%	\$440,254.10	0.4%	7,121	5.6%	\$61.82	\$2.89
VASODILATING AGENTS	81,617	1.6%	\$886,624.12	0.7%	14,755	11.6%	\$60.09	\$5.82
ANALGESICS/ANTIPIRETTICS	236,311	4.5%	\$4,557,723.98	3.8%	45,810	36.0%	\$99.49	\$29.90
NSAIDS	77,197	1.5%	\$2,143,002.25	1.8%	18,605	14.6%	\$115.18	\$14.06
COX-2 INHIBITORS	32,958	0.6%	\$1,757,224.94	1.5%	5,846	4.6%	\$300.59	\$11.53
OPIATE AGONISTS	133,982	2.6%	\$2,106,078.24	1.8%	31,211	24.5%	\$67.48	\$13.82
PSYCHOTHERAPEUTIC AGENTS	238,129	4.6%	\$5,929,553.63	5.0%	30,401	23.9%	\$195.04	\$38.90
ANTIDEPRESSANTS	202,327	3.9%	\$3,419,019.22	2.9%	28,303	22.2%	\$120.80	\$22.43
SSRI ANTIDEPRESSANTS	88,073	1.7%	\$202,306.92	0.2%	14,651	11.5%	\$13.81	\$1.33
ANTIPSYCHOTICS	35,802	0.7%	\$2,510,534.41	2.1%	5,155	4.0%	\$487.01	\$16.47
ANXIOLYTICS/SEDATIVES/HYPNOTICS	183,549	3.5%	\$1,426,671.68	1.2%	29,021	22.8%	\$49.16	\$9.36
BENZODIAZEPINES	136,668	2.6%	\$723,572.61	0.6%	22,734	17.9%	\$31.83	\$4.75
MISCELLANEOUS ANX/SED/HYPNOTICS	43,869	0.8%	\$690,531.77	0.6%	8,871	7.0%	\$77.84	\$4.53

**TABLE 7.1A  
NUMBER AND PERCENT OF PACE CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS  
BY THERAPEUTIC CLASS  
JANUARY - DECEMBER 2009**

THERAPEUTIC CLASS <sup>1</sup>	TOTAL	% OF	TOTAL	% OF	CARD-	% OF	ANNUAL COST	
	CLAIMS	TOTAL	EXPENDITURE	TOTAL	HOLDERS WITH ANY CLAIMS	PARTICIPATING CARDHOLDERS	(PERSONS WITH CLAIMS IN CLASS)	ENROLLED <sup>2</sup>
REPLACEMENT PREPARATIONS	106,879	2.0%	\$382,705.79	0.3%	19,543	15.4%	\$19.58	\$2.51
DIURETICS	278,208	5.3%	\$268,176.45	0.2%	45,931	36.1%	\$5.84	\$1.76
LOOP DIURETICS	155,977	3.0%	\$109,515.87	0.1%	29,009	22.8%	\$3.78	\$0.72
POTASSIUM-SPARING DIURETICS	45,161	0.9%	\$79,932.04	0.1%	7,886	6.2%	\$10.14	\$0.52
THIAZIDE DIURETICS	75,683	1.4%	\$53,286.57	0.0%	14,280	11.2%	\$3.73	\$0.35
ANTITUSSIVES, EXPECTORANTS AND MUCOLYTICS	28,310	0.5%	\$761,606.96	0.6%	12,043	9.5%	\$63.24	\$5.00
EYE, EAR, NOSE AND THROAT PREPARATIONS	162,795	3.1%	\$4,906,651.27	4.1%	31,795	25.0%	\$154.32	\$32.19
GASTROINTESTINAL AGENTS	347,568	6.6%	\$14,320,994.80	12.1%	51,600	40.5%	\$277.54	\$93.96
H2-RECEPTOR ANTAGONISTS	28,379	0.5%	\$97,905.55	0.1%	6,063	4.8%	\$16.15	\$0.64
PROTON PUMP INHIBITORS	270,608	5.2%	\$13,027,360.61	11.0%	39,977	31.4%	\$325.87	\$85.47
OTHER MISCELL. ANTI-ULCER AGENTS	10,077	0.2%	\$603,450.03	0.5%	2,200	1.7%	\$274.30	\$3.96
HORMONES AND SYNTHETIC SUBSTANCES	602,603	11.5%	\$13,589,203.17	11.5%	63,694	50.0%	\$213.35	\$89.16
ADRENALS AND COMB.	92,720	1.8%	\$3,862,498.05	3.3%	22,805	17.9%	\$169.37	\$25.34
ESTROGENS AND COMB.	12,646	0.2%	\$291,158.57	0.2%	2,895	2.3%	\$100.57	\$1.91
ANTI-DIABETIC AGENTS	310,748	5.9%	\$9,068,258.31	7.7%	29,134	22.9%	\$311.88	\$59.61
THYROID AND ANTITHYROID AGENTS	185,437	3.5%	\$264,460.99	0.2%	25,532	20.1%	\$10.36	\$1.74
SMOOTH MUSCLE RELAXANTS	69,976	1.3%	\$2,817,895.27	2.4%	10,980	8.6%	\$256.64	\$18.49
THEOPHYLLINE AND RELATED DRUGS	6,460	0.1%	\$42,579.08	0.0%	978	0.8%	\$43.54	\$0.28
DRUGS FOR OSTEOPOROSIS	147,560	2.8%	\$4,947,028.53	4.2%	20,893	16.4%	\$236.78	\$32.46
ALL OTHER DRUGS	444,779	8.5%	\$12,449,266.72	10.5%	65,107	51.1%	\$191.21	\$81.68
ALL CLASSES COMBINED	5,229,217	100.0%	\$118,462,503.54	100.0%	127,307	100.0%	\$930.53	\$77.22

<sup>1</sup>The average annual number of unique therapeutic classes used by cardholders with one or more claims in 2009 was 5.9.

<sup>2</sup>The annual cost per enrollee is based on total cardholders enrolled in PACE for any portion of calendar year 2009 (N=152,419).

SOURCE: PDA/CLAIMS HISTORY AND DRUG FILES

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS.

**TABLE 7.1B  
NUMBER AND PERCENT OF PACENET CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS  
BY THERAPEUTIC CLASS  
JANUARY - DECEMBER 2009**

THERAPEUTIC CLASS <sup>1</sup>	TOTAL CLAIMS	% OF TOTAL	STATE SHARE EXPENDITURE	% OF TOTAL	CARD- HOLDERS WITH ANY CLAIMS	% OF PARTICIPATING CARDHOLDERS	ANNUAL COST (PERSONS WITH CLAIMS IN CLASS)	ANNUAL COST (ALL ENROLLED) <sup>2</sup>
ANTI-INFECTIVE AGENTS	172,808	2.9%	\$3,540,907.01	2.2%	68,167	44.0%	\$51.94	\$18.27
QUINOLONES	38,241	0.6%	\$871,526.41	0.6%	25,213	16.3%	\$34.57	\$4.50
CEPHALOSPORINS	19,868	0.3%	\$92,827.90	0.1%	14,235	9.2%	\$6.52	\$0.48
ANTINEOPLASTIC AGENTS	36,343	0.6%	\$5,924,346.22	3.7%	6,213	4.0%	\$953.54	\$30.57
AUTONOMIC DRUGS	218,405	3.6%	\$12,315,913.89	7.8%	38,009	24.5%	\$324.03	\$63.56
ANTICHOLINERGICS	59,440	1.0%	\$3,625,267.15	2.3%	12,067	7.8%	\$300.43	\$18.71
ADRENERGIC AGENTS	69,039	1.2%	\$2,048,123.02	1.3%	18,403	11.9%	\$111.29	\$10.57
BLOOD FORMATION & COAGULATION AGENTS	293,283	4.9%	\$13,980,743.59	8.8%	40,276	26.0%	\$347.12	\$72.15
CARDIOVASCULAR DRUGS	2,042,864	34.1%	\$33,884,011.33	21.4%	126,941	81.9%	\$266.93	\$174.86
CARDIAC DRUGS	1,289,105	21.5%	\$15,740,862.51	10.0%	111,902	72.2%	\$140.67	\$81.23
ANGIOTENSION RECEPTOR BLOCKERS	251,302	4.2%	\$8,736,249.18	5.5%	31,291	20.2%	\$279.19	\$45.08
ACE INHIBITORS	249,504	4.2%	\$409,942.69	0.3%	40,996	26.4%	\$10.01	\$2.12
CARDIAC GLYCOSIDES	49,730	0.8%	\$3,626.37	0.0%	8,528	5.5%	\$0.43	\$0.02
ANTIARRHYTHMIC AGENTS	19,679	0.3%	\$456,493.26	0.3%	3,656	2.4%	\$124.86	\$2.36
BETA BLOCKERS	398,839	6.7%	\$1,961,802.60	1.2%	62,543	40.3%	\$31.37	\$10.12
CALCIUM CHANNEL BLOCKERS	301,542	5.0%	\$3,378,103.96	2.1%	44,506	28.7%	\$75.90	\$17.43
LIPID-LOWERING AGENTS	608,305	10.2%	\$16,442,951.07	10.4%	78,057	50.4%	\$210.65	\$84.85
HYPOTENSIVE AGENTS	56,536	0.9%	\$555,790.54	0.4%	9,313	6.0%	\$59.68	\$2.87
VASODILATING AGENTS	88,918	1.5%	\$1,144,407.21	0.7%	17,383	11.2%	\$65.83	\$5.91
ANALGESICS/ANTIPIRETTICS	265,325	4.4%	\$5,933,327.02	3.8%	53,294	34.4%	\$111.33	\$30.62
NSAIDS	80,119	1.3%	\$2,474,475.26	1.6%	20,719	13.4%	\$119.43	\$12.77
COX-2 INHIBITORS	34,522	0.6%	\$2,115,012.50	1.3%	6,460	4.2%	\$327.40	\$10.91
OPIATE AGONISTS	156,099	2.6%	\$3,122,834.68	2.0%	37,042	23.9%	\$84.31	\$16.12
PSYCHOTHERAPEUTIC AGENTS	276,854	4.6%	\$7,768,106.34	4.9%	36,036	23.2%	\$215.57	\$40.09
ANTIDEPRESSANTS	237,889	4.0%	\$4,573,678.68	2.9%	33,969	21.9%	\$134.64	\$23.60
SSRI ANTIDEPRESSANTS	101,038	1.7%	\$155,482.37	0.1%	17,805	11.5%	\$8.73	\$0.80
ANTIPSYCHOTICS	38,965	0.7%	\$3,194,427.66	2.0%	5,639	3.6%	\$566.49	\$16.48
ANXIOLYTICS/SEDATIVES/HYPNOTICS	193,472	3.2%	\$1,198,584.66	0.8%	32,791	21.2%	\$36.55	\$6.19
BENZODIAZEPINES	142,030	2.4%	\$429,380.33	0.3%	25,398	16.4%	\$16.91	\$2.22
MISCELLANEOUS ANX/SED/HYPNOTICS	48,529	0.8%	\$761,124.88	0.5%	10,287	6.6%	\$73.99	\$3.93

**TABLE 7.1B  
NUMBER AND PERCENT OF PACENET CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS  
BY THERAPEUTIC CLASS  
JANUARY - DECEMBER 2009**

THERAPEUTIC CLASS <sup>1</sup>	TOTAL	% OF	STATE SHARE	% OF	CARD-	% OF	ANNUAL COST	
	CLAIMS	TOTAL	EXPENDITURE	TOTAL	HOLDERS WITH ANY CLAIMS	PARTICIPATING CARDHOLDERS	(PERSONS WITH CLAIMS IN CLASS)	ANNUAL COST (ALL ENROLLED) <sup>2</sup>
REPLACEMENT PREPARATIONS	109,024	1.8%	\$351,677.18	0.2%	21,037	13.6%	\$16.72	\$1.81
DIURETICS	296,544	5.0%	\$237,913.16	0.2%	51,352	33.1%	\$4.63	\$1.23
LOOP DIURETICS	163,183	2.7%	\$108,030.03	0.1%	31,839	20.5%	\$3.39	\$0.56
POTASSIUM-SPARING DIURETICS	49,829	0.8%	\$60,673.05	0.0%	9,220	5.9%	\$6.58	\$0.31
THIAZIDE DIURETICS	81,976	1.4%	\$48,370.79	0.0%	16,572	10.7%	\$2.92	\$0.25
ANTITUSSIVES, EXPECTORANTS AND MUCOLYTICS	33,004	0.6%	\$981,616.75	0.6%	14,568	9.4%	\$67.38	\$5.07
EYE, EAR, NOSE AND THROAT PREPARATIONS	181,930	3.0%	\$5,399,328.38	3.4%	38,145	24.6%	\$141.55	\$27.86
GASTROINTESTINAL AGENTS	367,535	6.1%	\$16,312,032.49	10.3%	58,007	37.4%	\$281.21	\$84.18
H2-RECEPTOR ANTAGONISTS	27,116	0.5%	\$56,391.20	0.0%	6,299	4.1%	\$8.95	\$0.29
PROTON PUMP INHIBITORS	282,916	4.7%	\$14,415,615.28	9.1%	43,668	28.2%	\$330.12	\$74.39
OTHER MISCELL. ANTI-ULCER AGENTS	13,390	0.2%	\$1,047,564.98	0.7%	2,950	1.9%	\$355.11	\$5.41
HORMONES AND SYNTHETIC SUBSTANCES	711,455	11.9%	\$22,797,342.18	14.4%	77,401	49.9%	\$294.54	\$117.64
ADRENALS AND COMB.	118,533	2.0%	\$6,225,349.96	3.9%	28,997	18.7%	\$214.69	\$32.13
ESTROGENS AND COMB.	15,692	0.3%	\$326,896.01	0.2%	3,723	2.4%	\$87.80	\$1.69
ANTI-DIABETIC AGENTS	390,150	6.5%	\$15,884,034.92	10.0%	36,929	23.8%	\$430.12	\$81.97
THYROID AND ANTITHYROID AGENTS	185,247	3.1%	\$106,655.46	0.1%	27,682	17.9%	\$3.85	\$0.55
SMOOTH MUSCLE RELAXANTS	76,158	1.3%	\$3,419,374.52	2.2%	12,488	8.1%	\$273.81	\$17.65
THEOPHYLLINE AND RELATED DRUGS	7,686	0.1%	\$51,211.21	0.0%	1,235	0.8%	\$41.47	\$0.26
DRUGS FOR OSTEOPOROSIS	150,146	2.5%	\$5,274,361.18	3.3%	22,290	14.4%	\$236.62	\$27.22
ALL OTHER DRUGS	562,066	9.4%	\$18,732,192.64	11.9%	80,693	52.1%	\$232.14	\$96.67
ALL CLASSES COMBINED	5,987,216	100.0%	\$158,051,778.54	100.0%	155,002	100.0%	\$1,019.68	\$815.62


<sup>1</sup> The average annual number of unique therapeutic classes used by cardholders with one or more claims in 2009 was 5.7.

<sup>2</sup> The annual cost per enrollee is based on total cardholders enrolled in PACENET for any portion of calendar year 2009 (N=193,776).

SOURCE: PDA/CLAIMS HISTORY AND DRUG FILES


NOTE: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF SERVICE. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.

**FIGURE 7.1**  
**PERCENT OF PACE STATE SHARE EXPENDITURES BY THERAPEUTIC CLASS**  
**JANUARY - DECEMBER 2009**  
**(TOTAL EXPENDITURES = \$118,462,504)**




SOURCE: PDA/CLAIMS HISTORY AND DRUG FILES  
 NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS.

**FIGURE 7.2  
TIMELINE OF PRODUR IMPLEMENTATION**




**FIGURE 7.3**  
**NUMBER AND PERCENT OF PACE AND PACENET CLAIMS WITH A PROSPECTIVE**  
**REVIEW MESSAGE BY THERAPEUTIC CLASS**  
**JANUARY - DECEMBER 2009**  
**N = 124,743**



SOURCE: PDA/CLAIMS HISTORY  
 NOTE: DATA INCLUDE CLAIMS BY DATE OF SERVICE WITH MULTIPLE SUBMISSIONS OF SAME CLAIM ON SAME DAY DELETED.

**FIGURE 7.3 (CONTINUED)**  
**NUMBER AND PERCENT OF PACE AND PACENET CLAIMS WITH A PROSPECTIVE**  
**REVIEW MESSAGE BY THERAPEUTIC CLASS**  
**JANUARY - DECEMBER 2009**  
**N = 124,743**



SOURCE: PDA/CLAIMS HISTORY  
 NOTE: DATA INCLUDE CLAIMS BY DATE OF SERVICE WITH MULTIPLE SUBMISSIONS OF SAME CLAIM ON SAME DAY DELETED.

# **SECTION 8**

# **PENNSYLVANIA PATIENT ASSISTANCE PROGRAM CLEARINGHOUSE**



## **PENNSYLVANIA PATIENT ASSISTANCE PROGRAM CLEARINGHOUSE (PA PAP)**

In January 2001, the PACE Program began a referral program to assist Pennsylvanians ages 60 through 64, that facilitated contact between the Area Agency on Aging offices and the patient assistance programs offered by pharmaceutical manufacturers. That Program has evolved in recent years, and, as a result, the Program now accepts applications from individual patients, physician offices, social workers and other agencies throughout the Commonwealth. In late 2004, the name of the Program changed to reflect the Program's current objectives; it became the Pennsylvania Patient Assistance Program Clearinghouse (PA PAP). The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading research-based pharmaceutical and biotechnology companies. Some of these manufacturers offer limited prescription drug assistance to persons who are not eligible for other forms of pharmaceutical coverage and who cannot afford the cost of one or more of their medications. The PA PAP coordinator provides the expertise necessary to determine the likelihood of eligibility for persons seeking assistance from manufacturers' medication programs, gathers the patient information required to complete the pharmacy assistance applications, offers guidance and assistance to the patient throughout the application and—if successful—reorder processes.

In 2006, the Clearinghouse extended assistance to all adult Pennsylvania residents who appear to meet the selected guidelines, without regard to age. Pharmaceutical manufacturers which offer pharmacy assistance programs set their income and eligibility guidelines as individual companies; they limit the products and the length of time for assistance. Typically, the gross household income should be at or below 200% of federal poverty level guidelines, but many manufacturers will consider circumstances of hardship that fall outside their usual guidelines. Household income is one factor of many criteria used by the manufacturers to determine eligibility for medication. Manufacturers require a wide range of information on company-specific forms that further complicates the application and review process. A substantial amount of coordination needs to occur between the PA PAP coordinator, the patient and the patient's physician. Since the inception of Medicare part D, some manufacturers have instituted programs to assist cardholders while they are in the part D donut hole. The requirements for the Medicare part D donut hole programs differ from the base programs offered by the manufacturers.

As a result of different settlements from the Pennsylvania Attorney General's office, the Pennsylvania Patient Assistance Program Clearinghouse has been able to offer assistance for specific medications to patients who are not eligible for the manufacturer's assistance programs. Medications currently being offered are in the antidepressant and antipsychotic therapeutic classes. Eligible patients can receive a 30-day supply of medication for which they are charged a \$6.00 copay for generic or \$9.00 copay for each brand name medication. At the end of 2009, the Clearinghouse successfully enrolled 366 patients into this program.

Despite the inherent difficulties of application, the lengthy wait for approval from the manufacturer, and the strictly limited amount of medication granted with each approval, the collaborative efforts of the local and central coordinators responded to inquiries from 14,297 patients after eight years of operation. At the end of 2009, 47% (6,852 persons) were receiving medication assistance through the PA PAP Clearinghouse, compared to 40% at the beginning of the year. The Program successfully referred persons to the PACE Program (772), PACENET Program (1628), VA benefits (11), or other insurance (9). Among the remaining inactive patients, 1 was over the income limits set by the manufacturers and were not eligible for PACE or PACENET benefits. Among the 6,852 persons receiving assistance through the PA PAP Clearinghouse, a total of 44,349 medications were obtained.

Current initiatives include continuing to process manufacturers' pharmacy assistance applications for cardholders enrolled in the adultBasic Program of the Pennsylvania Department of Insurance and Medicare part D patients currently in the donut hole and to initiate new Programs that are the result of Attorney General lawsuit settlements. Also, to change current Attorney General lawsuit settlement programs to provide greater assistance to the uninsured or underinsured.

## APPENDIX A

### THE PACE/PACENET MEDICAL EXCEPTION PROCESS

#### **BACKGROUND:**

Act 134-96, the State Lottery Law, requires publication and dissemination of the medical exception process used by the Department of Aging for the Pharmaceutical Assistance Contract for the Elderly (PACE) and for the Pharmaceutical Assistance Contract for the Elderly Needs Enhancement Tier (PACENET). Specifically, the legislation addresses the medical exception process with regard to generic substitution when an A-rated therapeutically equivalent medication is available. The law further requires that the Department of Aging distribute the medical exception process to providers and recipients in the Program.

#### **THE MEDICAL EXCEPTION PROCESS:**

Through the online claims processing system, the PACE/PACENET Program provides prospective therapeutic review of prescriptions before the pharmacist dispenses the medication to the cardholder. The review checks for potential drug interactions, duplicative therapies, over-utilization, under-utilization and other misutilization. The Department of Aging, of course, recognizes the possibility of exceptional circumstances in connection with the application of therapeutic criteria and reimbursement edits. A medical exception will be considered by the Program when the cardholder's physician indicates the diagnosis, medical rationale, anticipated therapeutic outcomes, the expected length of exception therapy, and the last trial at alternative therapy.

Act 134-96 requires a pharmacist to dispense the A-rated, therapeutically equivalent, generic drug to the cardholder if they have a prescription for a multi-source brand product. If a cardholder seeks an exception to this mandate, a pharmacist may request a short term medical exception at the time of dispensing by calling 1-800-835-4080. The PACE Program may grant a 30-day medical exception if requested. Immediately following approval of the exception, the Program sends a follow-up letter to the cardholder's prescribing physician. This letter serves as notice that the Program granted a temporary medical exception to the mandatory substitution requirement. The letter seeks the therapeutic rationale for continuing the medical exception. The Program allows 30 days for the return of the written medical exception request from the prescriber. If the Program does not receive written documentation, the short term medical exception will expire. If the prescriber does respond to the letter and provides appropriate information, the Program may grant a longer medical exception period. The cardholder may continue to obtain the brand medication without paying the extra cost of a generic differential.

The Program may refer a request to a physician consultant or to a therapeutics committee for special review and consideration. The cardholder will receive a short term medical exception until completion of the review process.

If the Program denies a request for a medical exception to the mandatory generic requirement, the cardholder may opt to continue using the brand multi-source product and, then, pay the generic differential. If this occurs, the pharmacist must collect the copay for the brand name product plus 70 percent of the average wholesale price of the brand name product from the cardholder.

Please direct questions regarding the implementation of the medical exception process to 1-800-835-4080 or in writing to:

Mr. Thomas M. Snedden  
Director, Bureau of Pharmaceutical Assistance  
Pennsylvania Department of Aging  
555 Walnut Street, 5<sup>th</sup> Floor  
Harrisburg, PA 17101-1919

Source: Pennsylvania Bulletin, Vol. 26, No. 52, December 28, 1996; address change December 8, 1997.

**APPENDIX B**  
**AMERICAN HOSPITAL FORMULARY SERVICE (AHFS) CLASSIFICATIONS**  
**FOR THERAPEUTIC CLASSES USED IN REPORT**

The American Hospital Formulary Service (AHFS) provides a universal standard of drug classification. Listed below are the AHFS classifications corresponding to the drug classes reported in the tables and figures of this report.

<u>Name of Therapeutic Class</u>	<u>AHFS Classification</u>
Anti-infective agents	08
Quinolones	08:22
Cephalosporins	08:12.06
Antineoplastic agents	10
Autonomic drugs	12
Anticholinergics	12:08
Adrenergic agents	12:12
Blood formation and coagulation agents	20
Cardiovascular drugs	24
Cardiac drugs	24:04
ACE inhibitors	24:04.04 (Red Book)*
Cardiac glycosides	24:04.08 (Red Book)*
Antiarrhythmic agents	24:04.10 (Red Book)*
Beta blockers	24:04.16 (Red Book)*
Calcium channel blockers	24:04.20 (Red Book)*
Lipid-lowering agents	24:06
Antihypertensive agents	24:08
Vasodilating agents	24:12
Analgesics/antipyretics	28:08
NSAID's/COX-2 Inhibitors	28:08.04
Opiate agonists	28:08.08
Psychotropic drugs	28:12,16,20,24,28
Anxiolytics, sedatives, hypnotics	28:24
Antidepressants	28:16.04
Antipsychotic agents	28:16.08
Replacement solutions	40:12
Diuretics	40:28
Loop diuretics	40:28.02 (Red Book)*
Thiazide diuretics	40:28.12 (Red Book)*
Potassium-sparing diuretics	40:28.10 (Red Book)*
Antitussive, expectorant and mucolytic agents	48
Eye, ear, nose and throat preparations	52
Gastrointestinal agents	56
Miscellaneous gastrointestinal drugs	56:40
H <sub>2</sub> -receptor antagonists (H <sub>2</sub> RA's)	56:24 (Red Book)*
Hormones and synthetic substances	68
Adrenals and comb.	68:04
Estrogens	68:16
Antidiabetic agents (including insulin)	68:20
Thyroid and antithyroid agents	68:36
Drugs for Osteoporosis	multiple classes (68:16.12, 68:24, 92:01)
Theophylline and related smooth muscle relaxants	86:16

\*The Red Book therapeutic classification system expands upon AHFS for these categories.

SOURCE: AHFS Drug Information 2009 and Red Book Database Services

**APPENDIX C**

**PACE**

**PROSPECTIVE DRUG**

**UTILIZATION REVIEW**

**CRITERIA**

**Updated 11/24/2010**

### Angiotensin Converting Enzyme Inhibitors - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Benazepril (Lotensin)	No Criteria	---	Less than or equal to 80 mg/day	05/15/99	Concurrent with other ACE Inhibitors	05/15/99
Captopril (Capoten)	No Criteria	---	Less than or equal to 450 mg/day	05/15/99	Concurrent with other ACE Inhibitors	05/15/99
Enalapril (Vasotec)	No Criteria	---	Less than or equal to 40 mg/day	10/18/95	Concurrent with other ACE Inhibitors	10/22/96
Fosinopril (Monopril)	No Criteria	---	Less than or equal to 80 mg/day	10/18/95	Concurrent with other ACE Inhibitors	10/22/96
Lisinopril (Prinivil)	No Criteria	---	Less than or equal to 40 mg/day	10/18/95	Concurrent with other ACE Inhibitors	10/22/96
Quinapril (Accupril)	No Criteria	---	Less than or equal to 80 mg/day	10/18/95	Concurrent with other ACE Inhibitors	10/22/96
Ramipril (Altace)	No Criteria	---	Less than or equal to 20 mg/day	10/18/95	Concurrent with other ACE Inhibitors	10/22/96
Moexipril (Univasc)	No Criteria	---	Less than or equal to 30 mg/day	01/12/98	Concurrent with other ACE Inhibitors	01/12/98
Perindopril (Aceon)	No Criteria	---	Less than or equal to 16 mg/day	05/13/02	Concurrent with other ACE Inhibitors	05/13/02

### Angiotensin II Receptor Antagonists - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Valsartan (Diovan)	No Criteria	---	Less than or equal to 320 mg/day	08/18/97	No Criteria	---
Losartan (Cozaar)	No Criteria	---	Less than or equal to 100 mg/day	04/22/98	No Criteria	---
Candesartan (Atacand)	No Criteria	---	Less than or equal to 32 mg/day	05/19/99	No Criteria	---
Irbesartan (Avapro)	No Criteria	---	Less than or equal to 300 mg/day	05/19/99	No Criteria	---
Eprosartan (Teveten)	No Criteria	---	Less than or equal to 800 mg/day	10/08/01	No Criteria	---
Telmisartan (Micardis)	No Criteria	---	Less than or equal to 80 mg/day	10/08/01	No Criteria	---
Olmесartan (Benicar)	No Criteria	---	Less than or equal to 40 mg/day	08/19/03	No Criteria	---

### Beta Blockers - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Acebutolol (Sectral)	No Criteria	---	Less than or equal to 1200 mg/day	05/15/99	Concurrent with other Beta Blockers	12/09/95
Atenolol (Tenormin)	No Criteria	---	Less than or equal to 200 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Betaxolol (Kerlone)	No Criteria	---	Less than or equal to 20 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Carteolol (Cartrol)	No Criteria	---	Less than or equal to 10 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Labetalol (Normodyne)	No Criteria	---	Less than or equal to 2400 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Metoprolol (Lopressor)	No Criteria	---	Less than or equal to 450 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Metoprolol (Toprol XL)	No Criteria	---	Less than or equal to 400 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Nadolol (Corgard)	No Criteria	---	Less than or equal to 320 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Penbutolol (Levatol)	No Criteria	---	Less than or equal to 80 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Pindolol (Visken)	No Criteria	---	Less than or equal to 60 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Propranolol (Inderal)	No Criteria	---	Less than or equal to 640 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Propranolol LA (Inderal LA)	No Criteria	---	Less than or equal to 640 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Propranolol extended release (Innopran XL)	No Criteria	---	Less than or equal to 120 mg/day	03/29/04	Concurrent with other other Beta Blockers	03/29/04
Sotalol (Betapace)	No Criteria	---	Less than or equal to 320 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Timolol (Blocadren)	No Criteria	---	Less than or equal to 60 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Bisoprolol (Zebeta)	No Criteria	---	Less than or equal to 20 mg/day	10/18/95	Concurrent with other Beta Blockers	10/18/95
Carvedilol (Coreg)	No Criteria	---	Less than or equal to 100 mg/day	08/18/97	Concurrent with other Beta Blockers	08/18/97

### Cardiac Glycosides - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Digoxin (Lanoxin)	No Criteria	---	Less than or equal to .375 mg/day	10/18/95	No Criteria	---

**Calcium Channel Blockers - Criteria Elements and Implementation Dates**

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Amlodipine (Norvasc)	No Criteria	---	Less than or equal to 10 mg/day	12/09/95	Concurrent with Other Calcium Channel Blockers	12/09/95
Bepridil (Vascor)	No Criteria	---	Less than or equal to 400 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Diltiazem (Cardizem)	No Criteria	---	Less than or equal to 360 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Diltiazem CD (Cardizem CD)	No Criteria	---	Less than or equal to 540 mg/day	05/15/99	Concurrent with Other Calcium Channel Blockers	10/15/95
Felodipine (Plendil)	No Criteria	---	Less than or equal to 20 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Isradipine (DynaCirc)	No Criteria	---	Less than or equal to 20 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Nicardipine (Cardene)	No Criteria	---	Less than or equal to 120 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Nifedipine (Procardia)	No Criteria	---	Less than or equal to 120 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Verapamil (Calan, Isoptin)	No Criteria	---	Less than or equal to 480 mg/day	10/18/95	Concurrent with Other Calcium Channel Blockers	10/18/95
Nisoldipine (Sular)	No Criteria	---	Less than or equal to 60 mg/day	08/18/97	Concurrent with Other Calcium Channel Blockers	08/18/97
Amlodipine & Atorvastatin (Caduet)	No Criteria	---	Less than or equal to 80 mg/day (based on Atorvastatin)	02/14/05	Concurrent with Other Calcium Channel Blockers	02/14/05

### Lipid Lowering Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Max. Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Fluvastatin (Lescol)	No Criteria	---	Less than or equal to 80 mg/day	04/15/97	Concurrent HMG-Co A Reductase Inhibitors	04/15/97	No Criteria	---
Simvastatin (Zocor)	No Criteria	---	Less than or equal to 80 mg/day	05/15/99	Concurrent HMG-Co A Reductase Inhibitors	04/15/97	No Criteria	---
Lovastatin (Mevacor)	No Criteria	---	Less than or equal to 80 mg/day	04/15/97	Concurrent HMG-Co A Reductase Inhibitors	04/15/97	No Criteria	---
Pravastatin (Pravachol)	No Criteria	---	Less than or equal to 80 mg/day	04/15/97	Concurrent HMG-Co A Reductase Inhibitors	04/15/97	No Criteria	---
Atorvastatin (Lipitor)	No Criteria	---	Less than or equal to 80 mg/day	12/04/97	Concurrent HMG-Co A Reductase Inhibitors	12/03/97	No Criteria	---
Ezetimibe (Zetia)	No Criteria	---	Less than or equal to 10 mg/day	03/29/04	No Criteria	---	No Criteria	---
Rosuvastatin (Crestor)	Less than or equal to 5 mg	02/14/05	Less than or equal to 40 mg/day	02/14/05	Concurrent HMG-Co A Reductase Inhibitors	02/14/05	No Criteria	---

### Antiplatelet Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Max. Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Cilostazol (Pletal)	No Criteria	---	Less than or equal to 200 mg/day	04/10/00	No Criteria	---	No Criteria	---
Ticlopidine (Ticlid)	No Criteria	---	Less than or equal to 500 mg/day	05/15/99	No Criteria	---	No Criteria	---
Clopidogrel bisulfate (Plavix)	No Criteria	---	Less than or equal to 75 mg/day	10/18/01	No Criteria	---	No Criteria	---
Aspirin/ dipyridamole (Aggrenox)	No Criteria	---	Less than or equal to 50 mg/400 mg/day	10/18/01	No Criteria	---	No Criteria	---

**Oral Antihyperglycemic Agents - Criteria Elements and Implementation Dates**

Drug Name Generic (Brand)	Max. Initial Dose		Maximum Daily Dose		Plan Protocol		Duplicate Therapy	
	MG per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Rosiglitazone (Avandia)	No Criteria	---	Less than or equal to 8 mg/day	04/10/00	New therapy denied for reimbursement	01/06/09	No Criteria	---
Metformin (Glucophage)	No Criteria	---	Less than or equal to 2550 mg/day	04/10/00	No Criteria	---	No Criteria	---
Acarbose (Precose)	No Criteria	---	Less than or equal to 300 mg/day	04/10/00	No Criteria	---	No Criteria	---
Repaglinide (Prandin)	No Criteria	---	Less than or equal to 16 mg/day	04/10/00	No Criteria	---	No Criteria	---
Miglitol (Glyset)	No Criteria	---	Less than or equal to 300 mg/day	04/10/00	No Criteria	---	No Criteria	---
Pioglitazone (Actos)	No Criteria	---	Less than or equal to 45 mg/day	10/08/01	Prior therapy with either metformin, a sulfonylurea or insulin in the previous 60 days.	---	No Criteria	---
Nateglinide (Starlix)	No Criteria	---	Less than or equal to 360 mg/day	10/08/01	No Criteria	---	No Criteria	---
Glyburide/ metformin (Glucovance)	No Criteria	---	Less than or equal to 20 mg/2000 mg/day	10/08/01	No Criteria	---	No Criteria	---
Pioglitazone/ glimepride (Duetact)	No Criteria	---	Less than or equal to 30 mg/day	06/02/09	No Criteria	---	No Criteria	---

### Non-Steroidal Anti-Inflammatory Agents (NSAIDs) - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Aspirin (Legend) (Easprin, Zorprin)	Less than or equal to 6000 mg/day	08/06/94	No Criteria	---	Concurrent NSAIDS	08/16/92
Choline Magnesium Sulfate (Trilisate)	Less than or equal to 3000 mg/day	10/28/94	No Criteria	---	Concurrent NSAIDS	10/28/94
Diclofenac (Voltaren) (Normal Release)	Less than or equal to 225 mg/day	03/25/95	No Criteria	---	Concurrent NSAIDS	08/16/92
Diclofenac (Cataflam) (Quick Release)	Less than or equal to 200 mg/day	10/28/94	No Criteria	---	Concurrent NSAIDS	10/28/94
Diflunisal (Dolobid)	Less than or equal to 1500 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Etodolac (Lodine)	Less than or equal to 1200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Fenoprofen (Nalfon)	Less than or equal to 3200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Flurbiprofen (Ansaid)	Less than or equal to 300 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Ibuprofen (Motrin)	Less than or equal to 3200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Indomethacin (Indocin)	Less than or equal to 200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Indomethacin SR (Indocin SR)	Less than or equal to 200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Ketoprofen (Orudis, Oruvail)	Less than or equal to 300 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Ketorolac (Toradol) I.M. Therapy	Less than or equal to 60 mg/day	07/05/93	5 days/ 30 days	05/15/95	Concurrent NSAIDS	08/16/92
Oral Therapy	Less than or equal to 40 mg/day	07/05/93	5 days/ 30 days	05/15/95	Concurrent NSAIDS	08/16/92
Meclofenamate (Meclomen)	Less than or equal to 400 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Mefenamic Acid (Ponstel)	Less than or equal to 1250 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Nabumetone (Relafen)	Less than or equal to 2000 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Naproxen (Naprosyn)	Less than or equal to 1500 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Naproxen Sodium (Anaprox)	Less than or equal to 1650 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Oxaprozin (Daypro)	Less than or equal to 1800 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Piroxicam (Feldene)	Less than or equal to 40 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Salsalate (Disalcid)	Less than or equal to 3000 mg/day	10/28/94	No Criteria	---	Concurrent NSAIDS	10/28/94
Sulindac (Clinoril)	Less than or equal to 400 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Tolmetin (Tolectin)	Less than or equal to 2000 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS	08/16/92
Meloxicam (Mobic)	Less than or equal to 15 mg/day	05/15/02	No Criteria	---	Concurrent NSAIDS	05/13/02
Diclofenac Epolamine (Flector Patch)		05/15/02	No Criteria	---	Concurrent NSAIDS	03/10/09

**COX-2 Inhibitors - Criteria Elements and Implementation Dates**

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Celecoxib (Celebrex)		Less than or equal to 400 mg/day	04/10/00	No Criteria	---	Concurrent NSAIDS	04/10/00
Valdecoxib (Bextra)		Less than or equal to 10mg/day	08/19/03	No Criteria	---	Concurrent NSAIDS	08/19/03

**Centrally Acting Analgesics - Criteria Elements and Implementation Dates**

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Tramadol (Ultram)		300 mg daily if over 75 years of age 400 mg daily if under 75 years of age	12/04/97	No Criteria	---	No Criteria	---

**Combination Analgesics - Criteria Elements and Implementation Dates**

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Hydrocodone and Ibuprofen (Vicoprofen)		Less than or equal to 37.5 mg/day	04/22/98	10 days/ 30 days	04/22/98	No Criteria	---

**Opiate Agonists - Criteria Elements and Implementation Dates**

Drug Name (Brand)	Generic	Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Tramadol/acetaminophen (Ultracet)		Less than or equal to 300 mg/day	08/23/03	5 days out of every 30	08/20/03	No Criteria	---

**Agents to Treat Benign Prostatic Hyperplasia - Criteria Elements and Implementation Dates**

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Initial Dose		Gender Edit	
		MG Per Day	Date Begun	MG Per Day	Date Begun	Male/ Female	Date Begun
Tamsulosin HCl (Flomax)		No Criteria	-	No Criteria	-	Male Only	01/04/07
Dutasteride (Avodart)		No Criteria	-	No Criteria	-	Male Only	02/22/07
Finasteride (Proscar)		No Criteria	-	No Criteria	-	Male Only	02/22/07
Alfuzosin (Uroxatral)		No Criteria	-	No Criteria	-	Male Only	02/22/07

**Inhaled Corticosteroids - Criteria Elements and Implementation Dates**

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Initial Dose		Gender Edit	
		MG Per Day	Date Begun	MG Per Day	Date Begun	Male/ Female	Date Begun
Budesonide (Pulmicort-Respules)		Less than or equal to 1 mg/day	06/03/09	No Criteria	-	No Criteria	-

**Other Analgesics - Criteria Elements and Implementation Dates**

Drug Name Generic (Brand)	Maximum Daily Dose		Plan Protocol		Initial Quantity		Maximum Duration		Maximum Quantity	
	MG Per Day	Date Begun	Drug	Date Begun	Quantity	Date Begun	Period	Date Begun	Quantity	Date Begun
Propoxyphene HCl (Darvon)	Less than or equal to 390 mg/day	05/13/02	No Criteria	---	No Criteria	---	No Criteria	---	No Criteria	---
Propoxyphene napsylate (Darvocet)	Less than or equal to 600 mg/day	05/13/02	No Criteria	---	No Criteria	---	No Criteria	---	No Criteria	---
Acetaminophen/Codeine Combinations	Less than or equal to 4000 mg/day	05/13/02	No Criteria	---	No Criteria	---	180 days out of 210	10/18/04	No Criteria	---
Morphine Sulfate (Kadian, Various)	No Criteria	No Criteria	Must show prior conversion with opiate before reimbursement of 200 mg extended release tab.	10/18/04	No Criteria	No Criteria	No Criteria	10/18/04	No Criteria	---
Fentanyl Citrate (Actiq)	No Criteria	No Criteria	No Criteria	10/18/04	6 units	10/18/04	No Criteria	---	48 units in a 30 day period	10/18/04
Fentanyl Transdermal (Duragesic)	No Criteria	No Criteria	Patches greater than 50 mcg must show prior conversion with opiate.	10/27/04	No Criteria	No Criteria	180 days out of 210	10/18/04	10 patches in a 30 day period. Dose increase will permit an additional 10 patches.	10/18/04
Oxycontin	Less than or equal to 320 mg	03/29/04	No Criteria	No Criteria	No Criteria	No Criteria	180 days out of 210	10/18/04	No Criteria	No Criteria

**Calcium Phosphate Binder - Criteria Elements and Implementation Dates**

Drug Name Generic (Brand)	Maximum Daily Dose		Plan Protocol		Initial Quantity		Maximum Duration		Maximum Quantity	
	MG Per Day	Date Begun	Drug	Date Begun	Quantity	Date Begun	Period	Date Begun	Quantity	Date Begun
Sevelamer Carbonate (Renvela)	Less than or equal to 7200 mg/day	04/21/08	No Criteria	No Criteria	No Criteria	No Criteria	---	---	No Criteria	No Criteria

### Histamine H<sub>2</sub> Receptor Antagonists - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Cimetidine (Tagamet) Maintenance Therapy	Less than or equal to 1600 mg/day	08/16/92	Unlimited	10/08/04	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Famotidine (Pepcid) Maintenance Therapy	Less than or equal to 40 mg/day	08/16/92	Unlimited	10/08/04	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Nizatidine (Axid) Maintenance Therapy	Less than or equal to 300 mg/day	08/16/92	Unlimited	10/08/04	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Ranitidine (Zantac) Maintenance Therapy	Less than or equal to 300 mg/day	08/16/92	Unlimited	10/08/04	Proton Pump Inhibitors and Concurrent H2.	08/16/92

### Miscellaneous Gastrointestinal Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Metoclopramide (Reglan)	Less than or equal to 60 mg/day	10/28/94	No Criteria	---	No Criteria	---
Misoprostol (Cytotec)	Less than or equal to 800 mcg/day	07/05/93	No Criteria	---	No Criteria	---
Omeprazole (Prilosec)	Less than or equal to 40 mg/day	07/05/93	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	08/28/95
Sucralfate (Carafate)	Less than or equal to 4000 mg/day	07/05/93	No Criteria	---	No Criteria	---
Lansoprazole (Prevacid)	Less than or equal to 30 mg/day	08/28/95	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	08/28/95
Pantoprazole (Protonix)	Less than or equal to 40 mg/day	10/08/01	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	10/08/01
Esomeprazole (Nexium)	Less than or equal to 40 mg/day	10/08/01	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	10/08/01
Rabeprazole (Aciphex)	Less than or equal to 20 mg/day	10/08/01	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	10/08/01
Naproxen and Lansoprazole (Prevacid NapraPAC)	1000 mg (based on Naproxen)	02/14/05	No Criteria	---	No Criteria	---

### Agent to Treat Irritable Bowel - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Maximum Initial Dose		Gender Edit	
	MG Per Day	Date Begun	mg/day	Date Begun	Male/Female	Date Begun
Alosetron (Lotronex)	No Criteria	No Criteria	No Criteria	No Criteria	Female only	10/08/04

## Antipsychotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Chlorpromazine (Thorazine)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Clozapine (Clozaril)	Less than or equal to 25 mg/day	01/16/95	Less than or equal to 100 mg/day	08/18/97	No Criteria	---
Fluphenazine (Prolixin)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---
Haloperidol (Haldol)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---
Loxapine (Loxitane)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 100 mg/day	01/16/95	No Criteria	---
Mesoridazine (Serentil)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 125 mg/day	01/16/95	No Criteria	---
Perphenazine (Trilafon)	Less than or equal to 8 mg/day	01/16/95	Less than or equal to 24 mg/day	01/16/95	No Criteria	---
Risperidone (Risperdal & Risperdal-M)	Less than or equal to 0.5 mg/day	01/16/95	Less than or equal to 6 mg/day	01/16/95	No Criteria	---
Thioridazine (Mellaril)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Thiothixene (Navane)	Less than or equal to 4 mg/day	01/16/95	Less than or equal to 20 mg/day	01/16/95	No Criteria	---
Trifluoperazine (Stelazine)	Less than or equal to 2 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---
Quetiapine (Seroquel)	Less than or equal to 50 mg/day	04/22/98	Less than or equal to 400 mg/day	04/22/98	No Criteria	---
Olanzapine (Zyprexa)	Less than or equal to 2.5 mg/day	08/18/97	Less than or equal to 10 mg/day	08/18/97	No Criteria	---
Ziprasidone (Geodon)	No Criteria	---	160 mg per day Oral 40 mg/day IM	08/16/03	No Criteria	---
Aripiprazole (Abilify)	No Criteria	---	Less than or equal to 15 mg/day	08/16/03	No Criteria	---
Paliperidone (Invega)	No Criteria	---	Less than or equal to 12 mg/day	06/02/09	No Criteria	---

## Antidepressants - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Amitriptyline (Elavil)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Amoxapine (Asendin)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 300 mg/day	01/16/95	No Criteria	---
Bupropion (Wellbutrin)	Less than or equal to 200 mg/day	01/16/95	Less than or equal to 450 mg/day	01/16/95	No Criteria	---
Citalopram (Celexa)	Less than or equal to 20 mg/day	05/15/99	Less than or equal to 40 mg/day	05/15/99	No Criteria	---
Clomipramine (Anafranil)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Desipramine (Norpramin)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Doxepin (Sinequan)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Fluoxetine (Prozac)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---
Imipramine (Tofranil)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Isocarboxazid (Marplan)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 50 mg/day	01/16/95	No Criteria	---
Maprotiline (Ludiomil)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Mirtazapine (Remeron)	Less than or equal to 15 mg/day	8/18/97	Less than or equal to 45 mg/day	08/18/97	No Criteria	---
Nefazodone (Serzone)	No Criteria	---	Less than or equal to 600 mg/day	08/28/95	No Criteria	---
Nortriptyline (Pamelor)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 150 mg/day	01/16/95	No Criteria	---
Paroxetine (Paxil)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---
Phenelzine (Nardil)	Less than or equal to 45 mg/day	01/16/95	Less than or equal to 90 mg/day	01/16/95	No Criteria	---
Protriptyline (Vivactil)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---
Sertraline (Zoloft)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Tranlycypromine (Parnate)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---
Trazodone (Desyrel)	Less than or equal to 150 mg/day	01/16/95	Less than or equal to 400 mg/day	01/16/95	No Criteria	---
Trimipramine (Surmontil)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Venlafaxine (Effexor)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 225 mg/day	01/16/95	No Criteria	---
Paroxetine (Paxil CR)	Less than or equal to 12.5 mg/day	08/16/03	Less than or equal to 50 mg/day	08/16/03	No Criteria	---
Escitalopram (Lexapro)	Less than or equal to 10 mg/day	08/16/03	Less than or equal to 20 mg/day	08/16/03	No Criteria	---
Bupropion (Wellbutrin XR)	Less than or equal to 300 mg/day	02/06/97	Less than or equal to 400 mg/day	02/06/97	No Criteria	---
Fluoxetine (Prozac weekly)	Prior to Prozac weekly being approved, 90 days of therapy with Prozac daily is required					
Duloxetine (Cymbalta)	No Criteria	---	Less than or equal to 11860 mg/day	02/11/08	No Criteria	---

### Benzodiazepines/Miscellaneous Sedative/Hypnotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Estazolam (Prosom)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 2 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Flurazepam (Dalmane)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 30 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Quazepam (Doral)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 15 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Temazepam (Restoril)	Less than or equal to 7.5 mg/day	03/01/94	Less than or equal to 15 mg/day	03/01/94	240 mg/ 6 mos	03/01/94	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Triazolam (Halcion)	Less than or equal to .125 mg/day	01/31/92	Less than or equal to .25 mg/day	01/31/92	4 mg/6 mos	01/31/92	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Zolpidem (Ambien)	Less than or equal to 5 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	10/25/05
Zaleplon (Sonata)	No Criteria	---	Less than or equal to 10 mg/day	02/19/07	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	10/25/05
Zolpidem (Ambien CR)	No Criteria	---	Less than or equal to 6.25 mg/day	11/01/05	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	10/25/05
Ramelteon (Rozerem)	No Criteria	---	Less than or equal to 8 mg/day	02/19/07	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	10/25/05
Eszopiclone (Lunesta)	No Criteria	---	Less than or equal to 2 mg/day	02/19/07	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	10/25/05

### Obsessive-Compulsive Disorder Agent - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Fluvoxamine (Luvox)	Less than or equal to 50 mg/day	08/28/95	Less than or equal to 300 mg/day	08/28/95	No Criteria	---	No Criteria	---

### Benzodiazepines - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Alprazolam (Xanax)	Less than or equal to .75 mg/day	01/16/95	Less than or equal to 3 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Alprazolam (Xanax XR)	Less than or equal to 0.5 mg/day	03/29/04	Less than or equal to 6 mg/day	03/29/04	Only for Panic Disorder			
Chlordiazepoxide (Librium)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 100 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Clonazepam (Klonopin)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 4 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Clorazepate (Tranxene)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Diazepam (Valium)	Less than or equal to 5 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Halazepam (Paxipam)	Less than or equal to 40 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Lorazepam (Ativan)	Less than or equal to 2 mg/day	01/16/95	Less than or equal to 6 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00
Oxazepam (Serax)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---	Concurrent	03/13/00

### Miscellaneous Sedative/Hypnotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Amobarbital (Amytal)	No Criteria	---	Less than or equal to 200 mg/day	01/19/98	14 days out of every 180	04/20/98	No Criteria	---
Butobarbital (Butisol)	No Criteria	---	Less than or equal to 90 mg/day	11/26/97	14 days out of every 180	04/20/98	No Criteria	---
Chloral Hydrate	No Criteria	---	Less than or equal to 1 gm/day	11/26/97	14 days out of every 180	04/20/98	No Criteria	---
Ethchlorvynol (Placidyl)	No Criteria	---	Less than or equal to 500 mg/day	11/26/97	14 days out of every 180	06/01/98	No Criteria	---
Secobarbital (Seconal)	No Criteria	---	Less than or equal to 100 mg/day	11/26/97	14 days out of every 180	06/01/98	No Criteria	---
Amobarbital/Secobarbital (Tuinal)	No Criteria	---	Less than or equal to 50 mg/day	11/26/97	14 days out of every 180	04/20/98	No Criteria	---

### Anti-Obesity Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Sibutramine (Meridia)	No Criteria	---	Less than or equal to 30 mg/day	07/26/99	60 days out of every 90	08/09/99	No Criteria	---
Phentermine HCL (Adipex-P)	No Criteria	---	Less than or equal to 37.5 mg/day	07/26/99	60 days out of every 120	08/09/99	No Criteria	---
Phendimetrazine	No Criteria	---	Less than or equal to 105 mg/day	07/26/99	60 days out of every 120	08/09/99	No Criteria	---
Diethylpropion (Tenuate)	No Criteria	---	Less than or equal to 100 mg/day	07/26/99	60 days out of every 120	08/09/99	No Criteria	---
Orlistat (Xenical)	No Criteria	---	Less than or equal to 360 mg/day	07/26/99	60 days out of every 90	08/09/99	No Criteria	---

### Bisphosphonates - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Alendronate (Fosamax)	No Criteria	---	Less than or equal to 10 mg/day	08/19/03	No Criteria	---	No Criteria	---
Risedronate (Actonel)	No Criteria	---	Less than or equal to 5 mg/day	03/29/04	No Criteria	---	No Criteria	---

### Skeletal Muscle Relaxants - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Carisoprodol (Soma)	No Criteria	---	Less than or equal to 1400 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Cholorzoxazone (Parafon Forte)	No Criteria	---	Less than or equal to 3000 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Cyclobenzaprine (Flexeril)	No Criteria	---	Less than or equal to 30 mg/day	04/18/06	No Criteria	---	21 days out of 30	06/12/00
Dantrolene (Dantrium)	No Criteria	---	Less than or equal to 400 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Metaxalone (Skelaxin)	No Criteria	---	Less than or equal to 3200 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Methocarbamol (Robaxin)	No Criteria	---	Less than or equal to 4500 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Orphenadrine Citrate (Norflex)	No Criteria	---	Less than or equal to 200 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Tizaridine (Zanaflex)	No Criteria	---	Less than or equal to 36 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Baclofen (Lioresal)	No Criteria	---	Less than or equal to 80 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00

### Cholinesterase Inhibitors - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Maximum Duration	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Donepezil (Aricept)	Less than or equal to 5 mg per day	05/15/99	Less than or equal to 10 mg per day	05/15/99	No Criteria	---	No Criteria	---
Tacrine (Cognex)	Less than or equal to 40 mg per day	05/15/99	Less than or equal to 160 mg per day	05/15/99	No Criteria	---	No Criteria	---
Rivastigmine (Exelon)	Less than or equal to 3 mg per day	05/17/02	Less than or equal to 12 mg per day	05/13/02	No Criteria	---	No Criteria	---
Galantamine (Reminyl)	Less than or equal to 8 mg per day	05/17/02	Less than or equal to 24 mg per day	05/13/02	No Criteria	---	No Criteria	---
Memantine (Namenda)	Less than or equal to 5 mg	02/14/05	Less than or equal to 20 mg per day	02/14/05	No Criteria	---	No Criteria	---

### Erectile Dysfunction Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Duplicate Therapy		Maximum Daily Dose		Gender Edit		Maximum Duration	
	Class	Date Begun	MG Per Day	Date Begun	Male/ Female	Date Begun	Period	Date Begun
Sildenafil Citrate (Viagra)	Concurrent with other erectile dysfunction agents	05/07/04	Less than or equal to 50 mg/day	06/01/98	Male	10/18/04	8 days out of every 30	01/04/99
Vardenafil (Levitra)	Concurrent with other erectile dysfunction agents	05/07/04	No Criteria	---	Male	10/18/04	8 days out of every 30	10/31/03
Tadalafil (Cialis)	Concurrent with other erectile dysfunction agents	04/29/08	Less than or equal to 20 mg/day	03/15/04	Male	10/18/04	8 days out of every 30	05/05/04
Alprostadil (Caverject)	Concurrent with other erectile dysfunction agents	05/07/04	No Criteria	---	Male	02/11/08	8 days out of every 30	02/11/08

### Antibiotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Maximum Duration	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Doxycycline (Periostat)	No Criteria	---	Less than or equal to 40 mg/day	05/13/02	No Criteria	---	9 months out of every 12	05/13/02
Rifaximin (Xifaxan)	No Criteria	---	No Criteria	---	No Criteria	---	3 days out of every 180	06/03/09

### Antihistamines - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Cetirizine (Zyrtec, Zyrtec-D)	No Criteria	---	Less than or equal to 10 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---
Desloratadine (Clarinet, Clarinet-D)	No Criteria	---	Less than or equal to 5 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---
Fexofenadine (Allegra, Allegra-D)	No Criteria	---	Less than or equal to 120 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---
Fexofenadine (Allegra, 180 mg strength tablet)	No Criteria	---	Less than or equal to 180 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---

### Antimigraine Agents - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Zolmitriptan (Zomig, ZMT)	No Criteria	---	Less than or equal to 10 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	3 days out of every 30	08/16/03
Almotriptan (Axert)	No Criteria	---	Less than or equal to 25 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
Methysergide mealeate (Sansert)	No Criteria	---	Less than or equal to 8 mg/daily	08/16/03	Concurrent with other anti-migraines	08/16/03	150 days out of every 180	08/16/03
Naratriptan (Amerge)	Not Recommended for the Elderly							
Frovatriptan (Frova)	No Criteria	---	Less than or equal to 7.5 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
DH Enesylate (Migranal)	No Criteria	---	Less than or equal to 2 bottles daily	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
Rizatriptan (Maxalt, Maxalt MLT)	No Criteria	---	Less than or equal to 30 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
Eletriptan (Relpax)	No Criteria	---	Less than or equal to 40 mg/day	03/29/04	Concurrent with other anti-migraines	03/29/04	3 days out of every 30	03/29/04

### Smoking Cessation Agent - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun
Varenicline (Chantix)	No Criteria	---	No Criteria	---	12 weeks followed by another 12 weeks if smoking cessation has been documented	02/14/07

### Thioglitazones – Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Step Therapy	Date Begun
Rosiglitazone and combinations (Avandia, Avandamet, Avandaryl)	Medical exception required	1/6/2009
Pioglitazone (Actos)	Previous therapy required with a sulfonylurea, metformin or insulin.	1/6/2009

**MATRIX OF DRUG-DRUG INTERACTIONS**

<i>Check for Drugs Already in History</i>																			
<b>Incoming Claim</b>	<b>Propulsid</b>	<b>Monistat IV</b>	<b>Sporanox</b>	<b>Nizoral</b>	<b>TAO</b>	<b>Macrolides other than TAO</b>	<b>Non-Sedating Antihistamines</b>	<b>Serzone</b>	<b>Effexor</b>	<b>Luvox</b>	<b>MAO Inhibitors</b>	<b>Nitroglycerin</b>	<b>Viagra</b>	<b>Anti-arrhythmics Class 1A, III</b>	<b>Tricyclic Antidepressants</b>	<b>Anti-psychotics</b>	<b>Vascor, Hismanal, Zagam</b>	<b>Cymbalta</b>	
Propulsid	co-admin		co-admin	co-admin	co-admin											co-admin			
Monistat IV	co-admin						co-admin												
Sporanox	co-admin						co-admin												
Nizoral	co-admin						co-admin												
TAO	co-admin						co-admin												
Macrolides other than TAO							co-admin												
Non-Sedating Antihistamines			co-admin	co-admin	co-admin	co-admin		co-admin		co-admin									
Serzone							co-admin				co-admin, 14 days								
Effexor											co-admin, 14 days								
Luvox											co-admin, 14 days								
MAO Inhibitors								co-admin, 7 days	co-admin, 7 days	co-admin, 14 days								co-admin, 14 days	
Nitroglycerin													co-admin						
Viagra												co-admin							
Antiarrhythmics Class 1A, III	co-admin																		
Tricyclic Antidepressants	co-admin																		
Antipsychotics	co-admin																		
Vascor, Hismanal, Zagam	co-admin																		
Cymbalta											co-admin, 14 days								